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ABSTRACT 
―Surgery is a profession defined by its authority to cure by means of bodily invasion. The 
brutality and risks of opening a living person's body have long been apparent, the benefits 
only slowly and haltingly worked out‖, says Atul Rawande on reviewing 200 yrs. of Surgery 
as a specialty in NEJM. My research focuses on working out these benefits, specifically 
looking at reduction of scar tissue formation in ENT, Abdominal & Spine surgery. 
Scar tissue formation is an outcome of healing process that can be excessive due to 
inflammation or infection and thereby has the ability to curtail the benefits or warrant 
revision surgery. Multiple strategies have been tested and employed thus far and none have 
given favourable results without causing additional harm or economic burden in health care 
costs. I propose to use a hydrogel synthesized by combining Chitosan  and Dextran aldehyde 
- Chitin is an exoskeleton extracted polymer and Dextran Aldehyde a sugar, with added novel
drugs Deferiprone and Gallium Protoporphyrin providing additional anti scaring and 
antibiotic properties which could potentially augment the healing properties of the gel. 
I have conducted 3 types of studies. There are 2 animal studies and a Phase 1 Human clinical 
trial.  The animal studies are an abdominal surgery rat model and a spine surgery sheep 
model. These studies show the safety and efficacy of this chitogel-drug combination at 




Surgery is a ‗risky art‘ turned scientific discipline, wherein disease conditions were treated by 
creating bodily wound, these wounds have had 3 principles challenges right from its 
inception, namely bleeding, pain and infection. Not all wound healing is in-conspicuous and 
un-noticeable, some remain as scars, and these scars may hide disorderly healing. Wound 
healing and orderly restoration of broken tissues were human needs since the beginning of the 
time, ‗I will restore you to health and heal your wounds,‘ (Jeremiah 30:17 KJV)
1
 is hence the
promise of God in the Bible.  
Practioners of medicine have been studying wound healing over the ages and there has been 
constant attempt to improve outcomes of the healing process. Attempts have been made to 
regulate the petite steps of scar formation by the ways the wound is created,  the way it is put 
back together and even by the materials it is being held to-gether by.  Susrutha & Charaka - 
ancient Indian surgeons have dedicated 2 chapters in their treatise Suśrutasaṃhitā in the 1st
Millennium Before the Common Era (BCE), to the management of wounds caused in battle 
and in domestic life. They have laid out a detailed description of wound creation and also 
describe how to treat poorly healing wounds
2
 using surgical techniques and medicinal herbs.
The aim of this thesis is to explore scar tissue formation in different surgical specialties and 
evaluate the wound healing effects ofChitogel-Drug combination. 
Scar tissue  is connective tissue disease referred to collectively as 'fibrosis'. This is generally 
excessive formation of connective tissue during wound healing process leading to hardening 
of the native tissue and ―scarring‖ within the affected organ. In principle, this process could 
affect any organ system and very often leads to disruption of organ function
3
. Connective
tissue cells play a key role in normal wound healing in healthy individuals, but in diseased 
tissues and surgically traumatised wounds the process of wound healing can be over activated 
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due to various factors such as genetic, immune related and infection. This results in activation 
of connective tissue cells that cannot be switched off, forming fibrotic tissue.  This can lead 
to an enormous amount of matrix deposited in the tissue, leading to scarring and dysfunction 
of the affected tissue. In the nose and para-nasal sinuses it results in the loss of ciliary 
function or blocked pathways of mucosal clearance.  In the abdomen it is obstruction of the 
bowel caused by the fibrotic bands, while in the spine fibrotic tissue causes compressive 
neurological dysfunction leading to persistent pain and dysfunction after surgery.  
Chitin is a derivative of glucose, fibrous in nature consisting of polysaccharides and is a 
major constituent in the exoskeleton of arthropods and the cell walls of fungi, including hard 
outer skeleton of shellfish, crab, lobster, and shrimp. It is biocompatible and biodegradable 
4
and has been widely used by food and beverage industry, fashion and now in the medical 
field. In our studies we use the hydrogel form of Chitosan. In this form it is succinylated and 
combined with dextran aldehyde to form a post-operative wound dressing that reduces scar 
formation but can also act as a drug carrier for treating drug resistant organisms. 
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Figure 1: Schematic representation of the possibilities of processing chitosan into 
different forms for medical use 
4 
Modifying wound healing and PO outcome 
Wound Healing 
1.1.1 Historical Perspective 
Caring for the wound is an ancient art practiced by human beings and has been found in 
Mesopotamian tablets 2200BC and later the Egyptian papyrus in 1400BC.  In these ancient
texts honey, grease, and lint was used to dress open wounds to remove dead tissue and pus to 
encourage wound healing 
5
. The Hippocratic Collection discusses the ancient (400 BC) 
Greek practice of surgical drainage of pus and in the middle ages the Bible describes ―the 
Samaritan soothed his wounds with olive oil and wine and bandages‖. Oil may have provided 
some protection from infection as bacteria grow poorly in oil, and oil would have prevented 
the bandage from sticking to the wound as a non-adherent dressing.  Wine (which has 
an alcohol content of around 10%) is more bactericidal than 10% alcohol. Wine's 
antibacterial components are the pigments malvoside and oenoside. Ancient salves used a 
mixture of one-third honey and two-thirds grease (butter) and have been shown to 
decrease a 10
5




Haemostasis is a necessary step for wound healing, was vaguely practiced by Hippocrates but 
came into modern usage in 1674 when reintroduced by French Army surgeon Etienne J. 
Morel with the use of the tourniquet
6
.  Ambroise Paré (1510-1590) a clinician in the 16th 
century is often quoted, ―I dressed the wound; God healed it‖. He cared for battlefield 
wounds by using "oyle of Elders scalding hot" and cauterizing the wounds.  He performed 
amputations as treatment for gunshot wounds
7
. This was an accepted form of wound care 
until 1865, when Dr. Joseph Lister (1827-1912) first demonstrated the benefit of anti-sepsis in
surgery by his treatment of wounds with dressings soaked in carbolic acid.  This was the 
beginning of the germ theory and infection being understood. Modern practice of wound care 
with debridement is credited to Belgian Army surgeon Antoine Depage (1862-1925)
5
. It was
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Depage who often found that the wound environment was fertile ground for the growth of 
pathogens and causing gangrene.  At this time Alexander Fleming was doing many of his 
bacteriologic studies in the research laboratories of Depage's military hospital at La Panne 
and identified Bacillus aerogenes capsulatus (Clostridium perfringens, Clostridium welchii), 
Clostridium tetani, streptococci, and staphylococci
5,8
.
Ignaz Semmelweis (1818-1865), an unrecognised Hungarian surgeon discovered sepsis as 
cause for wound infection and death. This was later espoused by the great scientist Louis 
Pasteur (1822-1895) but the surgery world only accepted this after Joseph Lister (1827-
1912), working in Scotland, discovered the value of antisepsis
7
.  Several others in the 20
th
and 21 st century have contributed to the biology of wound healing. Jerome Gross a 
scientist/physician discovered collagenase while studying tadpole development 
during metamorphosis. Together with Charles Lapierre, a Belgian dermatologist, working in 
his laboratory, and Harvard surgeon Hermes Grillo, they studied the process of wound 
contraction in great detail. Grillo then took this knowledge to the operating room, where he 
devised procedures to correct and prevent recurrent tracheal stenosis. In the late 1950s, a 
young academic plastic surgeon at the University of North Carolina, stimulated by the work 
of Gross and others, began a quest to discover how to control scaring and transform the 
biology of wound healing into what he termed ―surgical biology.‖ At the same time Stanley 
Cohen discovered the first epidermal growth factor (EGF) growth factor, EGF and  Anita 
Roberts discovered  transforming growth factor (TGF-β). The understanding of wound 
healing had entered the current era based on the historical concepts of managing trauma, 
haemostasis and antisepsis.   
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1.1.2 Surgical trauma and wound healing: 
Over the past 300 years historical texts have shown that the wound has an innate ability to 
heal (in the absence of infection and repeated trauma) and is able to control this process, 
largely through the local inflammatory cells. James Carrick Moore‘s ―vis medicatrix naturae‖ 
dictated the philosophy of wound care in the early 19
th
 century. Which stated ―When any
accident or disease injures the human frame, it was early observed, that the body possessed 
within itself, a power of alleviating or remedying the evil. In consequence of this power it 
happens, that whenever the structure or functions of any part of the body are disturbed, such 
operations are immediately excited as have a tendency to restore the machine to its former 
state‖
9
, which essentially meant leaving it to nature or body‘s natural healing mechanism to
take over and with minimal intervention from surgeons.  
Surgical induced trauma in any part of the body can occur from any number of mechanical or 
thermal forces that lead to disruption of the skin and damage to the connective tissue and 
vasculature. Injury can be caused by blunt trauma due to instrument or tissue handling, a 
clean cut with knife or powered instruments such as shavers and drills or by thermal injury 
caused by burns or cauterization
10
. A wound is defined as an injury to the body that typically
involves laceration or breaking of a membrane and damage to the underlying tissues
11
.
1.1.3 Wound Healing: Patho-physiology 
Trauma or a wound result in bleeding along with exposure of collagen, endothelium, and 
intravascular and extravascular proteins. This environment serves as a stimulus for 
haemostasis, the body‘s first step in the wound healing process, clot formation is enabled by 
chemokines and fibroblastic activity.  
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1.1.4 First Phase:Haemostasis and Inflammation:
Wound healing in general begins with haemostasis- a complex process 
involving vasoconstriction, plateletaggregation, bloodcoagulation. Vasoconstrictionis a 
reflexive saving reaction designed to limit the blood flow by release of endothelin, 
vasoconstricting circulating catecholamines (epinephrine) and prostaglandins from injured 
cells which in turn causes stimulus of the sympathetic nervous system (norepinephrine) with 
further vasoconstriction. 
The clotting mechanism is driven by chemical triggers (von Willebrand factor (vWF) and 
collagen
12
 that are released from the injured endothelium which otherwise when intact secrete
prostacyclin and nitric oxide that inhibit platelet activation
13
. Platelets are the first responders
in wound healing, when activated platelets contribute to haemostasis through the process of 
adherence, aggregation, and degranulation.  
Figure 2: Steps of Haemostasis; Intrinsic and ExtrinsicPathwaysAdaptedfrom(13)with 
permision. 
Plateletsare the first cells to respond in wound healing, activated platelets contribute to 
haemostasis through the process of adherence, aggregation, and degranulation. Exposed 
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collagen and thrombin at the site of injury comes in contact with blood flow, leading to 
stimulation of the circulating platelets causing adhesion. Platelet adherence is a result of 
interactions between platelet glycoproteins VI and collagen, glycoprotein Ib-V-IX complex 
and collagen-bound von Willebrand's factor.  
Figure 3: Activation of Platelets in clot formation, adapted with permission from (13) 
Tissue factor activates the extrinsic coagulation pathway leading to the production of 
thrombin an independent initiator of platelet activation. Thrombin interacts with a receptor on 
the platelet surface leading to the release of Adenosine diphosphate 
14
, serotonin, and 
thromboxane A2 causing platelet aggregation. This in the presence of fibrin matrix forms a 
clot or thrombus which in turn blocks the endothelial defect and stops the bleeding. This 
forms a layer which conserves degranulated substances from platelets. This is made up of 
numerous cytokines, growth factors, and matrix proteins stored within platelet alpha granules 
(Table 1).  These substances promote a variety of cellular and extracellular mechanisms 
which promote the wound healing process including matrix deposition, chemotaxis, cell 
proliferation, angiogenesis, and remodelling.  
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Table1:  Platelet alpha granule components and their role in wound healing (14) 
Fibrin is a fibrous protein and forms a key component of the coagulation cascade. It is 
sourced from soluble circulating fibrinogen. Fibrin mesh is critical for establishing 
haemostasis following injury along with platelets. Fibrin has multiple binding sites for cells 
and growth factors that promote platelet spreading, cell infiltration, fibroblast proliferation, 
and angiogenesis. Fibrin degradation products also play a functional role in the wound repair 
process by encouraging cell infiltration and subsequent tissue remodelling of wound. 
Enhancing clot formation with substances derived from harvested fibrin or those that mimic 
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Inflammation: Clot or thrombus formation initiates the next phase of wound healing, i.e.
Inflammation. This stage is mainly driven by chemokines (or chemotactic cytokines).  These 
are small heparin binding proteins that recruit circulating inflammatory cells to the injury 
sites via interaction with specific membrane-bound receptors.  
In the first 48 hrs Neutrophils are the predominant cell type in the inflammation phase after 
which monocytes take over the wound healing as they mature into tissue macrophages. 
Chemokines IL-8 released by neutrophils attracts the macrophages and other cells to the 
wound site. CXC chemokines primarily attract neutrophils and lymphocytes(CXCL7 
[neutrophil-activating peptide-2 (NAP-2)])
15
, and are believed to orchestrate the early phases 
of wound healing. 
Monocytes migrate to the wound site and become macrophages who then play a central role in 
both the inflammatory phase and all stages of repair. Macrophages act as scavengers by 
phagocytosing debris and bacteria, and orchestrate inflammatory cytokines (including growth 
factors) such as TNF, IL-6, IL-1, bFGF, etc. IL-1 stimulates the proliferation of inflammatory 
cells and promotes angiogenesis through endothelial cell replication. TNF-a is a mitogen for 
fibroblasts. bFGF is a chemotactic and mitogenic factor for fibroblasts, endothelial cells and 
other mesenchymal cells, and in turn provides the stimulus for angiogenesis. in addition, 
bFGF stimulates wound contraction, epithelialization and production of collagen, fibronectin, 
and proteoglycans. Macrophages also secrete collagenases and elastases, which break down 
injured tissue and debride the wound
16
.
1.1.5 Second Phase: Proliferation 
Post injury day 4-12, proliferation or constructive phase begins, and 3 major activities take 
place during this period, namely matrix deposition, angiogenesis, and epithelialization. 
11 
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In this  period, fibroblasts, smooth muscle cells, and endothelial cells infiltrate the wound and 
bridge the surgically created void over which epithelial cells begin to cover the site of 
injury
10
. This Phase is also characterised by the corresponding increase in blood flow into the 
damaged tissue by angiogenesis, which is new blood channel formation, seen as granulation 
tissue (a mix of fibroblasts, macrophages and neovascualture). Once the fibroblasts migrate 
into the area of wound, they switch their role to protein synthesis and this activity reaches its 
peak 21 days from injury.  
During the same process, epithelial cells at the edges of the injury also begin to proliferate 
and try to reach the counterpart on the opposite side attempting to close the wound. In the 
case of abdomen, the entire breach in continuity of endothelium is filled by proliferation of 
cells in the form of membranous sheet. Each tissue on the body has a set rate at which they 
regenerate.  This can be controlled by various internal and external factors.  
1.1.6 Third Phase: Remodelling 
The last stage of wound repair begins 14–21 days after injury and this can go for a year or 
more. In this period all the active injury related activities have ceased, and the extra cellular 
matrix 
17
 is gradually replaced by type I collagen, the predominant constituent of the normal 
human dermis. The healed tissue shrinks to a smaller size due to reduced blood supply and 
contraction of myofibroblasts
18
, and is composed of 80% to 90% type I collagen and 10% to 
20% type III collagen. This is in contrast to the early phase of healing, wound matrix is 
weaker due the presence of 30% type III collagen
10
. In addition there are other host of 
external and internal factors that affect the wound healing 
19
including the  production of 
elastin fibres with proteoglycans within in the ECM.  This will eventually  affect the tensile 
strength of the scar.  
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In some fibroproliferative disorders, this process can be prolonged and can clinically 
recognized as hypertrophic scar 
20
 formation, adhesions or fibrous bands. This is due to
proliferation of fibroblasts, with excessive deposition of fibroblast-derived ECM proteins 
and collagen
19
.  Inflammation is key to normal wound healing, in adhesions or
hypertrophic scars excessive inflammation results in abnormal healing
21
.  This could be a
result of hematoma  or infection leading to recruitment of neutrophils and macrophages, 
producing inflammatory cytokines and reactive oxygen species (ROS) followed by 
fibroblast migration and proliferation into the wound are critical factors in these 
processes
21,22





, and ENT surgery
28-30
.
Figure 4: Figure 4 Adapted from Scott-Brown et.al representing the various phases of 
wound healing and cellular recruitment (29) 
Modifying wound healing and PO outcome 
13 
1.1.7 Types of Wound Healing
There are mainly 3 types of wound healing 
1. Primary healing (healing by first intention in wounds with approximated
wound edges)
2. Secondary healing (healing by secondary intention where the cut edges are not
approximated)
3. Tertiary healing (wound edges are deliberately left unopposed due to infection
or other reasons)
Healing by first intention is when cut edges are closely approximated to each other and 
wound heals within 12–24 hours. These wounds are clean and well perfused as in a surgical 
excision or a clean laceration. Wound edges are approximated using sutures, skin glue, steri-
strips or other mechanical devices/instruments. Healing by secondary intention is when the 
cut edges are wide apart either due to loss of tissue or infection and wound edges come 
together by myofibroblasts. Tertiary wound healing occurs in wounds which are deliberately 
left open without approximating the wound edges due to infection and or soiling in 
abdominal wounds and usually approximated after 3-4 days.  











All these factors affect the outcome of the wound healing in different ways
19
 and impairment 
in any of these determines the final outcome of the wound either individually or in 
combination. Different surgical situations have different combinations of the above factors, 
causing poor wound healing.  
1.1. 9  Complications of wound Healing
Excessive scarring or adhesions after surgery are common. This is often from excessive 
bleeding resulting in clot formation and a framework allowing a fibrinous bridge to occur. 
Studies suggests infections either acute or chronic increase the likelihood of these fibrinous 
band forming post operatively. Whilst the outcome in sinus surgery would be a narrowing of 
the air passage, the same fibrous band could cause compression of sensitive neural tissue in 
the spine after spine surgery or form bands that obstruct the bowels in the abdomen causing 
dysfunction, infertility and even death if untreated. 
There has been research through the ages to find agents that improve healing and scar 
formation. Historically, these have been designed to reduce bleeding, infection and loss of 
function with the help of various agents and methods (as listed in table 2).  
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1.1.10  Adjuncts in Wound Healing
Table2: adapted from (30) Historical aspects of topical wound agents 
Research has a number of methods that have been used to reduce surgical scars such 











, silicone gel sheeting
36
  and onion extract gel
37
. Of these 
the most commonly used are pressure on the wound, silicone support and intra-
lesional steroid. Pressure therapy is hypothesized to prevent scar formation by 
initially promoting haemostasis and then in the later phases of healing suppressing 
collagen production by restricting nutrient supply. Silicone have limited beneficial 
effect on skin scars because of their potential to cause a rash, pruritus and excessive 
sweating
38
. Intralesional injections are second-line therapies for the treatment of 
hypertrophic scars in the skin, Corticosteroids and bleomycin are hypothesized to 
inhibit the inflammatory process and expression of genes related to collagen and 
Agents Used Surgeon 
Olive oil, honeycomb, gum Arabic, incense Johannes DeKetham, 1491 
Zinc ointments, alum, sal ammoniac, turpentine John Bell, 1810 
Oil or wax, honey, copper sulphate, mercurial salts Dominique Jean Larrey, 1814 
Wine, lead acetate Astley Cooper, 1825 
Zinc sulphate, lead acetate, copper acetate, mercuric chloride James Syme, 1832 
Mercuric chloride, ammonium chloride, mercury and zinc 
cyanide, antiseptic treatment 
Joseph Lister, 1884–1889 
Sodium hypochlorite, epicutaneous treatment Alexis Carrell, 1910 
Silver foil, mercuric chloride, sodium hypochlorite William Halsted, 1883–1917 
Sulphonamide, penicillin, sodium hypochlorite, allantoin Hamilton Bailey, 1947 
Sulphonamide, penicillin, acetic acid George Crile, 1947 
16 
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glycosaminoglycan synthesis, decreasing fibroblast proliferation. Intralesional 
steroid injections are highly responsive (50% to 100%), indicating a profound effect 
of reducing inflammation on limiting hypertrophic scar formation
39,40
. However, 
63% of the patients experience side effects, especially in the form of 




Chitosan has recently been used in multiple wounds in the body as it is a bio-
compatible wound healing adjunct that is able to conform itself to shapes and forms 
that is required for the area of injury/wound and is able to be cleared by absorption 
within the body. 
Chitogel 
1.1.12 General Properties: 
Chitogel is a polysaccharide hydrogel formed between succinyl-chitosan and dextran 
aldehyde (dissolved in a sodium phosphate buffer). Succinyl-chitosan is a polymer of 
chitosan which is produced by the hydrolysis of chitin, found in shellfish. Both chitosan and 
chitin as a group make up the second most abundant polysaccharide occurring in nature (after 
cellulose). Chitosan has been widely applied in a variety of settings including use in: 
(1) Foods as a preservative and antimicrobial agent
(2) Agriculture as an adhesive agent on seeds, pesticides and fungicides
(3) Cosmetics as a hydrating agent
(4) Shampoos and toothpastes as a preservative agent
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(5) Medications as a weight and cholesterol lowering agent
(6) The United States (US) Military as a haemostatic dressing
(7) In wastewater management as a flocculent that absorbs greases, oils, metals, and
other toxic substances
More recently chitosan has become recognised as having a potential role in biomedical and 
other more formal pharmaceutical applications. Its properties as an effective haemostat, anti-
adhesive and pro-wound healing agent, as well as its antimicrobial action against a number of 
bacterial species has made it an attractive candidate for many medical and surgical 
applications and has been recently approved by FDA as a post-surgical device in sinus 
surgery. Non-clinical and clinical studies investigating both chitosan in general as well as 
Chitogel specifically are outlined in the sections to follow. 
Succinyl-chitosan is supplied via the Department of Chemistry, The University of Otago 
(Dunedin, New Zealand). The raw material (chitosan) is sourced from Sigma-Aldrich 
Chemicals (Sigma-Aldrich New Zealand Ltd., Auckland, New Zealand). The solution is 
packaged as 10 ml samples in glass vials by The Department of Chemistry, The University of 
Otago then sent to The Department of Otorhinolaryngology, The University of Adelaide (The 
Queen Elizabeth Hospital site, Woodville, South Australia, Australia). It is extensively 
chemically devitalized and can be regarded as synthetic. It is a buff coloured solution with no 
odour. It has a molecular formula of (C8H16NO7)n [Figure 5] and a molecular weight of 
450,000 Da. It is produced at a concentration of 5% in water with 0.3% sodium hydrogen 
phosphate buffer and has a pH of 7.4 (physiological pH). Succinyl-chitosan has a number of 
synonyms which include: Chitosan, N-(3-carboxy-1-oxopropyl), chitosan succinate, Chitosan 
succinamide, Chitosan succinyl amide, Hydrases, and N-Succinyl chitosan. 
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Figure 5:The chemical structure of N-succinyl-chitosan (12) 
Succinyl-chitosanisnon-flammable. It is incompatible with strong oxidisers and acids. 
Dextran Aldehyde is a white coloured solid powder with a slight odour. Its molecular formula 
is (C6H8O6)n and its molecular weight is 80,000 Da. It is designed to be dissolved in the 
sodium phosphate buffer. It has a neutral pH, however when mixed with the buffer solution, 
the pH is 7.4 (physiological pH).Dextran aldehyde is flammable; however it is mixed 
immediately prior to application into the sino nasal sinuses with non-flammable sodium 
phosphate buffer to form a solution, then with non-flammable succinyl-chitosan to form a 
gel, therefore its flammable risk is minimised. It is incompatible with strong oxidisers and 
acids.  
The sodium phosphate buffer solution is an isotonic fluid in which the dextran aldehyde is 
dissolved. It is produced at a concentration of 0.3% in water and has a pH of 7.4.  
1.1.13 Pharmaco kinetics and Toxicology 
Specific to Chitogel, The Department of Chemistry, The University of Otago (Dunedin, New 
Zealand) had conducted an animal toxicology study
42
 where radiolabelled-Chitogel and 
control (normal saline) was injected intra-peritoneally into BALB/c mice to determine 
three factors: 
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(1) the biodistribution/degradation rate of Chitogel
(2) the clearance rate of Chitogel from the intact physiological rat system and
(3) to assess the pro-inflammatory response of Chitogel.
Mice were monitored over a 6-day period where faeces samples were collected to measure 
radioactivity levels and Tritium was detected in faeces, organs, tissues, and serum of mice 
intraperitoneally injected with Chitogel. The study showed that majority of the Chitogel 
biodegraded within 3 days and biodistribution of its metabolites were highest in the spleen, 
followed by the organs of excretion: the liver and kidney. These results suggest that Chitogel 
is well-tolerated within the intraperitoneal space and is eliminated into non-toxic waste 
products in a timely manner (by Day 6). 
As a follow-on study, The Department of Chemistry, The University of Otago (Dunedin, 
New Zealand) conducted a similar study using the same protocol in BALB/c mice, but with 
subcutaneous rather than intraperitoneal injections 
42
. They also added another arm to the
study: a positive control with lipopolysaccharide (LPS) to induce inflammation. The follow-
on study assessed 5 time points: 2 hours, 4 hours, 1 day, 3 days and 7 days. Fluorescence 
imaging of Chitogel showed that the steady degradation over a 3-day period [Figure 6]. There 
was no fluorescence detected in mice imaged on day 6. 
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Figure 6: XR and NIR-fluorescence imaging of mice injected with Chitogel(42) 
The general well-being of Chitogel-injected mice was excellent. No toxic response or death 
occurred during the 6-day observation period. In that study, Chitogel-injected mice showed 
no statistically significant differences in any of the following serum indices: total protein , 
albumin, alanine aminotransferase, creatinine phosphokinase, creatinine, urea  and globulin  
as an indicator of inflammatory response.  
To investigate the in-vivo inflammatory response resulting from Chitogel, the following pro-
inflammatory cytokines: TNF-α, IL- 1b, IL-6, IL-12, anti-inflammatory cytokines, IL-10 and 
IL-13 and chemokines, macrophage inflammatory protein (MIP) 1a and 1bwere measured. 
LPS-injected mice had statistically significant increases in the amount of both pro-
inflammatory cytokines as well as anti-inflammatory cytokines released as compared to 
saline and Chitogel-injected mice. The chemokines measured followed the same trend as the 
pro-inflammatory and anti-inflammatory cytokines. There was no statistically significant 
difference between saline and Chitogel-injected mice. These results indicated that 
subcutaneously - injected Chitogel did not affect the blood system, liver or renal function, nor 
was there significant inflammation in muscle tissue, heart, or brain. As well, Chitogel did not 
elicit an inflammatory response when compared to the LPS positive control. 
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This second study also investigated Chitogel distribution and degradation in vivo at the same 
time points. The concluding remark was that there was no toxic response or histological 
changes due to subcutaneous injection Chitogel in mice compared to control [Figure 7]. 
Cytokine and chemokine levels were consistent with histological examination of tissue 
around the injection site with >80% of the mice  injected showing no inflammation. There 
were no signs of chronic inflammation in any mouse. Thus, the results from this second study 
suggest that the gel is well-tolerated within the subcutaneous space and exhibited acceptable 
biocompatibility for practical use in in vivo applications. 
Figure 7: Images of H&E stain of surrounding tissues at the Chitogel subcutaneous 
injection site at (A) 4 hours and (B) 24 hours post injection in mice. *Indicates 
Chitogel(43) 
Again, the general well-being of the Chitogel-injected mice was excellent. No toxic response 
or death occurred during the 7-day observation period. The animals displayed normal energy, 
normal behaviour, free movement, and shining hair. There was no flare or ulceration in the 
skin, no mouth, nose dryness or oedema; as well as no vomit, running nose or eye secretion. 
Animal faeces were in regular form and normal colour, without mucus, pus, or blood. 
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To support further the safety of Chitogel, animal toxicology studies evaluating chitosan alone 
is summarized in the table below which indicates the animal species, chitosan product, 
concentration and main outcome/conclusion(s) [Tables 3 and 4] 
Table3:  Animal toxicologystudiesevaluatingchitosan 
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Table4:Animal toxicologystudiesevaluatingchitosan (continued) 
Chitogel has inherent haemostatic and anti-adhesive properties and an excellent safety 
profile. Both in vitro studies and in vivo animal and human randomised trials have shown that 
Chitogel achieves haemostasis significantly quicker than control 
43,44
, and reduces the 
incidence of post-surgical adhesions in endoscopic sinus surgery 
45,46
.
1.1.14 Chitosan as a haemostatic agent: 
Chitosan has a longhistory of being used as a haemostaticagent: 
(1)Wedmoreet al
47
described a chitosan patch that is distributed to over 400,000 military
personnel with significant improvement in haemostasis when applied to a wound and
no adverse effects attributed to the chitosan patch.
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(2) A chitosan patch has been marketed for use in dental extractions 
48
 with claims of
significant improvement in haemostasis and no adverse or allergic events since its 
introduction in 2003. 
(3) Valentine et al (2009)
49
 conducted a study in 21 sheep infected with Oestrusovus
that underwent standardised mucosal injuries in the sinuses. They evaluated the 
bleeding scores at Time = 0 (at time of mucosal injury) and every 2 minutes in 
Chitogel-applied mucosa vs. control (nothing) mucosa. That study found that Chitogel 
was significantly more haemostatic at 2, 4 and 6 minutes after injury. The average 
time to haemostasis was significantly better in Chitogel sides compared to control 
sides (4.09 vs 6.57 minutes, p=0.049). Furthermore, complete haemostasis occurred 
within 6 minutes for all Chitogel sides, whereas control sides were still bleeding at 8 
minutes in 3 sheep and 10 minutes in 1 sheep. 
(4) Valentine et al (2010)
50
 followed on from sheep to demonstrate the same outcome
in 40 human subjects undergoing ESS for CRS in which patients were their own 
controls such that one side was randomised to receive Chitogel and the other served as 
control. Similarly, they scored baseline bleeding (Time = 0) immediately after the 
sinus operation, and every two minutes thereon. In that study, Chitogel achieved 
haemostasis within a mean time of 2 minutes (2-4 minutes) and compared with 10 
minutes for the control sides. Wound healing evaluated in that studyis discussed in the 
section below. 
(5) Valentine et al
51
 then conducted another study in 20 sheep with standardised carotid
artery injuries. Each sheep was randomised to 1 of 5 haemostatic techniques; of which 
1 was Chitogel. The outcomes measures in that study was time to haemostasis, 
duration of time that MAP was <55 mmHg, total blood loss, volume and survival 
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time. The findings of that study were that Chitogel was inferior to the muscle patch 
and U-clip anastomotic device, but superior to control. Those results suggested that 
Chitogel is more effective in low-flow mucosal bleeding than high volume, high 
pressure bleeding (as is the case with carotid artery injuries). 
(6) Chitogel Hemocon patch
48












 are all FDA-approved chitosan dressings for use as topical
haemostatic dressings. Both the Hemocon patch and the Syvek patch have extensive 
scientific data with promising results in RCTs indicating effectiveness as topical 
haemostats. There have not been any adverse reactions due to these topical patches 
reported in any of these trials. In Japan chitosan is used as a dressing (Beschitin) 
58
that is used specifically for post-operative wound healing following sinus surgery. 
This has some scientific data to support its use in the Japanese literature and to date no 
adverse events have been recorded with its use. 
1.1.15 Chitosan as an anti-adhesive agent: 
Chitosan has a long history of being used as an anti-adhesive agent: 
(1) Diamond et al
59
 showed chitosan gel used topically in a gynaecologic randomised
controlled trial of 34 women did not result in any adverse events. Furthermore, there 
were lower grades, severity and extent of adhesions. 
(2) Kennedy et al
60
 found that the topical application of chitosan in 20 rats resulted in a
significant reduction of adhesion formation in abdominal and pelvic adhesions. 
(3)Costainet al
61
found that the topical application of chitosan in 56 rats resulted in a
significant reduction of adhesion formation in abdominal and pelvic adhesions.
(4)Vlahos et al
62
found that the topical application of chitosan in 44 rats resulted in a
significant reduction of adhesion formation in abdominal adhesions.
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(5) Zhang et al
63
 found that the topical application of chitosan gel inhibited adhesion
formation in 240 rats whilst chitosan film resulted in increased adhesion formation. 
1.1.16 Chitosan as a weight-loss and/or anti-cholesterol agent: 
Chitosan has beenused in other medical applications: 
1 Kaats et al64showed in a double blind randomised controlled trial of 150 women who
were given placebo or 3 g of chitosan/day showed no adverse effects from chitosan. 
Some parameters of weight and lipid distribution were significantly improved in the 
chitosan group. 
2 Wuolioki et al65showed in a randomised controlled trial of 51 overweight women who
were given 800 mg chitosan or placebo for 8 weeks, that chitosan was well tolerated and 
no side effects were reported. As well, there was no change in serum levels of fat-soluble 
vitamins or serum iron/transferrin levels. However, there was also no significant 
reduction in weight between the two groups. 
3 Bokura66 showed in a randomised controlled trial of 90 female volunteers who received
either placebo or 1.2 g chitosan daily for 56 days, that cholesterol levels were mildly 
reduced in the chitosan arm. Also, there were no adverse effects recorded. 
4 Landes and Bough67 showed progressive growth reductions in male Sprague-Dawley rats
fed 10 or 15% chitosan diets for 8 weeks. They observed enlarged liver and kidneys with 
15% chitosan diets. 
5 Vahounyet al68showed no significant differences in weight gain in male rats fed 1 or 5%
chitosan for 4 weeks. In rats fed with 5% chitosan, oleic acid and cholesterol absorption 
was lowered by 58% and 63% respectively. 
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6 Fukadaet al69foundno significant differences in growth, food intake, liver weight, and
dried faecal weight between control and 2% or 5% chitosan-fed male Wistar rats after 21 
days on a low cholesterol diet. However, 5% chitosan diets did reduce serum cholesterol 
levels. Chitosan feeding also suppressed the formation of coprostanol in the intestines. 
7 LeHoux&Grondin70 showed that high-molecular-weight chitosan (>750 kDa) was a less
effective cholesterol-lowering agent than a low molecular-weight chitosan (70 kDa). A 
7.5% chitosan formula-maintained cholesterol homeostasis in male Long-Evans rats 
even with increased cholesterol intake. 
8 Deuchi et al71showed that ascorbate had a synergistic effect with chitosan on the
inhibition of fat digestion in male Sprague-Dawley rats. 
9 Razdanet al72 showed significant reductions of feed intake, body weight, total plasma
cholesterol, and HDL-cholesterol in broiler chicks that were fed chitosan for 12 days. 
10 Ormrodet al 73 showed inhibition of hypercholesterolemia and atherogenesis in gene
knockout apolipoprotein E-deficient mice that were fed 5% chitosan for 20 weeks. 
1.1.17 Chitosan as a drug delivery agent: 
The chemical structure of Chitosan facilitates drug delivery: 
(1)Illum
74
indicated that a chitosan gel influenza vaccine administered intranasally was
successful in a human trial and was now introduced in Europe.
(2) Chitosan has also been successfully trialled in mice, rat, guinea pig and bovine
animal models as a drug delivery agent for various factors such as Growth Hormone, 
insulin, anti-angiogenesis peptide as well as influenza/diphtheria/pertussis vaccines.  
Studies that have investigated chitosan for use orally (e.g. as weight and/or cholesterol-
lowering agents) indicate that chitosan is well tolerated orally, with minimal side effects 
28 
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(mild and transitory nausea and constipation in 5-6% of patients)
66,75
. A Cochrane review of 
14 trials evaluating chitosan as a weight loss agent 
76
 suggests that: whilst there is some 
evidence for minimal weight loss with oral chitosan, it is safe for human consumption with 
no difference in the adverse events between chitosan and control groups. 
1.1.18 Chitogel as a wound healing agent: 
Chitogel has been investigated in both animal and human models for its anti-adhesive 
properties. A prospective randomised controlled trial of Chitogel was performed in 20 
sheep
77
. After creating standardised injuries and applying three types of haemostatic agents 
(Chitogel, SprayGel™ and recombinant tissue factor) compared to control in a randomised 
fashion, sheep were reviewed by a blinded observer monthly for four months. Results of that 
study showed that Chitogel was the only agent significantly superior to control in preventing 
adhesions. Chitogel was shown to reduce adhesions from 56% in control to 5% in the 
treatment group (p<0.01). Wound healing was determined by light and electron microscopy 
and measurements of ciliary beat frequency. The results of that study showed that Chitogel 
was significantly better (30% improved) than SprayGel™ group (13% improved), compared 
to control (p<0.05). 
In the study mentioned above Valentine et al
44
 investigated the haemostatic effect of Chitogel 
in 40 humans, adhesions and other factors of wound healing were also evaluated in the 
postoperative period up to 3 months post-ESS surgery. Following intra-operative bleeding 
evaluation, patients were followed up at 2, 6 weeks and 3 months where their adhesions, 
crusting, mucosal oedema, infection, and granulation tissue were graded. That study indicated 
that there was a significant reduction in adhesions post-ESS compared to control. There was 
no significant difference in the other parameters. 
29 
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Ha et al
46
 showed in 26 humans in a prospective, randomised, controlled trial of Chitogel vs. 
control (nothing), with each patient having intervention on one side with the other side 
serving as control, that Chitogel was significantly better in terms of preventing ostial stenosis 
post-ESS. The patients were evaluated at 2 weeks, 2 months and 3 months post-procedure by 
endoscopic measurements using a custom-designed ball probe. The results of that study 
showed that the frontal ostia maintained their diameters at 66% vs 31% for Chitogel vs 
controls. Similarly, the sphenoid ostia maintained their diameters at 85% vs 47%, and 
maxillary ostia at 74% vs 54% for Chitogel vs. control respectively (all p≤0.002). 
A follow-on study to these investigated the effect of Chitogel combined with Pulmicort 
Respules® (budesonide, 1 mg/2 mL) in the early post-operative period
78
. The budesonide 
solution was used for its anti-inflammatory properties in that study. Again, using patients as 
own controls, Chitogel and budesonide was compared with control (nothing) and steroid-only 
(betamethasone cream). Results have shown that Chitogel with budesonide is superior to both 
control and betamethasone cream at improving healing in the early post-operative period. In 
the frontal sinuses, sides treated with Chitogel and budesonide maintained 71% of their ostial 
diameter at 12 months, compared to 51% on the control side (no treatment). Similar results 
were seen in the sphenoid and maxillary sinuses, but less pronounced.  
1.1.19  Chitogel as an anti-bacterial/anti-biofilm agent: 
Bae et al
79
 used chitosan as a mouth wash in 12 dental students for 6 weeks to show a 
significant reduction in bacterial biofilm growth and no adverse events. Paramasivam et 
al
80 
investigated the anti-bacterial and anti-biofilm effects of Chitogel in anin-vitro study 
using fibroblasts isolated from human nasal tissue. They set out to determine the effects of 
Chitogel on (1) cell proliferation, (2) wound healing, (3) inflammation in fibroblast cultures 
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challenged with superantigen, Staph aureus enterotoxin B (SEB) and toxic shock syndrome 
toxin (TSST) (4). They found that Chitogel was highly effective at reducing IL-8 expression 
after TSST and SEB challenge, and also reduced non-challenged fibroblasts, indicating its 
anti-inflammatory effects on fibroblasts in the diseased state. Chitogel also showed strong 
anti-biofilm properties at 50% concentration and dextran on its own showed anti-biofilm 
properties at 1.25% concentration. Chitosan on its own reduced proliferation of fibroblasts to 
82% of control and Chitogel reduced proliferation of fibroblasts to 0.04%. Furthermore, 
Chitogel significantly delayed epithelial cell defect closure rates over the first 2 days of 
wound-healing. In all trials that have been conducted involving Chitogel as a topical product 
in human subjects, there have been no adverse effects.  
Deferiprone (Def) 
Def is an oral iron chelator used as a second line agent in thalassemia syndromes
81
 when iron
overload from blood transfusions occurs . There are multiple synonyms to Def(1,2-dimethyl-
3-hydroxy-4-pyridinone,1,2-dimethyl-3-hydroxypyrid-4-one,1,2-dimethyl-3-hydroxypyridin-
4-one, 3-hydroxy-1,2-dimethyl-4-pyridinone, CP20, Deferiprone, DMOHPO, Ferriprox
82
.
Def as an iron chelator,  has  anti-microbial properties because of free radical scavenging and 
is known to improve wound healing (skin wounds)
14
. Scavenging ROS after abdominal
surgery has been shown to significantly inhibit postoperative adhesion formation
83
. Iron
being an enzymatic co-factor in biological systems becomes a target for bacterial cell wall 
synthesis. Staph aureus uses iron as oxidising and reducing agent is in membrane bound 
cytochromes and has developed specific human specific haemoglobin receptors
84
.  Chelation
of the circulating Fe leads to depletion from the bacteria‘s surrounding environment, forcing 
the bacteria to up-regulate its iron transporters. The wound-healing activities of different 
concentrations of Def on primary human fibroblasts and primary human nasal epithelial cells 
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in air liquid interface culture (HNEC-ALI) were studied
85
.  Along with this, effect of Def on
fibroblast and epithelial cell migration, collagen production, ROS activity and potential for 
anti-inflammatory effects were also evaluated for its potential to limit hypertrophic scar tissue 




 indicated rapid absorption in rats and monkeys. Elimination half-
lives of deferiprone in rodents were similar to that observed in humans, while those in 
monkeys were slightly shorter. Serum elimination half-lives were independent of iron loading 
status. In vitro studies indicated glucuronidation by UGT1A6 as the major route of 
metabolism
87
. Repeat dose toxicity studies of 52 weeks duration were performed in both iron
loaded and naive rats and monkeys. Maximum exposures were low; equivalent to that 
anticipated from a clinical dose of 75 mg/kg/day but estimated to be subclinical for a 100 
mg/kg/day dose. No adverse findings were evident in the monkey study. In rats, the bone 
marrow, thyroid, adrenal and mammary glands were target organs for toxicity. Findings 
included bone marrow hypocellularity (with accompanying haematological changes), diffuse 
colloidal basophilia and hypertrophy of the thyroid follicular epithelium, hypertrophy of the 
adrenal zona fasciculata, and increased incidence and severity of mammary gland 
hyperplasia/fibroadenoma.  
Regardless of iron status, Def at clinically relevant exposures, was genotoxic in a mouse 
micronucleus assay. No carcinogenicity studies were conducted with deferiprone. Aside from 
reduced oestrous cycling, no adverse effects on fertility were evident in either male or female 
rats at doses <0.5 times the clinical dose on a BSA basis. Based on long term rodent studies
88
,
the proposed specification for the process impurity, maltol, in the drug substance was 
considered acceptable. The low tested doses and concentrations, which were in general 
estimated to be subclinical for the proposed higher dose of 100 mg/kg/day, limit the 
predictive value of negative findings and do not help to mitigate safety concerns. 





GaPP mimics haem in its molecular structure and is actively accumulated by bacteria via high 
affinity haem-uptake systems. The same uptake systems can be used to deliver antibiotic-
porphyrin and antibacterial peptide-porphyrin conjugates
90
.
Ga(III) acts as an iron mimetic and is supposed to exploit Fe(III) transport systems to enter 
bacterial cells. Basic information on Fe(III) uptake and metabolism in bacteria are therefore 
instrumental to understanding the mechanism(s) of action and uptake routes of Gallium
91,92
.
The synonyms of GaPP are Ga-Protoporphyrin IX; Gape; Protoporphyrin I containing Ga; 
7,12-Diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid, gallium 
complex. Its Molecular Formula:C34H32GaN4O4 and Molecular Weight:630.377 g/mol
93
.
Although gallium compounds show antimicrobial and antibiofilm activity against various 
bacteria, they have not found their way into clinical practice. There are two FDA approved 
gallium formulations on the market that are used as diagnostic agents in cancer therapy; these 
are the radioactive labelled gallium injections (i) gallium citrate Ga 67, FDA approved since 
1976, and (ii) gallium dotatate Ga 68, FDA approved since 2016. The formulation Ganite (a 
gallium nitrate-citrate injection for cancer-related hypercalcaemia, FDA approved from 2003 
to 2014) showed antimicrobial activity in vitro, however, this effect appeared species and 
strain dependent. Concentrations higher than the recommended dose would be required for a 
broad antibiofilm effect, raising toxicity concerns.  
There is one gallium citrate formulation in the drug development pipeline, trade named 
Panaecin by Aridis Pharmaceuticals
94
. Clinical phase I studies commenced in November
2011 in the USA and indicated promising treatment efficacy in cystic fibrosis-associated 
respiratory tract infections after intravenous administration of gallium citrate. In January 
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To test for toxicity on mammalian cells, semiconfluent monolayers of four cell lines (MRC-5 
primary human fibroblasts, Vero cells, MDCK cells and CaCO-2 cells) were incubated for 24 
to 48 hours in the presence of 5, 25, 50, 250 and 400 μg/ml of Ga-PPIX dissolved in 0.02 M 
NaOH
90
. No detachment or rounding of cells was noticed in any of the monolayers. 
Preliminary toxicity testing on animals showed that a single intraperitoneal dose of 25 mg/kg 
of Ga-PPIX does not cause any hyperacute or acute effect on the health and behaviour of 
mice. 
Combination of Def & GaPP: 
Def/GaPP combination has synergistic anti-microbial properties against MDR Gram-positive 
and Gram-negative bacteria. To further enhance Chitogel‘s anti-microbial properties, the 
team has developed a novel treatment combination (Def and GaPP) that has potent 
synergistic anti-microbial effects against Gram-positive and Gram-negative bacteria. 
Methicillin-Sensitive and Resistant S. aureus strains (frequent in surgical site infections) as 
well as MDR E. Coli and P. aeruginosa strains have been found to be highly susceptible to 
this novel treatment combination with eradication of planktonic and biofilm infections with 
extremely low dosages of Def and GaPP as low as 5µg/ml and 50µg/ml respectively. 
Def/GaPP combination is non-toxic in vitro. An LDH assay showed the absence of toxicity 
for both compounds alone and in combination for dosages up to 20mM Def and 500 µg/ml 
GaPP for 24 hours in L929 fibroblasts and bronchial epithelial (Nuli-1) cells (results not 
shown). Def has potent anti-adhesive properties - in addition to synergistically potentiating 
the anti-microbial effects of GaPP, Def has dose-dependent effects on fibroblast migration, 
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proliferation and collagen production in vitro (Fig. 8)AU2017900650, discovered here in the 
department of ENT, TQEH
85
.
Def/GaPP, when used in  Chitogel has anti-microbial properties that are significantly more 
effective than commonly used antibiotics. Def and GaPP in Chitogel has a release profile 
over 2 weeks, this was measured using UV-V spectroscopy and HPLC (Figure 8). The gel 
provides a vehicle for the immediate and complete release of Def, with the maximal release 
occurring within 48-72 hours . GaPP had a delayed release profile with a maximal release of 
16% after >72 hours. Combining Def and GaPP did not affect the release of either compound 
from the gel. 
A comparison of anti-microbial effects of the Def-GaPP-Chitogel to the potent antibiotic 
Ciprofloxacin (Cip) and Chitogel control against different microbial biofilms (MSSA, 
MRSA, MDR P. aeruginosa and E. Coli clinical isolates and reference strains) was done. 
Whilst the sensitivity to different dosages and combinations of the compounds differed, all 
microbes tested showed a significant reduction in viability when treated with Def-GaPP-
Chitogel compared to Cip-Chitogel and control Chitogel  
In vitro data of Def-GaPP being nontoxic was studied by Richter, K. et al.  wherein, 
cytotoxicity studies were performed on cell cultures by measuring LDH 
96
. Def (20 mM) as a 
single treatment was tested on L929 and Nuli-1 cell lines. No statistically significant 
difference was observed between treatments and controls. Similarly, single treatment with 
GaPP had no significant effect on either cell lines at concentrations ranging from 100 to 400 
μg/mall Only 500 μg/mL GaPP induced cell toxicity on both cell lines. Consecutive, dual 
treatment L929 cells were not sensitive to any of the tested concentrations in consecutive 
35 
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treatments with 2 hours Def and 2 hours GaPP. In the Nuli-1 cell line, treatment with Def and 




Chitogel acts a good carrier for Def-GaPP with studies indicating that all Def was released 
from the gel within 48 to 72 h, while the release of GaPP gradually increased over time, 
reaching approximately 20% to 25% after 460 h within the medium. These release profiles 
were independent of drug concentrations in the gels (Def, 20 mM; GaPP, 100 [GaPP 100] 
and 500 g/ml [GaPP 500]). Interestingly, there was no statistical difference between the 
release of individual compounds and the release of the corresponding compounds from the 
combination gel. 
Determination of drug release kinetics: 5 ml of Def-GaPP gel was prepared in a falcon 
tube(Fig 8a) and 10 ml of release medium (phosphate-buffered saline) was added(Fig 8b). 
This was incubated at 37°C on a rotating platform (70 rpm) for 20 days. Aliquots of 0.5 ml 
were taken at specific time points (0.5, 1, 2, 8, 16, 24, 48, 72, 96, 120, 170, 220, 290, 460 h) 
(Fig 8c) and replaced with fresh release medium. The concentrations of Def and GaPP were 
quantified by UV-visible spectroscopy at 280 nm and 405 nm, respectively, by interpolating 
from a standard curve. 
 Figure 8 a : 5 ml of Chitogel (drug-free gel, Def gel, GaPP gel, Def-
GaPP gel, different concentrations) 
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Figure 8 b:10 ml PBS added 
Figure 8 c: Release over time 
Figure 8: Determination of drug release kinetics 
Safety / Adverse effects and efficacy studies
Def-GaPP-Chitogel is safe and effective in vivo. Preclinical studies were carried out to test 
the in vivo safety and efficacy of the Def-GaPP-Chitogel in a large animal-
sheep
43,77
andinfected wound model of porcine abdomen and sheep sinusitis. Results showed
(1) absence of any toxic effects,
(2) highly significant reduction of Staph aureus biofilms,
(3) reduction in inflammatory cell counts and
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Using an established spinal surgery sheep model (non-infective model), pilot laminectomy 
study on 6 sheep to determine the anti-adhesion properties of the Def-Chitogel compared to 
Chitogel and untreated control were performed. Post-operative recovery and clinical 
examinations of the sheep were uneventful for all sheep over a 3-month period following 
surgery. MRI and histopathology showed absent toxicity and significantly reduced adhesion 
scores of paraspinal muscle fibres to the dura at three months post operatively (mean 
adhesion scores of  93.33% +/- 10.33 for the no-treatment control surgical sites compared to 
86.67% +/- 10.33 for Chitogel compared to 66.67% +/- 10.33 for the Def-Chitogel treated 
sites, P=0.0076, Kruskal-Wallis).No effects were observed in bone or dura healing in any of 
the sheep, indicating Def-Chitogel reduced adhesion formation without negatively affecting 
the healing process of the dura. Together, these results strongly support the hypothesis that 
Chitogel loaded with Deferiprone and Gallium-Protoporphyrin is safe and effective to reduce 
adhesions after endonasal surgery.  
Serum level quantification in animal sinusitis model showed maximum Def concentration 
after one day(Fig 9) and no evidence of GaPP in the serum(Fig 10 A) in comparison to a 
GaPP spiked plasma(10 B).  
Modifying wound healing and PO outcome 
38 
Figure 9: Plasma concentration (µg/ml) ± standard deviation of deferiprone (Def) over 6 
days, n=4. The maximum Def concentration was reached after 1 day (0.85 µg/ml Def) in 
the 4 sheep treated with Def-GaPP 
Figure 10A: Example of a HPLC chromatogram of plasma samples. No gallium-
protoporphyrin 
89
 was detected for any of the 4 sheep treated with Def-GaPP. 
Figure10B. As a comparison: HPLC chromatogram of plasma sample spiked with GaPP (final 
concentration 0.2 µg/ml). 
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Manufacture/Chitogel Preparation: 
The gel consists of 3 parts: chitosan, dextran and a buffer solution. Currently, Def is 
dissolved in the buffer that is used to dissolve the dextran aldehyde before it is mixed with 
Chitosan to form a gel.  This means this is free drug in gel.  
a. To prepare the Chitogel, 300 mg dextran-aldehyde, 10 ml succinyl-chitosan, and 10 ml of
a buffer solution is mixed in situ in the operation theatre. The buffer solution is either drug
free or contains Def-GaPP.
b. Def and GaPP are individually dissolved in buffer, making a Def-buffer solution and a
GaPP-buffer solution. Both of these solutions are able to be mixed with the dextran
powder to create a solution to be mixed with the Chitosan.  Depending on what
combination is required these solutions can make up a Def Chitogel, GaPP Chitogel or a
Def-GaPP Chitogel.
Def is water soluble and dissolves in the buffer over 1 day. GaPP is low water soluble and 
dissolves in the buffer over 3-5 days. Both buffer solutions are stored at room temperature 
because storing in the fridge causes precipitation of the drugs, which decreases their 
antibacterial activity. To prevent drug degradation, stock solutions are also stored in the 
dark. Buffer solutions are used within 2 weeks. 
Stability: The drug concentrations of a Def- and a GaPP-buffer solution (freshly prepared and 
after 3 weeks of storage at room temperature, protected from light) were tested by high 
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performance liquid chromatography (HPLC). No loss of drug was observed and there were 
no degradation products detected. 
Sterility: Once the drugs are dissolved in buffer, the buffer will be filter sterilised in an 
aseptic environment using 0.22-micron sterile filters. Following the sterilisation process, the 
integrity of the filters were confirmed by the Bubble-Point Test (quality control 1). An 
aliquot of each buffer (100 ul) will be streaked out on an agar plate and incubated at 37‘C for 
24 hours to confirm the absence of bacteria (quality control 2). In case of bacterial 
contamination, the buffer was again filter sterilised and tested for bacteria. Sterile Def-buffer 
and GaPP-buffer will be stored at room temperature protected from light and used within 2 
weeks; the unsterile buffer discarded.  
41 
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2 Wound healing in chronic rhinosinusitis 
2.1.1 Definition and Disease Burden 
Chronic rhinosinusitis (CRS) is a disorder characterized by mucosal inflammation of the nose 
and paranasal sinuses lasting at least 12 consecutive weeks. There are four pairs of paranasal 
sinuses which along with the nasal cavity may be affected by CRS
98
. These are pneumatic or 
air-filled extensions of the respiratory part of the nasal cavity, they are lined by 
pseudostratified columnar ciliated (respiratory) epithelium and are named according to the 
bones in which they are located, namely the frontal, ethmoid, sphenoid and maxillary sinuses. 
Multiple extrinsic and intrinsic etiological factors play a role, in combination, to cause 
prolonged symptoms and signs associated with this  condition. The Task Force on 
Rhinosinusitis, established in 1996
99
, passed the first consensus to subclassify rhinosinusitis 
into acute and chronic based on the duration of symptoms:  
1) < 4 weeks – Acute Rhinosinusitis
2) 4-12 weeks – Subacute Rhinosinusitis
3) > 12 weeks – Chronic Rhinosinusitis
The diagnosis of chronic sinusitis is based on the presence of major and minor clinical 
symptoms (Table 4.1) that persists more than 12 weeks along with objective evidence of 
inflammation by endoscopy and/or CT scan found in the sinuses
100
. This is usually associated
with the presence or absence of polyps
98
, hence, further phenotypically classified as CRS
with nasal polyps (CRSwNP) or CRS with absence of nasal polyps (CRSsNP). The European 
position paper on Rhinosinusitis and Nasal polyps 2020
101
 has furthere simplified it and
defined as defined as:presence of two or more symptoms, one of which shouldbe either nasal 
blockage / obstruction / congestion or nasaldischarge (anterior / posterior nasal drip): 1. facial 
pain/pressure; 2. reduction or loss of smell;for ≥12 weeks;with validation by telephone or 
interview. 
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Table 4. 1: Symptoms of sinusitis 
Major Symptoms Minor Symptoms 
Nasal obstruction/blockage Ear pain/pressure/fullness 
Nasal discharge/purulence/ discoloured Headache 
Facial pain/pressure Halitosis 
Facial congestion/fullness Fever (all nonacute) 
Fever (acute rhinosinusitis only) Fatigue 
Nasal discharge / postnasal drainage Dental pain 
Hyposmia/anosmia Cough 
2.1.2 Epidemiology: 
CRS affects 10-20% of the western population
102,103
, causing a significant impact on quality
of life of the individual and significant socio-economic burden on the community.  The 
prevalence of CRS varies according to geographical region and is influenced by the methods 
used for diagnosis. Hence, in the USA is reported to be between 12.5-16%
104
 and  is listed as
the second most common chronic disease after orthopaedic impairments, and is more 
common than ischaemic heart disease and hypertension. In Europe, the prevalence ranges 
from 6.9%-27.9%
103
 and in Korea of 6.95%
105
 . Sinusitis is one of the most common primary
care presentations in Australia, with 1.4 in every 100 general practice outpatient visits 
estimated to be for rhinosinusitis
102
. In 2014-15, 7.1 million Australians were diagnosed to
have a chronic respiratory condition by the National Health Survey (NHS)  which includes a 
host of sinus related illnesses,  2.5 million with Asthma, 4.5 million with allergic rhinitis and 
1.9 million people with chronic sinusitis 
106
.
CRS contributes to a significant amount of healthcare expenditure due to direct costs arising 
from physician visits and medical treatment. Studies have reported that patients diagnosed 
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with CRS undergo an additional 3.5 outpatient visits , requiring  5.5 prescriptions more than 
non-CRS patients, and also suffer excessive financial costs of   $773 +/- 300 per year
107
.The 
actual  economic burden to society is significantly greater when calculated  along with the 
loss of productivity and absenteeism from work for health-related reasons. In the working age 
population, an estimated average loss of 4.8-5.7 days‘ work in a week compared to healthy 
people is due to CRS
107
. CRS also impacts a patient‘s quality of life significantly and 
comparative studies find  lower quality of life scores in CRS patients when compared to 
congestive heart failure, angina, chronic obstructive pulmonary disease or back pain.  
2.1.3 Patho-physiology
Factors contributing towards CRS have been broadly categorized into intrinsic (host related 
factors) and extrinsic (non-host related factors). Intrinsic factors predispose the patients to the 
development of CRS, such as anatomic / structural abnormalities, genetic diseases and 
immune mediated abnormalities. Anatomic variations narrow the sinus drainage pathways in 
the frontal recess and osteomeatal complex and any inflammation in these areas lead to 
complete sinus obstruction, mucus stagnation and bacterial colonization and superinfection 
108
. If associated with underlying genetic disorders such cystic fibrosis
109
 and  primary ciliary
dyskinesia reduce ciliary movement and mucocilary clearance, this further contributes to 
mucus stasis and bacterial colonisation
110
. Non-infectious causes commonly seen associated
with CRS are allergy and gastro-oesophageal reflux disease
111
, although their causative
mechanism remains debated. Other intrinsic factors such as defects in innate immune 
responses and/or the physical barrier can also contribute to the development of CRS when 
exposed to pathogens including microbes
112
.
Modifying wound healing and PO outcome 
44 
 Extrinsic factors such as microbial agents, cigarette smoke and environmental irritants can 
initiate inflammation in CRS. Use of tobacco is one of the common extrinsic factors 
associated with CRS, tobacco smoke on epithelial cells downregulates the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene and thereby contributes to the formation 
of thick mucus, facilitating the growth of bacteria
113
. Studies have reported that tobacco
smoke may enhance biofilm formation
114
. Animal studies have shown that environmental
irritants such as air pollution can also cause structural damage to the ciliated epithelium and 
affect the mucociliary clearance
115
.A recent Canadian study also suggests that certain
pollutants may  predispose to polyp formation
116
.
CRS patientswithmedically and surgicallyrecalcitrantdiseasehavecharacteristicfeatures of 
chronicinflammationwithpersistentinfectionwhich are oftenattributable to thepresence of 
biofilms
117,118
. Biofilms are found in 25-100% of CRS patients
117
, with S. aureus cultured in
approximately 50% of them
118
, common organisms isolated from the adult CRS population
include aerobes such as coagulase negative Staphylococcus(35%), 
Corynebacteriumspp(23%) and Staphylococcus aureus(8%) gram-negative bacteria and 
anaerobic
119
 organisms.They include Prevotella, Fusobacterium, Pepto streptococcus and
Propionibacterium. In children Streptococcus pneumoniae, Haemophilus influenza and 
Moraxella catarrhalis
120
are seenboth in CRS and during episodes of acute exacerbations.
Among the bacterial causes Staphylococcus aureusisthe most common pathogen isolated by 
culture in both CRSwNP and CRSsNP 
121
. Superantigens produced from bacteria such as S.
aureushave been thought to play a pathogenic role in CRS. These antigens bypass antigen 
recognition and promote polyclonal T lymphocyte proliferation with massive release of 
cytokines which is very often seen in the case of polyp production
122
.  Compared to free
floating planktonic bacteria, those living as communities (biofilms)
123
 contained within
extracellular polymeric substances (EPS) have longer survival and propagation rates. Biofilm 
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bacterial communities are complex and coexist with different strains and species. Cryer et al 
in 2004 was the first to provide evidence of biofilms on sinus mucosa
124
. Slow growing
persister bacteria within biofilms resist conventional antimicrobial treatment leading to 
chronicity and disease recalcitrance. 
125
. Psaltis et al found  that biofilms are associated with
recalcitrance of disease especially in the post-operative period after endoscopic sinus 
surgery
126
. The presence of biofilms in CRS  and absence in controls is a common finding in
the literature
127
, however the mechanism(s) by which they trigger and perpetuate
inflammation are still unanswered and warrant further research. 
The role of fungal infections in the pathogenesis of CRS has been debated for decades. They 
are broadly grouped into invasive and non-invasive fungal infections. The fungal hypothesis 
suggests that the presence of fungal elements in CRS activates T cells and eosinophils 
causing inflammation and damage to mucosa 
128
.However, this theory was disproven when
fungal elements were seen in control patients and antifungal treatments were ineffective to 
treat CRS patients
129
. In the absence of clinical improvement with antifungal therapy, the role




Viral infections of the upper respiratory tract play an important role in the etiopathogenesis of 
acute sinusitis rather than in CRS, however, the presence of virus in CRS patients has been 
shown to be associated with worse disease severity
131
, this may be in part due to an abnormal
or exaggerated  immune response reported in CRS patients with viral positivity  
131,132
.
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2.1.4 Management of recalcitrant CRS 
Diagnosis of CRS requires documented presence of two or more symptoms, along with 
objective evidence of inflammation either on endoscopy and/or on CT scan. Patient 
symptoms are documented on a widely accepted validated questionnaires such as Sino-Nasal 
Outcome Test 22  (SNOT – 22)
98
. This patient-reported outcome measures enables the
physician to assess the severity of disease based on a numerical score and also provides a tool 
to monitor patient response to treatment.  The Adelaide Disease Severity Score (ADSS)  is 
another scoring system  that has been validated against the SNOT 22 and shown to have 
higher correlation with Lund–Mackay CT score and the Lund–Kennedy endoscopy score
133
.
Unlike the SNOT22, this scoring system only assesses the severity of the 5 most common 
rhino logic symptoms. Another instrument used in rhinology to quantify symptom severity is 
the visual analogue scale (VAS)
134
. In this scale, patients graphically represent the severity of
their symptoms on a continuous scale ranging from 1-10. 
The tools used to document objective evidence of CRS are the Lund-Mackay and the Lund-
Kennedy Score (LKS) scores. The Lund-Mackay CT scan staging system grades the 
opacification of the sinuses. Although commonly used it has never been truly validated. It is 
however an easy and a reproducible method to assess treatment response in CRS 
135
.  The
LKS is an endoscopic scoring system that assesses the severity of disease based on the 
presence and severity of secretions, mucosal oedema, scarring and crusting.  The Modified 
LKS system, proposed by Psaltis et al, is a refinement of the LKS, whereby scarring and 
crusting are removed from the scores. This allows the system to be used also for un-operated 
patients and removed the effect that poor surgical technique, often associated with crusting 
and scarring, may have on the score. Psaltis et al found higher intra and inter-rater reliability 
of the MLKS compared to the LKS  and a higher correlation to symptom scores 
136
.
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There are currently (at least) 2 challenges in themanagement of RCRS, these are: 
(1) biofilms that have up to 1000 times the resistance to routine antibiotics when
compared with planktonic bacteria
137
, and are therefore difficult to gain control of
with current antimicrobial therapies and
(2) theanatomy and orientation of theSino nasalcavitiesmakeit a difficult-to-
accessareaforthedelivery of therapeuticagents.
2.1.5 Medical Management 
The Management of CRS has been directed predominantly against microbes that cause 
inflammation and a combination of local and systemic therapies against other causative 
factors of inflammation along with those that bring symptomatic relief.  They could be 
generally classified into: 
1.Local therapy– SalineIrrigation,
SteroidIrrigation,Antibioticirrigation&Antifungalapplication 
2. Systemictherapy – Antibiotics, Steroids, Anti Leukotriene, Anti-Ig E, Immunotherapy (anti
IL-5 Dupilumab) and aspirindesensitization‘s. 
Local Therapy: 
a. Saline: The primary role of saline irrigation is removal of secretions/mucous with
inflammatory substances in the sinuses. High-volume (>100ml) saline irrigations are a well-
accepted and widely used  cost-effective treatment for all forms of CRS. The use of Saline 
along with  antibiotics and/or adjunctive treatment is supported by A-1 evidence and is a 
recommended form of treatment by the comprehensive international consensus statement 
138,139
. Low-volume delivery either by spray topical or nebulization is generally not 
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recommended because it has been shown to be less efficacious
140
. Studies examining
different formulations of saline irrigations have found similar effects with both Isotonic and 




b. Intranasal corticosteroids (INCS): Evidence based Cochrane review of Randomised
controlled trial (RCT‘s)  show an improvement in symptom and endoscopic disease severity 
scores in both CRSsNP and CRSwNP patients. There is a definite  reduction in  the polyp 
size and associated improvement in olfaction 
140
. Various types of INCS are in use such as
beclomethasone propionate, mometasone furoate, fluticasone propionate and budesonide 
which have similar effects
140
. Early concerns of systemic absorption and its impact on the
hypothalamus-pituitary-adrenal axis is now settled with very minimal side effects
142
. Hence ,
this is often used as the first line of therapy. 
c. Saline Irrigation with Corticosteroids:
Topical delivery of gluco-corticosteroids in combination with saline irrigation has gained 
increased popularity amongst clinicians despite its off-label use. RCTs have demonstrated the 
efficacy of controlling the disease with significant improvements in validated symptom and 
endoscopic scores of disease severity, particularly in the post-operative setting
143
.Although
safety studies suggest that steroid irrigations are generally well tolerated with little in the way 
of side effects on hypothalamus-pituitary-adrenal (HPA) axis suppression, a study by Soudry 
et al
144
did show mild but reversible asymptomatic HPA suppression in a small subset of
patients, all of whom were concurrently using inhaled corticosteroids
145
. Early evidence
suggests that high-volume corticosteroid irrigations (i.e., techniques that involve delivering 
>100 mL of solution into the nasal cavity along with budesonide)
146
 irrigations are more
effective than low-volume corticosteroid spray techniques (i.e., meter-dosed spray, atomized, 




,clinical trials are required before a recommendation on optimal
delivery method can be provided. 
d. Saline Irrigation with Antibiotics or Antifungal:
Systematic reviews
147-150
have shown improved short-term symptom score and no difference
in sinus specific quality of life (QOL) with use of  topical antibiotics for CRSsNP.  Bardy et 
al demonstrated this using a high-volume (240 mL divided between 2 nasal cavities) 
mupirocin irrigation compared with placebo in a specific cohort of patients with a sinus 
culture positive for Staphylococcus aureus 
151
.
Use of topical amphotericin B demonstrated no benefit compared with placebo for patients 
without nasal polyps in randomized control trials (RCT‘s)
129
. Rudmik et al
152
 reviewed the
use of topical therapies in CRS and recommended the use of irrigations with saline and nasal 
steroid treatment instead of the use of topical antimicrobials and antifungal treatments. 
Therefore, use of topical antifungals for chronic sinusitis without nasal polyps is not a routine 
practice. 
Systemic Therapy: 
a. Oral corticosteroids:  Steroids as anti-inflammatory agents are now the accepted line of
therapy and is widely accepted
153
. A combination of oral and topical steroid therapy are
followed to reduce polyp size more efficiently
154
. No more than 2–3 courses per year is
suggested to avoid risk of side-effects due to high dose or frequent use
155
. Although high-
level evidence exists supporting oral steroid use in CRSWNP patients, evidence supporting 
their use in CRSsNP is lacking
138
 and therefore they are not routinely recommended in these
patients, except for those of fungal aetiology.  
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b. Antibiotics: CRS remains one of the most common indications for which oral antibiotics
are prescribed, but,  evidence supporting their use in the treatment of CRS remains limited
156
.
A Cochrane review assessing the value of antibiotics for CRS, revealed a limited overall 
benefit  and a transient improvement in QOL was seen in some CRS patients receiving 3 
months of macrolide therapy
157
.
A recent systematic review of published low-dose macrolide studies suggested that this 
antibiotics class may be more beneficial in CRSsNP than CRSwNP patients, with subgroup 
analysis showing more benefit when used for 24 weeks compared to shorter durations. No 
difference between 14-membered and 15-membered ring macrolides was noted
158
 .The effect
of low-dose macrolides is thought to be primarily mediated through their local immune 
modulating/anti-inflammatory properties rather than their antibiotic action
159
. Although
macrolides are generally well tolerated with a favourable side-effect profile, the FDA has 
released a recent warning of the possible increased risk of all-cause mortality over 10 years in 
patients with cardiac disease taking macrolides 
160
 suggesting caution in these patients. Given
the lack of evidence supporting the use of non-macrolide oral antibiotics for CRS and the risk 
of serious adverse effects and emerging issues regarding antibiotic resistance, the use of these 
agents should be justified by endoscopic evidence of an infective exacerbation or 
complication. In such conditions, antibiotic therapy should ideally be culture directed. 
Topical antibiotics may seem to have a better systemic side effect profile than their oral 
counterparts, they are associated with an increased local side effects such as burning, 
bleeding, and nasal dryness and to date, no high-level evidence supports their use for CRS. 
c. Antifungal Therapy: The role of antifungal therapy for CRS in general remains
controversial,  Cochrane review of this topic published in 2018 included eight studies with 
490 adults. Results indicate  a lack of high-level evidence to support the use of oral or topical 




. As a result there are no generally recommended consensus guidelines
for the routine use of these agents in  treatment of CRS
162
. But in case of culture
proveninvasivefungalaetiology, systemic and local therapyisrecommended
163
. The use of
antifungals is being recognized as ineffective in the treatment of CRS, as reported by a meta-
analysis that included six studies (380 participants). The use of topical antifungals was 
investigated in five studies and one study investigated the effect of systemic antifungals. This 
pooled meta-analysis demonstrated that there was no significant benefit of topical or systemic 




Strong pathos-physiological link between nasal polyp and Asthma has led to research in the 
use of biological therapy in CRS 
165
, trials of monoclonal antibodies with FDA approval as
chronic inflammatory conditions are currently under investigation for CRS. Independent 
phase 3 study in CRS patients receiving subcutaneous injections of Omalizumab, an anti-Ig E 
antibody approved for patients with refractory asthma, has shown improvements in polyp 
sizes, nasal and asthma symptoms, there was also improvements in radiological severity 
scores and QOL with 16 and 24 weeks of treatment 
166,167
. These agents act by targeting  the
IL-5 pathway, which is thought to be central for Th2 eosinophilic inflammation associated 
with CRS. Erlizumab and Mepolizumab, humanized monoclonal antibodies approved for the 
treatment of severe asthma, both showed a significant reduction in polyp size in patients 
treated for 4 weeks compared to placebo
168,169
.Dupilumab a fully human monoclonal
antibody that inhibits signalling of interleukin (IL)-4 and IL-13, key mediators of type 2 
inflammation. Currently, it is FDA approved for use in atopic dermatitis, asthma and CRS. 
Results from two multicentred, randomized, double-blind, placebo-controlled, parallel-group 
phase 3 trials involving 276 patients showed that adult patients with severe CRS there  was 
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reduced polyp size, sinus opacification and severity of sinus symptoms. The medication was 
generally well tolerated by patients with a few experiencing a slightly high rate of headaches, 
epistaxis, injection site reactions nasopharyngitis, and worsening of nasal polyps and asthma 
than placebo
170
. Biologics hold promise as a means of offering patients personalized




Challenges and current research in Medical Therapy: 
CRS is the most common diagnosis treated with antibiotics
173
, withrepeated use
itseffectiveness has decreasedleading to increasing levels of antibiotic resistance
174
.
Treatment of CRS with antibiotics are reserved only for those patients with evidence of 
bacterial infection manifesting as fever, purulent discharge and pain or pressure
175
. Those
who fail to respond to antibiotic treatment have usually received multiple courses of 
antibiotics before going in for surgery, this includes both systemic antibiotics and topical 
corticosteroids
176
. Increasing treatment cost due to repeated use of antibiotics to the tune of
direct cost of $ 921 USD per patient year and yearly economic cost of $1539 USD per patient 
has been reported by Bhattacharya et al in a cohort of 332 CRS. They also found an average 
2.7 antibiotic course for a duration of 18.3 weeks, over a 12-month period.  
Globally there is a rise in antibiotic resistance and a reduction in the number of novel 
antibiotics in clinical development, new experimental treatments are being developed. Since 
the use of antimicrobials in CRS remains contentious, anti-inflammatory drugs have become 
the mainstay of treatment for CRS. Intranasal corticosteroids remains  effective in both 
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CRSsNP and CRSwNP patients and are recommended based on evidence-based review 
177
.The use of monoclonal antibodies (MAs) as biologic therapies are promising new 
therapies, these target inflammatory signalling molecules to treat inflammation in CRS
178
 .
Drilling et al 
179
 used bacteriophage (phage) for topical application in the treatment of
CRS specifically in drug resistant clinical Isolates in sheep and found improved outcomes in 
comparison to saline. The use of phage as a single dose proved to significantly decrease the 
formation of biofilms of Pseudomonas aeruginosa in vitro
180
, it was shown to be safe and





 PFU/mall. Bacteriophage (phage) therapy as intranasal irrigation with the phage cocktail
AB-SA01 of doses 3  ×  109 plaque-forming units (PFU) for 14 days was proven efficacious
in the treatment of patients with recalcitrant CRS due to S aureus
181
. The challenges in
antibacterial therapy in CRS has led investigators to look into alternative treatments such as  
replacement of abnormal microbiota 
182
, the principle was using healthy commensal bacteria
Staphylococcus epidermidis (SE) in a mouse sinusitis model supporting microbial 
rehabilitation as a promising avenue for the management of CRS.  
The overall outcome of the current medical treatment protocols is limited in CRS; hence they 
require surgical clearance of obstruction to remove diseased mucosa and bony deformities. 
Thereby, post-surgical delivery of anti-inflammatory and anti-microbial drugs to the mucosal 
sinuses deep within crevices could be done to  eradicate biofilms and microbial colonies to 
achieve long term benefit.  
2.1.6 Surgical Management 
Surgical treatment of CRS has come full circle in its primary principle and technique
183
 with
the invention of Microscopes and endoscopes, along with understanding in the physiology of 
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the nasal mucosa based on the work of Messerklinger, a radical shift to the middle meatus as 
the route of approach to remove focused diseased mucosa and  in restoring the drainage of the 
sinuses is the standard of care. Mucosal preservation being the corner stone for the muco-
ciliary clearance of sinus surgery and hence the term Functional endoscopic Sinus Surgery 
184
. 
2.1.7 Indications and aim of ESS 
Surgery as a treatment of CRS is indicted only in those patients in whom maximal medical 
treatment fails or there are anatomical or structural abnormalities that prevent the resolution 
through medical therapy. However, this list of indication has changed with the improvement 
of instruments and surgical technology to include vasomotor rhinitis, Septal deviations, 
turbinate surgeries, polyps in the nares or antrum of sinuses, mucoceles, retention cyst, 
dacrocystic pathology epistaxis that is refractory to routine treatment
185
.
The aim of surgery itself is trifold
186
:
(1) to improve aeration of the sinuses
(2) to reduce the inflammatory burden of disease
(3) to increase the access of  the sinuses
2.1.8 Outcomes of ESS187 
ESS as a treatment of choice for CRS has been effective both with and without polyps and 
has been well evaluated and statistically proven by multiple studies in  treatment of chronic 
rhinosinusitis refractory to medical management
188-192
. A systematic review and meta-
analysis  demonstrates, improvement in patients having reduction in use of antibiotics, oral 
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steroids, inhaler use and improved  asthma controls with decrease in symptoms
193
. Even in




Although surgical treatment brings relief in majority of patients, a proportion of them 
approximately 16% required revision surgery because of pre-existent risk factors or etio-
pathological factors such as  Aspirin exacerbated respiratory disease, allergic fungal sinusitis 
195
or a prior polypectomy  . ESS impacts the patient with a considerable amount of 
humanistic and economic burden which is also part of the outcome in terms of expenditure 
for gaining relief
196
, and this significantly affects their quality of life (QoL)
197
2.1.9 Complications of ESS 
With a rise in the number of surgeries performed each year so are the rising cost of 
complications and undesired outcomes of surgery. Complications after ESS are classified as 
Major and Minor.  
Major Complications 
Major complications include intra-operative injury to orbital contents or orbital haemorrhage 
causing vision loss or  diplopia, skull base penetration causing CSF leak with the associated 
risk of meningitis or injury to major vascular structures including the anterior ethmoid artery 
or carotid artery
198
. Early reports suggest that the risk of major complications  could be as 
high as 1-4%, but recent studies have shown that the rate is in a range of 0.36%-0.46% for 
primary ESS and revision ESS, due to improvements in anatomical knowledge, surgical 
training,  equipment and the use of intra-operative navigation in patients undergoing ESS 
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Minor Complications 
The incidence of these is more common and frequent. Minor complications include bleeding, 
infection and synechiae formation with the later having a reported incidence in the range of 
15-30%. Synechiae and adhesions may lead to  stenosis of the sinus openings that are 
widened during ESS which interfere with normal muco-ciliary transport and mucosal 
function of the sinuses. This among many other factors lead to recurrence of disease and 
treatment resistance. 
2.1.10 Sino-nasal wound healing 
The sino-nasal mucosa is a defensive blanket that spreads from the beginning of the airway in 
the nose and continues into the lungs. It  forms a physical barrier and also warms and 
humidifies the inspired air before it reaches the  lower air way
200
. The epithelium is a pseudo 
stratified layer of columnar cells with and without cilia interspersed with goblet and basal 
cells which produce mucous and maintain the integrity of the barrier. The epithelium is 
supported by a basement membrane situated on the lamina propria, which is formed by 
superficial sero mucinous layer and a deeper vascular layer. Lymphoid tissues consisting of 
plasma cells and lymphocytes are present under this which help in protection at the barrier. 
Sino nasal wound healing has been studied in animal and human models and it has been  an 
established fact that preservation of the basement membrane is critical  for optimal wound 
healing, possibly due to the location of stem cells in this region of the epithelium. 




 are the pioneers in the study of 
sino-nasal healing in rabbit and dog model in the early part of 20th century. In their studies
57 
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they showed that the regenerated epithelium after an injury demonstrated a variety of 
response including  acute and chronic inflammation, ulceration or granulations and fibrosis. 
They observed that the subepithelial tissue was replaced by dense connective tissue in the 
lamina propria devoid of glands. Striping of periosteum lead to new bone formation with 
bone remodelling and polyp formation in the regenerated mucosa
205
. They also observed that 
preservation of the basement membrane enabled regeneration of epithelium within 3 days 
however  damage to this layer resulted in delayed and disorganized wound healing 
206
   with 
long term effects on the mucociliary action. 
Human Model studies: Sino-nasal wound healing has been studied in humans much more 
rigorously since the advent of endoscopes which enable a more magnified view of the 
mucosa,
207,208
 Four overlapping stages of healing have been described post operatively. These 
stages correspond to stage 1  (7-12 days post injury) which is characterized  by blood 
clot/crust covering the wound. Stage 2 (Week 2-4) is typically characterised by granulation 
formation while in Stage 3, oedema sets. It is not until stage 4( usually 12-18 weeks post-
operatively) that  macroscopic normalization is seen.  
Patho-physiology of Adhesion Formation: As described earlier, one of the complications 
of sino-nasal wound healing is adhesion formation. Adhesions result from epithelial and 
fibrin migration along crusts/clots connecting two traumatized surfaces. Studies suggest that 
CRS induces greater expression of TGF-ß
209
, leading to greater fibrosis formation and 
ostial stenosis. 15-30 % of patients undergoing ESS develop adhesions and  this is reported 
to be the commonest complication seen following sinus surgery. Adhesions may lead to 
muco-ciliary dysfunction and may obstruct sinus ostium
210,211
, and have been estimated 
to the
58 
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Adhesions around the ostium causing stenosis are in the order of 59.5% in the frontal ostium 
and 25% in the remaining sinuses
214,215
.
2.1.11 Adjuncts for improved wound healing in CRS 
Minimal mucosal damage and excellent haemostasis are the foundation of FESS and will also 
improve wound healing . These are highly variable and can be affected by  the skills and level 
of experience of the surgeon and the field provided by the anaesthetist. Post-operative 
measures including irrigations and meticulous debridement can also improve wound healing.  
Per operative considerations : 
Nasal Packing: Traditionally a wide variety of packing materials have been used to act as a 
tamponade to minimize post-operative  bleeding. Materials used include ribbon gauze 
impregnated with a lubricant (e.g., Vaseline Ribbon Gauze and Claudin Nasal Ribbon Gauze, 
Lohmann Corp, Hebron, Ky) and antibiotic ointment (e.g., Bismuth IodoformParaffin Pack, 
Evans Medical Ltd, Leatherhead, United Kingdom)
216,217
. Gauze packing although  very 
effecting in obtaining haemostasis confer significant discomfort to the patient when in situ 
but allows significant ingrowth of fibrinous tissue into the gauze which can result in bleeding 
upon its removal. . This itself can predispose to adhesion formation and mucosal dysfunction. 
To address this, absorbent nonadherent biomaterial nasal packings have been developed and 
include Haemostats and Antiadhesive agents of animal and plant origin
218
. Among the 
haemostats used intraoperatively  porcine gelatine and thrombin combination (Surgiflo, 
Ethicon Inc, Somerville, New Jersey); topical anti-fibrinolytics such as epsilon–aminocaproic 
acid (Amicar, Ederle Parenterals Inc, Carolina, Puerto Rico) and tranexamic acid (Cyclopoid, 
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Pfizer, Puurs, Belgium); and hyaluronic acid , Oxidized regenerated cellulose (Surgicel Nu-
knit; Ethicon Inc.), Fibrin glue (Quixil; Omrix Co., Brussels, Belgium), Microporous 
polysaccharide hemosphere (MPH; Medafor Inc., Minneapolis, Minnesota, USA) and 
FloSeal (Baxter International Inc., Deerfield, Illinois, USA) have all been investigated in 
human studies and used for their intraoperative haemostatic properties after ESS. Anti-
adhesive biomaterials such as MeroGel (Medtronic Xomed, Jacksonville, Florida) a 
hyaluronic acid with absorbable starch,Carboxy-methylcellulose (CMC; AthroCare, 
Glenfield, UK) a plant-based biomaterial is all used. Unfortunately, patients still report 
significant discomfort with these packing materials causing varying amount of adhesion 
which is undesirable for good wound healing outcome
29
.
Other complications of Nasal Packing include foreign body granulation, dislodgement, septal 
perforation, aspiration, toxic shock syndrome, obstructive sleep apnoea and even death 
219,220
.
Hence, research for a better nasal packing biomaterial that is least traumatic to the mucosa 
with properties that enhance mucosal healing is much needed.  
Post-Operative Care considerations in wound healing:  
Saline irrigations are commonly used  post-operatively. Irrigations aim to  improve muco-
ciliary clearance, remove  crusts, pus and debris, and thereby  improve mucosal healing.  
Endoscopic cleaning/debridement: Post-operative endoscopic cleaning or debridement is 
removal of dried mucus crusting and clots that can act as bridges for epithelial and fibrin 
migration between traumatized surfaces. Surgeons in general consider this as crucial as the 
surgery itself and when done at right time forms a critical post-operative care for an optimal 
outcome. At present there is  no consensus on the ideal time or frequency  of debridement  




, but it is generally agreed that the first debridement should occur within 10-14
days of  surgery to minimize the chance of adhesion formation 
211,222,223
. An RCT conducted
by Bugten et al 
210,224
 found that there was significant reduction of adhesion formation in
patients undergoing post-operative debridement at day 6 and day 12 in comparison to those 
not debrided. Whereas they also found that debridement increased pain needing more pain 
relief medication and prolonged treatment.  Although, it was found that increased crusting 
caused significantly increased adhesions supporting the theory that uncleared debris along 
with bony fragment forms potentially a bridge for fibrotic activity and  bacterial growth. 
Rudmik and Kennedy et al in their systematic review of level 1 RCT recommended the  use 
of nasal saline irrigation, sinus cavity debridement, and standard topical nasal steroid spray 
early in the postoperative care 
225
. Hence, the current evidence suggests early  post-operative
cleaning, in the first week  and the optimal frequency of subsequent sinus cavity 
debridements was at 12 days ‐ 2 weeks intervals226. During this procedure  epithelial avulsion
is a possibility as described by Kuhnel et al, who found 23% of his patients suffered mucosal 
avulsion if cleaned within 2 wks post operatively 
227
.  But,Kemppainen demonstrated that
patients who received 3 sinus cavity debridement‘s within the first week after ESS had 
reduced nasal discharge scores compared to patients who received a debridement at 1‐week 
after ESS
228
 contrary to the earlier.
Antibiotics: Role of antibiotic in CRS and post-operative wound healing has been 
contentious, and there are no level 1 evidence studies  to suggest routine prophylactic 
antibiotic prescription
229
. Saleh et al 
230
 conducted a meta-analysis of 3 trials demonstrating
that  the routine postoperative antibiotic prophylaxis did not show any statistically significant 
reduction in the incidence of infection, endoscopic scores, and symptoms. Antibiotics not 
only have direct antimicrobial effects that promote wound healing, many antibiotics also have 
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immunomodulatory functions and have been shown to affect ROS (reactive oxygen species) 
production an important signalling molecule in cell migration and wound healing 
231
.Of the
routinely used first line and second line antibiotics in CRS,  Fluroquinolones such as 
Ciprofloxacin exerts anti-inflammatory effects in S. aureus Newman driven nasal 
inflammation 
232
. Doxycycline promotes and hasten wound by means of its 
immunomodulatory and anti‐inflammatory actions 233,
Gouzos et al 
231
, have demonstrated invitro that Amoxicillin/clavulanate, commonly preferred
antibiotic in rhinology for its activity against a majority of common nasal pathogen, does not 
have any effect on wound healing but other commonly used antibiotics such as 
clarithromycin, linezolid, and mupirocin have significant effects on ROS and promotes 
wound healing. 
Anecdotally some surgeons recommend  antibiotics if signs of infection are found during 
surgery or also if culture proven with sensitivity specific antibiotic. Although, some authors 
randomised patients to receive prophylactic antibiotics and found no difference in their 
subjective or objective outcomes after surgery
234
 and others randomised patients to receive




Cortico-steroids: The anti-inflammatory properties of steroids make these medications a 
cornerstone in the management of  CRSwNP. Pundir et al 
236
 in a systematic review and
metanalysis recommend pre-operative use of local and/or systemic corticosteroids in ESS for  
reduction in blood loss, operative time and improved surgical field quality. Systematic review 
of RCT by Rudmik et al 
225
 for early post-operative care,  recommends the use of oral
steroids with caution and to balance the local benefits with systemic side effects of oral 
steroids.  A recent review by Poetker et al strongly recommends a short course of oral 
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corticosteroids for CRSwNP and those secondary  to fungal aetiology post-operatively
237
.
Rudmik et al also review looks at the use of intranasal topical steroid spray after surgery and 
found evidence for use to be level 1b quality and found maximum benefit in CRS patients 
with nasal polyps, by improving intra-operative surgical conditions and also in improving 
post-operative outcomes as it reduced the recurrence rate of polyps significantly
222,223
 . Post-
operative application of steroids in the form of irrigations or sprays have also become routine 
practice. High concentration intranasal dexamethasone application: ophthalmic drops (0.1%), 
prednisolone ophthalmic drops (1%), and ciprofloxacin/dexamethasone otic drops (0.3/0.1%) 
in revision ESS reduced the risk for sinus ostial stenosis and polyp recurrence
238
, this is non-
standard & off‐label use to deliver higher amounts and higher concentrations of topical 
steroid to the sino-nasal mucosa. 
Intranasal Steroid sprays(INS) have become standard of care for their anti-inflammatory 
property and  lengthens the time to recurrence of polyps significantly
225
. Multiple
formulations are in use of which, Mometasone spray group had better healing scores, 
especially in nasal polyp 
239
 and  Fluticasone propionate spray group had better symptoms as
well as  endoscopic scores at 5 years
234
and long-term benefit in reducing oedema and polyps
with good safety profile. A RCT study by Rowe Jones et al has also shown that patients 




Intranasal saline douching using high volume dispensers with steroid solution such as 
budesonide(off-label) have also been used as wound healing adjuncts, topical irrigation 
demonstrated no significant adrenal suppression by Bhalla et al
240
,  and Welch et al
241
demonstrated that twice daily budesonide nasal irrigations (0.5 mg/2 mL in 240 mL saline) 
post-operatively did not alter the serum cortisol or 24‐hour urine cortisol levels. Intranasal 
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drug eluding stents alsoact as spacers have potential benefit but the run a risk of inducing 
inflammation as a foreign material
152
.
All these adjuncts have potential to reduce scaring and thereby avoiding the stenosis of the 
ostium but carry the risk of systemic absorption through the disrupted sino-nasal barrier. 
2.1.12 Research in Nasal Packing: 
Draw backs in the use of removable nasal packing materials have led to ongoing research and 
development of absorbable biomaterials.  
Biomaterials and AdhesionPrevention 
 Animal studies: 
Extensive research has been conducted to study the nature of disease progression and wound 
healing in animal models including the sheep, rabbit and mouse. Sheep models are thought to 
be ideal due to their size, ease to inspect the sinuses using an endoscope and their similar 
nasal mucosa to humans 
74,242
. Multiple studies have been conducted creating a bacterial
sinusitis inoculation by blocking the maxillary sinus ostia with merocele along with 
Bacteroides fragilis
243-249
.Merocele as a biomaterial was studied in a sheep model to look for
rate of re-epithelization, total surface of cilia and the maturity of the cilia in packed sinuses 
Vs non packed
250
 by Mcintosh et al and found no significant changes, this was replicated
using Merogel in a CRS model of sheep and found no significant differences in adhesion or 
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Chitogel as a biomaterial has also  been investigated in a sheep model of CRS by 
Athanasiadis et al
252
, where 20 Sheep infested with nasal bot fly (causing eosinophilic
sinusitis) underwent a standardised mucosal injury. And they were randomised to be treated 
with Chitogel, Spray gel(Polyethylene glycol) and control. The results showed a greater 
advantage in the Chitogel treated group in cilia re-epithelization and re-ciliation and cilia 
grade(p<0.05)
252
. The sheep model was also used to study drug delivery by MeroGel as a
drug delivery, Robinson et al
253
studied the role of Prednisolone loaded MeroGel Vs plain
MeroGel and found no difference. Le et al conducted a RCT in 54 Sheep frontal sinuses to 
study antibiofilm drug combinations namely single mupirocin flush, 12-hourly mupirocin 
flushes for 5 days, Citric Acid Zwitterionic Surfactant (CAZS) via hydrodebrider, gallium 
nitrate, CAZS with gallium nitrate, CAZS with mupirocin, and  saline regular flushes in 
comparison to no treatment as control in a sheep sinus. Biofilm model and Confocal LSM 
evaluation showed regular Mupirocin washes showed significant reduction of biofilms that 
was sustained up to day 8
91
. More recently Chitogel as a drug carrier has been studied in a
Sheep sinusitis model to deliver Deferiprone (an Iron Chelator),  in combination with GaPP 
as an anti-biofilm agent. Preliminary results suggest that CD with Def & GaPP are safe and 
good bio-film elimination profile as compared to no treatment. 
Rabbits have also been used because of their well pneumatised sinus cavities and their similar 




 Human Studies: 
Merocel removable packs have been compared with MeroGel(a hyaluronic acid-based gel 
acts as an extracellular matrix scaffold for wound healing) in a number of studies. A  double 
blinded RCT by Miller et al
255
  found an adhesion rate of 8% in both groups, while  Vaiman
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et al and Pomerantz et al 
256,257
 showed no evidence of adhesion formation. Bugten et al
studied Merocel Vs no packing and found statistically significant adhesion with no packing in 
comparison to Merocel packing
224
. Franklin and Wright compared MeroGel with Non-
absorbable nasal packing and showed a trend towards improved endoscopic score post-
operatively, but this was not consistent at all time points of post op evaluation at 2wks, 1, 3 
and 6 months
258
. Wormald et al
259
 studied the effect of MeroGel on wound healing following
ESS in a single blinded RCT in 42 patients in comparison to no treatment. Post op follow up 
2, 4 & 8 wks showed no significant difference and had an incidence of adhesion of 16.7% 
and 19%  in MeroGel Vs No packing at 8 wks.  
Fibrin glue commercially available as Quixil (Omrix Co., Brussels, Belgium) contains human 
thrombin and fibrinogen in conjunction with amino acids and salts, is another product that 
has been studied by Vaiman et al
256
. They compared Quixil with Merocel prospectively in
158 nonrandomised pts and followed patients up for  1 month. They found no adhesions in 77 
of their Quixil treated patients and only 1 in  the 64 Merocel treated patients. Building on this 
study the authors conducted a randomised, double blinded study in 64 patients where Merocel 
was applied only for 2 days and all the patients were evaluated at 3 months post operatively. 
No adhesion was found in either group of patients, which is comparatively less than  all other 
studies. This is probably due to difference the grading system used by the authors in 
comparison to others. 
Floseal another commercially available fibrin glue was studied by Chandra et al
260
 in a
double blinded RCT in 20 patients in comparison to fibrin soaked Gelfoam. Patients were 
followed at 1 and 6 weeks post operatively. This study showed a significantly higher mean of 
adhesions in the floseal treated sinuses 56%, with increased granulation formation at 21 days 
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post op. Histopathological evaluation of the adhesion showed foreign body in the scar tissue 
suggesting incorporation of the Floseal. Similar results were noted by Shirme et al 
213
 when
they used Floseal to stop bleeding in the middle meatus and compared to the untreated side in 
retrospective analysis of 172 pts, where the incidence of adhesion was statistically higher 
(18.9%) with medialisation of Middle turbinate in comparison to medialisation alone without 
floseal (6.7%). An interesting outcome of this study was the multivariate analysis of 
adhesions in comparison to the various surgical and demographic variables. They found 
incidence of adhesion was significantly higher with the use of Floseal which indirectly 
explains the role of coagulation in adhesion formation which is enhanced by floseal
213
. And
in contrast, Jameson et al found no difference between Flo seal and No treatment in a double-
blinded RCT up to 3 months of follow up.  
Carboxy Methyl cellulose (CMC) is another nasal packing material that has been studied as a 
mesh and gel
261
, Kastl et al published data did not showed any significant difference
clinically on wound healing significantly between the two 
262
.
Gel film- denatured porcine collagen has also been studied in comparison to MeroGel.  In 
Catalano and Roffman‘s
263
 study of  115 pts after a minimally invasive sinus technique
(MIST), Gel film was placed as a stent and followed up to 3 months. They observed a 
significant increase in adhesion in sinuses stented with Gel film compared unstented sinuses . 
Tom et al 
264
 also conducted a RCT comparing Gel film to no treatment with patients acting
as their own controls and results showed no significant difference in adhesion, but there was 
increase granulation tissue formation on the Gel film side. 
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Mitomycin C a topically applied agent derived from Streptomyces cespitosus has also been 
shown to have inhibitory activity over nasal fibroblast by inducing apoptosis.
265
.  Chung et al
studied application of mitomycin on a cotton in the middle meatus compared to saline and 
followed up to 2 months. They observed relatively less adhesions in the mitomycin applied 
side although this did not achieve statistical significance
266
. Anand et al
267
 and Chan et al 
268
found similar out comes in double -blinded RCT conducted in different centres.  
2.1.12.1 Chitogel in CRS 
Chitosan a polysaccharide hydrogel prepared from chitin, a polymer that is found in a large 
number of natural animal and plant sources, has long been known to be an effective 
haemostatic agent and wound healing agent
29
. The potential use of this bio-inert material has




2.1.12.2 Chitogel as a haemostatic agent: 
Valentineet al (2009)
49
 conducted a study in 21 sheep infected with Oestrusovus that
underwent standardised mucosal injuries in the sinuses. They evaluated the bleeding scores at 
Time = 0 (at time of mucosal injury) and every 2 minutes in Chitogel-applied mucosa vs. 
control (nothing) mucosa. It was noticed that Chitogel was a better haemostatic agent at 2, 4 
and 6 minutes after injury. The average time to haemostasis was significantly better in 
Chitogel sides compared to control sides (4.09 vs 6.57 minutes, p=0.049). Furthermore, 
complete haemostasis occurred within 6 minutes for all Chitogel sides, whereas control sides 
were still bleeding at 8 minutes in 3 sheep and 10 minutes in 1 sheep. 
Modifying wound healing and PO outcome 
68 
Valentine et al (2010)
44
 followed on from the sheep study to demonstrate the same outcome
in 40 human subjects undergoing ESS for CRS in which patients served as their own controls. 
Similarly, they scored baseline bleeding (Time = 0) immediately after the sinus operation, 
and every two minutes thereon. In that study, Chitogel achieved haemostasis within a mean 
time of 2 minutes (2-4 minutes) compared to 10 minutes for the control sides. Wound healing 
was also evaluated in the study and will be discussed in the section below. 
2.1.12.3 Chitogel as a wound healing agent: 
Chitogel has been investigated in both animal and human models for its anti-adhesive 
properties. A prospective randomised controlled trial of Chitogel was performed in 20 
sheep
49
. After creating standardised injuries and applying 3 types of haemostatic agents
(Chitogel, SprayGel™ and recombinant tissue factor) compared to control in a randomised 
fashion, sheep were reviewed by a blinded observer monthly for four months. Results of that 
study showed that Chitogel was the only agent significantly superior to control in preventing 
adhesions. Chitogel was shown to reduce adhesions from 56% in the control group compared 
to 5% in the treatment group (p<0.01). Wound healing was determined by light and electron 
microscopy and measurements of ciliary beat frequency. The results of that study showed that 
Chitogel was significantly better (30% improved) than SprayGel™ group (13% improved), 
compared to control (p<0.05). 
In the study mentioned above. Valentine et al (2010)
44
 investigated the haemostatic effect of
Chitogel in 40 humans undergoing surgery for adhesions and other factors of wound healing 
also post-operatively for up to 3 months post-ESS surgery. Following intra-operative 
bleeding evaluation, patients were followed up at 2, 6 weeks and 3 months where their 
adhesions, crusting, mucosal oedema, infection, and granulation tissue were graded. That 
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study indicated that there was a significant reduction in adhesions post-ESS compared to 
control. There was no significant difference in the other parameters. 
Ha et al (2013)
46
 in a prospective, randomised, controlled trial of Chitogel vs. control
(nothing), in human patients, Chitogel on its own was significantly better in terms of reducing 
ostial stenosis post-ESS. The patients were evaluated at 2 weeks, 2 months and 3 months 
post-procedure by endoscopic measurements using a custom-designed ball probe. The results 
of that study showed that the frontal ostia maintained their diameters at 66% vs 31% for 
Chitogel vs controls. Similarly, the sphenoid ostia maintained their diameters at 85% vs 47%, 
and maxillary ostia at 74% vs 54% for Chitogel vs. control respectively (all p≤0.002). 
A follow-on study to these investigated the effect of Chitogel combined with Pulmicort 
Respule® (budesonide, 1 mg/2 mL) in the early post-operative period
45
. The budesonide
solution was used for its anti-inflammatory properties in that study. Again, using patients as 
self-controls, Chitodex+budesonide gel was compared with control (nothing) and steroid-only 
(betamethasone cream). Preliminary results have shown that Chitogel with budesonide is 
superior to both control and steroid-only at improving healing in the early post-operative 
period. In the frontal sinuses, sides treated with Chitodex+budesonide gel maintained 71% of 
their ostial diameter at 12 months, compared to 51% in controls (no treatment). Similar 
results were seen in the sphenoid and maxillary sinuses, but less pronounced. 
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2.1.12.4 Chitogel as an anti-bacterial/anti-biofilm agent: 
Paramasivanet al (2014)
80
 investigated the anti-bacterial and anti-biofilm effects of Chitogel
in an-in vitro study using fibroblasts isolated from human nasal tissue. They set out to 
determine the effects of Chitogel on (1) cell proliferation, (2) wound healing, (3) 
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inflammation in fibroblast cultures challenged with superantigen S, S. aureus enterotoxin B 
(SEB) and toxic shock syndrome toxin (TSST) and (4) S. aureus biofilms. They found that 
Chitogel was highly effective at reducing IL-8 expression after TSST and SEB challenge and 
non-challenged fibroblasts, indicating its anti-inflammatory effects on fibroblasts in the 
diseased state. Chitogel also showed strong anti-biofilm properties at 50% concentration and 
dextran on its own showed anti-biofilm properties at 1.25% concentration. Chitosan on its 
own reduced proliferation of fibroblasts to 82% of control and Chitogel reduced proliferation 
of fibroblasts to 0.04%. Furthermore, Chitogel significantly delayed wound healing rates over 
the first 2 days of wound-healing time. 
In all these trials involving Chitogel as a topical product in human subjects, there have been 
no adverse effects. 
3 Wound Healing in Abdominal Surgery 
Introduction 
Abdominal surgery is performed for various indications both planned or in emergency 
situations via laparotomy over organ systems in the abdominal cavity. The more common are 
the surgeries done for the Gastro-intestinal(GI) system and Gynaecological surgeries 
involving the pelvic or the female reproductive organ system.  Open laparotomy is deemed to 
be the primary cause of abdominal adhesions. An adhesion is a band of scar tissue that binds 
two parts of tissue together when they should remain separate. Adhesions may appear as thin 
sheets of tissue similar to plastic wrap or as thick fibrous bands. This tissue develops when 
the body's repair mechanisms respond to any tissue disturbance, such as surgery, infection, 
trauma, radiation. Tissue adhesions occur after 67% to 93% of abdominal surgeries, 
71 
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developing only hours after the operations
271-273
. The wound healing process is 
physiologically important; but adhesions, forming as part of that process are undesirable 
because they are associated with a reduced quality of life and can cause serious 
complications
271,274
. They form strangle holds over organs and cause chronic pelvic pain, 
infertility, urinary tract problems, sexual dysfunction, and bowel obstruction. Once the 
adhesions form, the risk of suffering from one or more of these associated problems is 
lifelong. 
It has been reported that infections in the abdomen are one of the most potent stimuli for 
adhesion formation
275
, as seen clinically in patients with perforated bowel (such as severe 
appendicitis and diverticulitis) or contaminated operations (faeces leakage)
276
. Such 
infections often cause severe dense adhesions in the abdomen that result in bowel 




3.1.1 Anatomy & Physiology: 
The GI tract wall, except for the oesophagus and distal rectum, consists of 4 layers: mucosa, 
submucosa, muscularis propria, and serosa.  The serosal layer is in contact with the 
peritoneum  a membranous sac that contains the abdominal contents — parietal peritoneum 
and forms folds over the organs in cover – visceral peritoneum . Peritoneum is the most 
extensive serous membrane in the body and its  area is generally equal to that of the skin and 
has 2 layers namely connective tissue and mesothelium
278
.




Figure 11:  A. Depicting the multiple layers of the Intestinal walls, B. Peritoneum – 
electron microscopy depicting mesothelial cells with microvilli, with permission(23) 
The main function of the peritoneum is to form a protective layer that help in the frictionless 
gliding of abdominal viscera and localize infection with the rich lymphoid organs in it and 
provide nutrition through the vasculature that passes through it.  It also helps in storage of fat 
and contains numerous elastic fibres, especially in the deeper layer of the parietal peritoneum. 
The mesothelial cells that form the outer layer of the peritoneum are lined by microvilli in its 
outer surface that help is in the transport of the peritoneal fluid that is present in the 
abdominal cavity. The peritoneal fluid physiologically is present between 5 to 20 ml, it is rich 
in fibrinogen which increases in inflammatory conditions and also contains four types of 
differentiated cells: macrophages, mesothelial cells, Lymphocytes, and polymorphonuclear 
leukocytes. All these play an important role during injury and wound healing. 
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Physiology of Wound healing in Abdomen: 
Mucosal injury of abdominal viscera during surgery is repaired by migration and proliferation 
of epithelial cells, thus sealing the defect and creating a barrier to luminal contents.  Direct 
mucosal apposition is important for this process to occur quickly (as short as 3 days) as 
compared with mucosal eversion or inversion. Submucosa is the most important layer of the 
intestinal wall for surgeons because it provides most of the tensile strength and is the anchor 
for holding anastomotic sutures. The serosa being the outermost layer in the GI tract is made 
of connective tissue and mesothelial cells, blood vessels, and lymphatics. Wound healing on 
the serosal surface of injury is unique. Contrary to epithelial wound healing occurring from 
the wound edges, the injured site is covered by the formation of a sheath of mesothelial cells 
by day 3 closing the defect (by day 5)
279
. The other forms of peritoneal injury is by
contamination of the peritoneal cavity at the time of operation with various materials such as 
glove powder, gauze fluff, suture material, and cellulose derived from disposable gowns and 
drapes. These substances can induce an inflammatory foreign-body reaction with consequent 
formation of granulomas and adhesions or both. Ellis et al reviewed the effect of glove 
powder, especially, because of it being blamed as a common cause
279
.
The term ―adhesion‖ is used in the context of different types of injury. The formation of 
peritoneal adhesions is unique and specific to the peritoneal response to injury. Watters et 
al
280
 in their seminal work in 1969, described the wound healing upon peritoneal injury by
examining adhesions under SEM: on injury a fibrin matrix is rapidly formed within 30 
minutes, and within 2 hours and over the course of the following 7 days fibroblasts and 
different immune cells infiltrate the fibrin plug, effectively forming fibrous bands 
(adhesions)
281
. At 7 days, fibroblasts and collagen form the main part of the adhesion as part
of the proliferative phase and no further adhesions are formed. In the inflammatory stage of 
wound healing the role of the molecular interactions between the Polymorphonuclear cells 
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(PMN‘s), extra cellular matrix and the chemical signalling substances such as TNF and 
interleukins(IL) play a crucial role in the outcome of wound healing
16
. The role of IL-6
cannot be understated in this process
282
, it becomes a critical factor in switching the phase of
wound healing process from being a prolonged inflammatory to the state of proliferation and 
then on leading to fibrosis or adhesion in the abdomen. The adhesions formed in the abdomen 
or pelvic region have a direct and proportional relation to the quantity of IL-6 production
283
.




Remodelling or Fibrinolysis in abdominal adhesion continues over several months, where the 
cellularity of the adhesion is gradually lost and replaced by collagen fibrils. Adhesion 
formation can be exacerbated by pathological processes such as infection and hematoma 
formation resulting in excessive fibroblast migration into the fibrin plug
278
. Optimal
prevention of adhesion formation thus requires intervention during the critical 7-day period 
after surgery. Intra-abdominal contamination is inevitable in abdominal surgery, particularly 
in cases where the lumen of the bowel is penetrated. The main factor contributing to the 
subsequent development of intra-abdominal infection
285
 is the quantity of bacterial
contamination as a consequence of spill of colonic contents during the procedure and/or 





 is a serious clinical problem with a mortality rate between 5 and 50% 
287
and is an
important cause of secondary adhesion formation
288,289
. While surgical techniques and
clinical care management have dramatically improved survival rates of IAIs from a mere 
10% one century ago to on average 75% in the 21
st
 century, the development of new potent
antibiotics is unable to follow the rapidly increasing number of resistant bacteria
287
. An
alarming 30-40% of microbes isolated in the context of IAI post-surgery, are resistant to 
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current antibiotic treatment regimens, severely compromising the therapeutic options 
available for these life-threatening complications
290
.
Post-Operative complications of Adhesion Formation 
Adhesion formation after surgery in the abdomen or the pelvis region is commonly seen in 50 
% to 100% of patients who undergo surgery
24,278
. The type of surgeries that are performed
include general surgical procedures, gynaecological, Urology or Oncology related. Adhesions 
are outcomes of wound healing after surgical trauma, either blunt or sharp, cold steel or heat 
related secondary to use of cautery/laser or post-operative complication such as faecal 
contamination because of dehiscence or secondary infection after an anastomotic leak
291-293
.
Adhesions also form after pelvic inflammatory disease and are a very common clinical 
situation causing infertility, pain, and bowel obstructions
294
. This cannot be confirmed unless
the patient develops complications for which they would undergo a surgery in case of 
intestinal obstruction or relook laparotomy as in conditions where relook laparoscopy is 
necessary to treat  infertility
24,59
.Bowel obstruction caused by adhesions requires major
abdominal surgeries to relieve and has significant impact on healthcare costs.  
3.1.2 Prevalence and consequences: 
Historically intra-abdominal adhesions were described in patients with tuberculosis on post-
mortem
295
, subsequently they were found to be the causative factors in small bowel
obstruction causing severe morbidity and mortality
296
.With modernisation and improvement
in surgical techniques and surgical procedures, the rise of abdominal adhesions have risen 
from a mere 7% in 1932 to 60-70% by 1977
293,297
.  The current advancements in surgery
using minimally invasive techniques and key hole surgeries using laparoscopes has not 
reduced the burden 
298
.
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The presence of intra-abdominal adhesions may remain inconspicuous without any symptoms 
but becomes evident when they present with adhesive small bowel obstruction, volvulus or 
chronic abdominal pain. Surgical and Clinical Adhesions Research (SCAR) Group report by 
Ten Brooke et al 
24
 report approximately 9-15% incidence of small bowel obstruction by any
cause in patients undergoing abdominal surgery in 92 studies  and adhesion seemed to be the 
commonest cause of post-operative small bowel obstruction in 56% of those patients.  In 




Adhesiolysis and bowel resection(s), are the treatment of choice in patients presenting with 
symptoms related to adhesion which itself is riddled with inherent surgical and anaesthetic 
risk. LAPAD (LAParotomy or LAParoscopy and ADhesiolysis) 
300
  reported a high rate
(62.9%) of adhesion releasing procedure being required for patients who were being treated 
for various abdominal surgeries of which 10.5% sustained an in-advertent bowel injury and 
this invariably increased the occurrence of sepsis and intra-abdominal complications, wound 
infections and longer hospital stay and expenditure related to care.  Adhesiolysis has been 
reported to generate complications in 19% of patients with a mortality rate of 8% 
300
; while
secondary bowel resections expose patients to further risks of anastomotic leaks, short bowel 
syndrome and enterocutaneous fistulae
24
.
In Australia the National Emergency Laparotomy Audit 
198301
, highlights that of 562 
emergency laparotomies conducted between a 2 year period in 4 hospitals catering to 550,000 
urban population, the most commonest was for Adhesiolysis (24.7%) and 10.5% of this high 
risk group died during or after care. The cost associated with adhesion- related readmissions 
following lower abdominal surgery in the UK is over £50 million/year (about $AUS 100 
million/year) while the cost for the US health care system is $US 2.3 billion annually 
302
.
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With millions of abdominal surgeries occurring annually worldwide, a product that reduces 
adhesions will significantly benefit the cost and quality of health care globally.  
Challenges in treatment of Adhesion: Despite advancements in detection and treatment, 
adhesions in the abdomen remain common in surgical practice. Perforation of bowel as a 
result of  severe infections (e.g., apendicitis, diverticulitis) orinadvertentbowel injuries result 
in abdominal sepsis and higher likelihood and severity of adhesion formation, and the 
associated complications. 
It has been estimated that the presence of pelvic or abdominal adhesions may prolong 
Subsequent abdomino-pelvic surgeries by an average of 21 minutes
24
, and has been reported
to extendoperating theatre time. Adhesions may also necessitate any sub sequent procedures 
to convert from laparoscopic (minimally invasive) to open and have been associated with 
inadvertententerotomy (surgical operation that creates a permanent opening through the 
abdominal wall into the intestine), resulting in higher complication rate associated with bowel 
perforation. Adhesive small bowel obstruction, in advertent enterotomy at reoperation, 
prolonged operative times, increased clinical workload, and high financial costs are important 
adhesion-related problems that need to be addressed. These complications are serious and 
require substantial further treatment, thereby increasing both the trauma to the patient and the 
cost of the surgery. Current bio-surgical solutions for abdomino-pelvic adhesion formation 
are suboptimal and thus the need for a more effective product remains. Unfortunately, no 
currently available method of treating and preventing adhesions is completely successful, 
particularly for blocking the mechanism of adhesion formation (of which the most potent is 
infection). 
78 
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Current options for adhesion prevention: 
Prevention of adhesion is directly dependent on injury over the peritoneum. This also 
depends on the surgical condition and various factors related around this. Numerous surgical 
techniques and treatment adjuncts have attempted to address the issue of adhesion formation, 
no agent has progressed to widespread clinical use due to lack of clinical efficacy or 
undesirable side effects. 
3.1.3 Surgical techniques to prevent adhesion: 
Since laparotomy was associated with high occurrence of adhesion formation, it was thought 
that minimal access surgery would reduce the same. Unfortunately, the occurrence of 
adhesion has not changed but the intensity probably has. Diamond et al 
59
found that 97% of 
patients who underwent second look surgery were diagnosed to have some form of adhesion. 
Even though it was not known if those adhesions were de-novo or were existing adhesions 
that underwent lysis. Nevertheless, it could be concluded that laparoscopy is less likely to 
cause adhesion de-novo than laparotomy. 
Various surgical techniques have been in practice over the ages, gentle handling of tissues, 
avoiding fresh blood clots left intraperitoneally- hence normal saline / ringer lactate wash 
post-surgery
303
, keeping the serosa wet with Nacl
304
, minimising ischemia being the 
commonly followed steps.  
79 
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3.1.4 Non-surgical Methods to prevent Adhesion 
Two principles have been extensively tested. Firstly, the local application of pharmacological 
agents that interfere with critical events in adhesion formation (18). These strategies have 
seen poor success rates mainly due to the rapid clearance from the abdominal cavity after 
local application 
293
. Secondly, the use of barrier systems to keep injured abdominal contents 
separated during the healing process
305







 and wound dehiscence
308
. 
Devices made of non-absorbable materials may offer longevity but their advantages are offset 
by the potential induction/perpetuation of infection and the threat of migration
307
.
3.1.5 Research in abdominal adhesion prevention: 
\An ideal barrier agent should be a biocompatible substance that is sufficiently flexible to 
conform to the abdominal cavity and able to be used during laparotomy or laparoscopy. It 
should also be able to adhere to the peritoneal surface and remain in-situ for 5 to 7 days after 
the surgery. Moreover, it should prevent thrombin formation and hydrolyse, without leaving 
degraded residue that is pro-inflammatory in nature, persist during the critical re-
mesothelialization phase, stay in place without sutures or staples, remain active in the 
presence of blood and be completely biodegradable.  
There are currently many researched absorbable barriers in the form of solution or 
membranous substance. The Solution based barriers, are the following:  Dextran (Hyskon®) 
solution (Pharmacia, Uppsala, Sweden), Oxidized regenerated cellulose(Interceed®, Ethicon, 
a Johnson and Johnson company, Sommerville, NJ ), Absorbable Adhesion Barrier; Ethicon, 
80 
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and Adept (Shire GmbH and Co. KG) is a 4% icodextrin solution.Among the membranous 
variety are: Expanded polytetrafluoroethylene (Preclude®) - membrane, hyaluronic acid 
(HA) / carboxy methylcellulose (Seprafilm®) – membrane.  
Table5: Various anti-adhesion agents researched 
Fibrinolytic agents 
Thrombokinase, fibrinolysin, streptokinase, urokinase, hyaluronidase, chymotrypsin, 
trypsin, papain and pepsin. 
Tissue plasminogen activators(t-PA) 
309
and recombinant t-PA 
310






Anti-proliferative medications: Paclitaxel 
313
 and Camptothecin 
314
Polypeptides: lysozyme, polylysine, and polyglutamate
315
Anti-coagulants 
Heparin, and Heparin with Amniotic membrane 
316,317









Corticosteroids: dexamethasone, hydrocortisone and prednisolone
322




Systemic antibiotics (cephalosporins or tetracyclines)
17
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Crystalloid solutions: normal saline and Ringer's lactate
278
Viscous solutions: 32% Dextran-70 (Hyskon
®




Carboxymethylcellulose (CMC): high MW polysaccharide gel 
326
Hyaluronic acid (HA): a naturally occurring glycosaminoglycan 
327





HA with iron 0.5% ferric hyaluronate gel: (Lubricoat
®
 , Lifecore Biomedical Inc.
Chaska, MN)
329
Auto-cross-linked hyaluronan solution or gel (ACP-gel)
330




















: is an intra-peritoneal fluid
338
 – FDA approved in 2006 for  general
surgical and Gynaecological use.
(4) Polyethylene glycol-PEG: (SprayGel
®
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(5) Poloxamer 407 (FlowGel
®, 







(7) Fibrin glue: composed of fibrinogen, thrombin, calcium, and factor-VIII
342






 (TC7, Ethicon, a Johnson and Johnson company, Sommerville, NJ
344




Films of polyethylene oxide and carboxymethylcellulose: (Oxiplex
®
, FzioMed, San Luis
Obispo, CA) 
Pluronic F127/F68 alginate–buprofen mixture (Sol–Gel
®





iv) Agents under research
(1) Colchicine
347
(2) Medroxyprogesterone acetate (MPA)
348
(3) Calcium channel blockers
349












(10) Epidermal growth factor (EGF)
355
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Of all these agents that have been researched for the same purpose, the ones that have been 











Oxidized regenerated cellulose (Interceed) is similar to its parent compound, Surgicel 
(Johnson & Johnson Medical, Arlington, TX, USA), this being absorbable material used 
regularly by surgeons to achieve and maintain haemostasis.Interceedis altered form of 
surgical and acts as a physical protective barrier and remains in the abdomen for a longer 
period of time compared to Surgicel by forming gelatinous protective layer  covering the 
damaged peritoneum, limiting its involvement in adhesion formation during the first 10 days 
until natural re-epithelialization. The material can be easily applied at the time of laparoscopy 
and follows the contours of the organs without the necessity for sutures and di-integrates after 
a few days. Limitation of the product is need for adherence to strict protocol for its optimal 
efficacy, removal of all peritoneal fluid, adequate haemostasis and  use of a sufficiently large 
piece with at least 3- to 5-mm margin around the raw area. All these being a difficult to 




Adept, Icodextrin 4%, developed by Baxter Healthcare Corporation (Deerfield, Illinois,418 
USA), is an approved product as barrier in Europe for use in both laparotomy and 
laparoscopy, and in the USA for gynaecologic laparoscopy with Adhesiolysis. It is a non-
viscous, iso-osmotic and clear solution, which can be re-absorbed by the lymphatic system in 
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3-5 days and broken down by serum amylase. But the use has become less favourable
because of the side effects and extravasation
357
.
3.1.5.3 Hyaluronic Acid (HA) 
HA is a polysaccharide and a major component of many body tissues andfluids. Aqueous 
solution of this polymer has a water-like or viscous consistency and is easily applicable in the 
abdominal cavity. It has been found to have increased viscosity by addition of ferric ion 
through chelation to FeHA.   
Intergel (Lifecore Biomedical Inc., Chaska, MN) Adhesion Prevention Solution is FeHA, and 
is used as a single administration (300ml) after surgery in the peritoneal cavity. In both 
animal studies and Phase 1 & 2 Clinical trials, Intergel solution had a significantly lower 
number of de-novo adhesions and reformed adhesions than control patients at second-look 
laparoscopy (p < 0.001). Intergel solution further decreased (p < 0.01) the number of 
adhesions at the primary surgical site in comparison to Ringer lactate or no treatment. But, 
Tang et al
358
 found a high rate of complications in the form of wound dehiscence in patients




,Baxter International Inc. is composed of hyaluronic acid with
carboxymethylcellulose. It turns into a hydrophilic gel 24 h after placement and provides a 
protective coat for traumatized tissue for up to 7 days.Approved by FDA in 1996,it has been 
safe and effective similar to that of Interceed, but it has been found not to be effective 
because of handling issues
359
, dry Seprafilm is brittle and they stick to instruments
360
, and is
not repositionable; and the wet film has poor mechanical integrity and cannot be manipulated 
over the bowel that has been cut open
361
.
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Hence, there is a need for research for anti-adhesive agent that is easy to prepare and apply 
and has the flexibility to be used in both open and laparoscopic surgery.  
3.1.5.5 Chitogel 
Chitosan Dextran (CD) - Chitogel, a surgical hydrogel, has been tested in a variety of 
applications due to its inherent anti-haemostatic, anti-adhesive and wound healing 
properties
44,49,80
. Importantly, whilst it has been found to be effective in preventing the
formation of adhesions after abdominal surgeries
362
, it has never been investigated in an
infected abdomen model. There is an urgent unmet need for the development of new 
treatment regimens that will prevent the formation of adhesions and prevent the development 
of IAI,  and New antimicrobial strategy/compounds are to be found. 
Research studies related to Chitosan: 
Chitogel has inherent haemostatic and anti-adhesive properties and an excellent safety 
profile, in animal and human studies in the sinuses
44,252
. Similarly, a murine and porcine
model were studied using Chitosan as an anti-adhesive agent by Lauder et al
332,362
. In the
murine model, eighty adults male Wistar albino rats were randomized to undergo a 
laparotomy as surgical procedure followed by  caecal abrasion or anastomotic simulation by 
enterotomy of the cecum with primary closure no extra treatment or to receive Chitogel after 
the surgery and a third control group using varying dosages of Dextran alone solution. The 
rats were euthanased and examined at postoperative day 21 and adhesions were graded by an 
investigator blinded to the treatment groups, using a predetermined adhesion measurement 
score. They found a significant reduction of adhesion in the group treated with Chitosan  in 
comparison to the untreated or control both in Laparotomy and abrasion alone, but they had 
86 
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suffered multiple challenges in their experiments. 1. The adhesion created in the controls 
were not consistent, 2. The dextran was being dissolved in sterile water and the dosage of 
Chitosan was not consistent in all the animals treated with, 3. The total volume of gel applied 
in each treated rat was not consistent and 4. There were multiple deaths in the groups, 
especially in the control groups which makes the comparison inconsistent.  
In the porcine model, twenty female domestic pigs were randomized to undergo surgery as  
laparotomy followed by ileocecal resection with ileo-colic anastomosis. Following which 
they left alone or received Chitogel at the time of surgery. At aninitial postoperative 21 days, 
a laparoscopy was performed to grade the adhesions under anaesthesia following which 
Adhesiolysis was then performed and Chitogel applied to all animals. At day 42 animals were 
euthanized and adhesions graded using the previously validated scoring regimen. Researchers 
found the Chitogel treated pig‘s abdomen had reduced adhesions on laparoscopy. 
Subsequent, Adhesiolysis and  application or re-application of Chitogel also decreased 
adhesion. This experiment was something that closely mimicked human surgical conditions 
and the comparison to resection and anastomosis provided an avenue to test the ability of the 
Chitosan to allow normal wound healing to occur and also reduce adhesions without causing 
any wound dehiscence or anastomotic failure. Minor inconsistencies were the dosage, volume  
and the viscosity of the gel applied. Even though there was enterotomy, there was no true 
infection that was created in the abdomen or there was no evaluation of the presence of 
infection that could be present in pathological conditions in human beings
273,363,364
.
3.1.6 Novel Anti – adhesion treatment: 
Deferiprone (Def) is an iron chelator approved for the treatment of thalassaemia major, a 
blood disease that is characterized by the release of high amounts of iron in the blood. 




 is a non-iron analog of haem, the protein that is complexing iron in
the blood and within cells. Our research has shown that GaPP has strong antibacterial 
effects
96
. In addition, it is also seen deferiprone also has strong wound healing effects 
85
and
enhances the antimicrobial effects of GaPP, also after these products are incorporated into the 
Chitogel
365
. Invitro studies showed that the anti-microbial effects of the Def-GaPP-Chitogel
is as potent as antibiotic Ciprofloxacin (Cip) and Chitogel control against different microbial 
biofilms (MSSA, MRSA, MDR P. aeruginosa and E. Coli clinical isolates and reference 
strains)
366
. Chitogel along with Def-GaPP is safe and effective in vivo as seen in a large
animal model sheep infected wound model of sinusitis
97
. Results showed (1) absence of any
toxic effects, (2) highly significant reduction of S. aureus biofilms, (3) reduction in 
inflammatory cell counts and (4) improved wound healing in the Def-GaPP-Chitogel treated 
sheep compared to Chitogel treated control sheep
97
). This was also studied in a spinal surgery
sheep model (non-infective model), Chitogel with Deferiprone alone in different dosages and 
untreated control. Post-operative recovery and clinical examinations of the sheep were 
uneventful for all sheep over a 3-month period following surgery. MRI and histopathology 
showed absent toxicity and significantly reduced adhesion scores of paraspinal muscle fibres 
to the dura at three months post operatively. No effects were observed in bone or dura healing 
in any of the sheep, indicating Def-Chitogel reduced adhesion formation without negatively 
affecting the healing process of the dura
367
.
3.1.7 Animal models for Abdominal Adhesion research: 
There are various models in literature that have been proposed to study the post-surgical 
intra-abdominal adhesion
368
, and are replete with differences. Hence, it is necessary to
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identify an appropriate model that suits the pathology understudy and the demonstrable 
outcome. The desired qualities in  model study the anti-adhesion properties is; 1. Consistent 
ability to create adhesion, 2. Reliability of the adhesion produced to be comparable with 
human pathology  and 3. Reproducible by other investigators
368
.
The animal models researched thus far used  three principles to create adhesion: injury, 
foreign materials, and ischemia. Injury models are the most widely used in 
research
358,369
. Injury models are the most widely routinely used in research, cecum and
uterine horn are the primary targets because intestinal obstruction and infertility are the main 
complications that result due to adhesions. Causing a mechanical or chemical injury to either 
of the target site increases the chance of producing adhesion and there by reliably replicating 
a human pathology to test. Multiple small and large animal models have been in use, among 
them mice or rat is preferred due to its ease of availability and handling with a lower cost
368
.
Along with this choice of adhesion site & stimulus , their size if in a membranous form or 
volume in a solution form also play a major role because of the limited nature of available 
space in small animal models. Hence, for membranous or acidic agent‘s larger animal model 
like a rabbit or dog is preferred to elicit a reaction and response that is appropriate. In small 
animal models such as mice and rats, the abdominal wall is thin in comparison to other and 
also the volume for expansion is limited and will put the animal in distress if applied more 
than recommended. Choice of adhesiogenic stimulus is also important they are classified as  
primary and secondary; mechanical abrasion over the intestine or uterine horn using a 
standard gauze, spring loaded template or electrocautery are the preferred methods
370
. Among
the secondary, chemical agents that initiate a foreign body reaction are used are,  starch, talc, 
nitrogen mustard, formalin, phenol, Tetracycline and cefazolin
371,372
.
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Haemostasis after surgery is a crucial step in wound healing and also adhesion formation, 
fibrin is the framework  on which platelets adheres and thereafter formal maturation into an 
organised tissue and band. Amount of residual bleeding differs in surgical scenario and hence 
the model is required to have a similar situation, where as it is seen that in less than 
"meticulous," situations commercially available-Interceed barrier, does not have an optimal 
effect on adhesion
373
. Infection at the site of the wound is a real-world possibility during
abdominal surgery after resection anastomosis or perforated appendix due to infection. And 
faecal material is a potent adhesiogenic and a challenge for anti-adhesive agent. Recreating 
that in an animal model is possible by either performing a enterotomy or resection 
anastomosis wherein a unknown quantity of faecal material could be split into the cavity to 
mimic the same, and very few studies have addressed this problem
372,374
.
Hence, there is need for designing a small animal model which recreates an abdominal 
adhesion with easily available substance such as kaolin, reliable and able to reproduce an 
infected abdominal wound. More challenging is to find an anti-adhesive agent which has 
haemostatic and antibiotic properties. 
90 
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4 Wound healing in Spine Surgery 
Introduction: 
Back pain either upper cervical or low back region is a bane of modern lifestyle is a leading 
disabling disease globally
375
 in the 21
st
 century. It is one of the top 10 most costly conditions 
to healthcare budgets, accounting for a combined $34.6 billion in lost productivity and 
expenditures annually in the US 
376,377
. Back pain results due to various causes, and they 
could be classified as arising from: Mechanical origin, Trauma/Fracture related, 
Inflammatory / Infective related, tumour or neoplastic caused or due to other systems. Those 
related to the mechanical causes are usually due to disc herniation or those that cause 
compression over the nerve rootlets causing radiculopathy or severe debilitating pain along 
the dermatomes of the nerve being compressed
378
.
Spinal surgery is often considered as a treatment where decompression of neural elements 
provides relief in most cases. However up to 40% of patients suffer significant post-operative 
ongoing pain known as failed back syndrome (FBS)
379
. In the USA, spinal fusion surgery was 
the highest aggregate hospital costs of any procedure (US$12∙8 billion) and in Australia from 
2003 to 2013
380
, the fastest increasing  surgical procedure for spinal stenosis was complex 
fusion, although the surgery provides no added benefit compared with decompression alone, 
it is more costly and associated with greater harms
381
. Based on Australian Bureau of 
Statistics data, FBS occurs in up to 6,660 of the 22,200 patients undergoing spinal surgery 
each year in Australia
382
. Epidural adhesions, formed after surgery, contribute to this pain 
through tension on neural elements in more than 80% of FBS patients with a direct 
relationship between the severity of adhesions and pain scores
383
. The accepted definition of 
FBS as defined by the International Association for the Study of Pain (IASP) is as follows: 
Lumbar (cervical) pain of unknown origin either persisting despite surgical intervention or 
appearing after surgical intervention for spinal (origin) pain originally in the same 
91 




There has been an increasing  trend over recent years to offer surgery as a modality of 
treatment
384
 and consequently we have seen a growing trend in FBSS after laminectomy
385
. 
Numerous strategies have been tested to reduce adhesion formation post spinal surgery, 
however, to date, no therapeutic approaches have been wholly successful and there are no 




Patho-physiology of wound healing in the spinal canal:
Understanding wound healing after spinal surgery is one of the crucial steps in treating the 
condition and to bring pain relief in FBSS. Epidural scar tissue formed in the surgical bed is 
unique in nature, wound repair by  secondary intention is a multi-staged process which has 
been researched since 1948, Key and Ford
388,389
 proposed the ‗annulus fibrosis theory‘  where 
the diseased intervertebral disc was believed to be the source of fibrosis, much later LaRocca 
and Macnab in 1974 proposed the ‗Laminectomy membrane‘ theory wherein he said the 
inner surface of the Sacro spinalis muscle could be the source of fibroblastic activity
27
. The 
current most accepted mechanism of fibrosis is as explained by Songor, Gosh & Spencer in 
1990
390
. They explained it as a ‗three dimensional‖ process and the scar tissue around the 
dura mater originates from Sacro-spinalis behind, the fibrous ring and also posterior 
longitudinal ligament causing hyperplasia of fibrous tissue around the ventrolateral nerve root 
to cause epidural adhesion.  
Normal wound healingis a highlyregulated and coordinatedprocess, innarrowareassuch 
as thespinal canal however, tissueinjuryoftenresults in scar tissue and adhesion formation 
and compression
383
. This adhesion formation can be
exacerbatedbypathologicalprocessessuch as
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infection, inflammation and haematomaformation
391
. Post-operative haematoma formation
may result in excessive fibroblast migration into the clot
391
. It has been demonstrated that the
critical time interval to block adhesion formation is primarily in the first 48 hours after the 
initial injury and the extent of adhesion formation is largely dependent on the inhibition of 
collagen production and of fibroblast proliferation and migration during that time
25
.
Haemostasis and coagulation are the first step in this process, bleeding from bone and 
muscles form clot, a major source of chemokine release such as phospholipase A2, which 
causes the aggregation of macrophagocytes, fibroblasts, mastocytes and endotheliocytes
388
.
Fibroblast proliferation and formation of fibrocytes which secrete collagenous fibres in the 
defect and forms granulation tissue eventually is the second step which could take 2 to 3 
weeks after initial insult. These fibroblastic activity in the extracellular space is regulated by 
various cytokines, such as transforming growth factor (TGF)-b1, interleukin-6 (IL-6) and 
fibroblast growth factor (FGF). Fibroblasts also secret TGF-b1, IL-6 and FGF-2 to improve 
fibroblast proliferation and extracellular matrix synthesis
387
. The third, tissue remodelling
phase lasts months to years; fibrillar connective tissues deposit around the defect lesion and 
transform into scar tissues (Figure 12 ).  
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Figure 12: Illustration of spinal canal woundhealingleading to adhesion formation
387
 
Symptomatology, Diagnosis and Management: 
The symptoms of lower back ache (LBA) and failed back surgery syndrome (FBSS) are due 
to entrapment of the nerve, either by the compression by herniated disc or in the abnormal 
scar that is formed after surgery.  An accurate diagnosis is dependent on a thorough history, 
physical examination, and imaging of which MRI with Gadolinium with T1 is the Gold 
standard
392
. Many factors play a role into the formation of FBSS, they are psychological, bio-
mechanical, surgical  and a combination of these. 
Treatment of FBSS includes a diagnostic nerve block and Physiotherapy as the first line of 
treatment
393
. Pharmacological therapy would be in the form of antiepileptics like Gabapentin
94 
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and Pregabalin for neuropathic pain, Non-steroidal anti-inflammatory drugs – 
Dexamethasone or methylprednisolone and opioids in preventing pain after surgery
394,395
. 
When oral drug therapy does not resolve interventions that are painful like epidural injection 
of anti-inflammatory steroidal therapy is done. 3 commonly used routes are 1. 
Transforaminal, 2. Interlaminar, or 3. Caudal approach
396
, and use of this procedure has 
become increasingly common and abused as well
397
. Surgery becomes the only option when 
none of these interventions resolve the pain and misery that LBA causes to a person and his 
family. 
Current strategies to prevent epidural fibrosis: 
The strategies used are modification of surgical technique, anti-inflammatory drugs and 
barriers placed between epidural space and muscular tissue. 
Figure 13: Illustration depicting the various treatment strategy to prevent spinal 
adhesion, adapted with permission 387 
95 
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4.1.1 Surgical methods: 
Open Lumbar  laminectomy is performed at any level with minor variations, during surgery 
after a posterior paraspinal incision the paraspinal multifidius and longissimus muscles are 
dissected off the spinous processes and held out to the width of the facet joints with the aid of 
retractors. Rongeurs and drill are used to remove the spinous processes and lamina. The 
ligamentum flavum is then exposed and removed, generally with a Kerrison punch. This 
exposes the thecal sac. From here the operation varies depending on pathology. On closing, 
haemostasis is achieved in the field and the paraspinal muscles re-approximated with
sutures. The lumbar fascia is closed, and the extra fascial space obliterated with sutures. The 
skin and subcutaneous tissues are then closed. Patients are then recovered and, generally, 
ambulate as tolerated immediately.  
Minimally invasive techniques were devised to reduce the trauma and bleeding leading to 
subsequent spinal adhesion. Posterior cervical foraminotomy and micro-discectomy was
one such procedure which is safe and effective this is used in the treatment of 
clinically significant foraminal stenosis resulting from lateral disc herniation or 
osteophytes
398
. Initially done through posterior approach was later changed to anteriorly
due to its ease of use and many advantages, but now there is a radicle shift with advent of 
posterior micro-endoscopic foraminotomy (MEF)
398
. Where in the cervical pathology is
visualised directly and the tissue destruction is minimal, muscle and ligamentous attachments 
to the spine are preserved
184
.Wu et al399 in a systemic review and meta-analysis reviewed 26
studies including 2028 patients who underwent Full-EndoscopicPosterior Cervical 
Foraminotomy surgery (FE-PCF) and Micro-endoscopic Foraminotomy (MI-PCF)
reported no significant difference in overall complication rate between the two. Dural tear 
is the most common undesired complication in 
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MI-PCF and transient neural palsy in FE-PCF. Hence, improvement of surgical technique
alone does not prevent adhesion and FBS. 
I II 
A 




Figure 14: Illustrative diagram showing the A. Cervical disc prolapse on an MRI, I - Sagittal 
view and II - Axial view, B. Location of pathology in relation to the lamina of the cervical 
vertebrae posteriorly, C. Placement of endoscope and excision of the compres 
98 
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4.1.2 Anti-inflammatory: 
Prevention of adhesion formation in spine surgery is imperative since epidural scars can 
result in extradural compression, and tension on surgically exposed dura mater and nerve 
roots. This may cause recurrent radicular pain and physical impairment as soon as 6-12 
weeks after surgery
400
. Because scarring is a necessary process of tissue repair, one 
possibility for avoiding post-laminectomy complications is to reduce the density and 
thickness of the scar tissue and limit adhesions to the dura mater and adjacent nerve roots 
without negatively affecting the process of normal wound healing. Administration of topical 
or systemic medications has thus far largely failed to prevent epidural scar tissue formation in 
animal models.  
Table 6:  Various treatment options researched 
Drug/Treatment Action Ref 
Mitomycin C Increases apoptosis of fibroblasts 
401
Dexamethasone Anti-inflammatory and reduces granulations 
402
Hydroxycamptothecine Anti-fibrocytes proliferation 
403
Rosuvastatin Anti- fibrosis via inhibiting the TGF-1β 
404
Radio frequency ablation Ablation` of specific nerve rootlets 
405
 Neuromodulation Spinal cord stimulation decreases pain sensation 
406
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Topical steroids such as dexamethasone  and budesonide are the main anti-inflammatory 
drugs that are used to target multitude of mechanisms faction that work synergistically and 
prevent leukocyte migration to areas of inflammation or injury. Steroids have also been used 
in combination with barrier methods, such as hydrogels. Chen et al
407
 described an  injectable 
hydrogel that was combined with dexamethasone with the aim of preventing epidural 
adhesions in rats. This study demonstrated a significant decrease in adhesions with the 
hydrogel barrier but that there was not a reliably significant decrease in adhesions with the 
addition of dexamethasone, nor was this dose dependant. This significant reduction in 
adhesions was only seen in the 2mg/ml dexamethasone concentration cohort. The authors 
attribute this to the possibility that the drug is not uniformly released from the hydrogel. The 
study would also seem to at least partially confirm the theory that, the migration of pro-
inflammatory cells and direct contact of paraspinal tissue with the thecal sac results in 
adhesions and that a physical barrier to this may inhibit adhesion formation. It also provides 
some evidence for the use of anti-inflammatory medications in this barrier but there is 
conflicting evidence regarding dose and the issue of medication release from the barrier 
medium and requires further study. The probable explanation is the issue of  mixing 
lipophilic steroid with a hydrophilic hydrogel and hence a delayed release.  
4.1.3 Barrier method: 
Barriers are  the most commonly used method, and they are preferred  due to the ease of use 
and better outcome; What makes an Ideal Barrier? An ideal barrier or scaffolding material 
should be one that could fill in the space created after surgery, bio-compatible and bio-
degradable after a set time. Autologous fat has been used as a spacer clinically for long time 
with limited long-term benefit, hence natural polymers and synthetic polymers have been 




. Combination barriers are scaffolds incorporated with drugs that could give an
added benefit. The polymers that have been studied as biomaterials in the last decade are 




 and silk-polyethylene glycol
388,412
.
Most of these studies were designed to implant a synthetic or organic material into the 
laminectomy site as a barrier between the exposed dura mater and surrounding muscles - 
Silastic, Dacron, methacrylate, bone graft, synthetic membranes and foams, free and pedicle 
fat grafts, and steroid agents have been used
387
. There is, however, no consensus amongst
spine surgeons as to the best and most effective option. Recently, surgical hydrogels have 
been developed and specifically marketed for the use to improve the clinical outcomes and 
prevent adhesions after spine surgery. With over 400,000 patients treated, FzioMed‘s surgical 







, is offered after spine surgery. It is proposed to serve as a protective physical
barrier and is specifically marketed for reducing pain, lower extremity weakness, and the 
incidence, extent, and severity of postoperative adhesions after laminectomy
377,413
. Clinical
trials have shown that coating the surgical site with Oxiplex improves clinical outcomes after 
spine surgery. However, due to efficacy data being discrete compared to control, only a 
confirmatory study approval has been granted to date despite FzioMed‘s repeated filings and 




Chitosan-Dextran (Chitogel) comprises succinyl-chitosan extracted from crustaceans and 
dextran-aldehyde has efficacious haemostatic ability
415
 and anti-adhesive properties
252
.
Chitogelmay help to prevent scar tissue formation after laminectomy in human because of its 
haemostatic and wound healing properties and an excellent safety profile. Chitogel efficiently 
addresses haemostasis as well as adhesion prevention in sinus surgery; the first in its class to 
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do so. Chitogelhas recently been FDA approved as a type III medical device in ENT surgery 
indications. Both in vitro studies and in vivo animal and human randomised trials have shown 
that Chitogel achieves haemostasis significantly quicker than control 
44,49
, and reduces the
incidence of post-surgical adhesions in endoscopic sinus surgery (ESS)
44,252
. Chitogel has
also been tested in a burr hole neurosurgical sheep model and in a sheep laminectomy model 
confirming the excellent safety profile and haemostatic properties of Chitogel when applied 
to brain tissue 
416
 and its capacity to reduce adhesions after laminectomy 
417
.
4.1.3.2 Deferiprone (Def) 
Def is an iron-chelator, capable of chelating free iron at the ratio 3:1. Def has anti-microbial 
properties by capturing iron from the environment around bacteria, causing a depletion of 
iron as a nutrient source 
418
. Mohammadpour et al haveshownthatDef can accelerate skin
closureaftertopicalDefapplication in vivo
14
. As specified by the FDA, the recommended dose
for use for the treatment of Thalassemia Major is75 mg/kg/day (up to 100 mg/kg/day). The 
long-term use of Defisassociatedwith (reversible) agranulocytosis in 1–2% of patientsand 




The theoretical framework for the use of deferiprone to prevent adhesions stems from its 
ability to inhibit free-radical formation. Hydroxyl radicals are liberated by free iron in vivo
470, 
471
. These hydroxyl radicals are toxic to tissues. Experimental induction of free radical 
damage to hepatocytes by exposure to hydrogen peroxide has been shown to be reduced by 
concurrent exposure of deferiprone 1mmol/L
472
. It has also been shown toprevent the
oxidative damage from low density lipoprotein oxidation to blood vessels in rats and protect 
against reperfusion injury in rat hearts
473
, possibly through the inhibition of free-radical
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formation, however human trials of these agents have no efficacy in the prevention or 
treatment of coronary heart disease
474, 475
.
Def has potent anti-inflammatory and anti-adhesive properties. Our in vitro assays have 
demonstrated that Def has potent dose-dependent effects on fibroblast migration and collagen 
production and efficiently blocks immune cytokine production in vitro.  
Sheep model for experimental epidural fibrosis post-lumbar laminectomy: 
The sheep model was chosen for our in vivo laminectomy studies because of our extensive 
practical knowledge of using sheep for preclinical studies, demonstrating suitability for in 
vivo spine surgery research 
417,420,421
 and because of the similar size and morphology of sheep
and human spinal columns
422
. To induce adhesions, spinous processes and laminae are
removed exposing the dura at different levels (Fig 5), followed by application of 2 ml 0.5g/ml 
Kaolin in normal saline
423
. Application of kaolin ensures extensive and consistent adhesion
formation and can be assessed using macroscopic and histopathologic examination and 
imaging (MRI) (Jukes et al, manuscript in preparation).  
Figure 15: Illustration of laminectomyonsheep exposing thedura mater (White arrow) and 
MRI sagittal view after treatment (red arrow) 
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5 Summary of Literature review and research question: 
Surgical treatment of CRS, Abdomen and Spine have a common deterrent for a 
complication free out come namely scar tissue or Adhesion.  Currentlyt here are no product 
or method available, which can effectively overcome the challenge along with delivering  
antimicrobial products in the site after surgery. This is proposed to be achieved by the use 
of Chitogel as a vehicle and scaffold for a novel anti-microbial combination 
Deferiprone with Gallium Protoporphyrin. Furthermore, Chitogel has also been 
shown to have antibacterial and pro-wound healing properties in its own right, 
characteristics that may act in synergy is more addition to the expected effects of Def and 
GaPP. 
This knowledge and benefit in surgical outcomes could be transferred to other 
surgical specialities like abdominal surgery and spine surgery. Hence the research questions 
are.
Research Question: 
1. Does Chitogel with Deferiprone and Gallium Protoporphyrin have better post-
operative outcomes in Chronic Sinusitis as compared to each of them alone?
2. Could post abdominal surgery adhesion be prevented with Chitogel with Deferiprone
and Gallium Protoporphyrin?
3. Does Deferiprone with Chitogel have anti fibrotic effect on post-operative wound
healing after laminectomy, if so at what dosage?
104 
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6 Chitogel with Def - GaPP in ENT-Endoscopic Sinus Surgery (ESS): 
Summary: Rhinosinusitis (RS) the disorder of the upper airway and sinus cavities is 
characterised by the inflammation of the mucosa lining the nasal cavity and associated sinus 
cavities. Chronic Rhino-Sinusitis (CRS)424 has multiple causative factors, many intrinsic in 
nature like anatomical defects, genetic and immune related abnormalities  and much more 
extrinsic causes such as smoking and pollution that have been implied as cause
425
. Infection 
as an extrinsic causative factor has been proved beyond doubt and has been the main target of 
antibiotic treatment. CRS recalcitrant to treat despite multiple courses of antibiotic therapy 
and surgical management  have been found to be due to Biofilms
126
. Biofilms as described by 
Costerton
426
are a niche of bacterial growth as a sessile community attached to substratum, 
and able to self-regulate growth and expression genetically. Foreman et al
427
, found a strong 
association between bacterial biofilms and sinusitis, Staphylococcus aureus was 
predominantly present in almost 61% of the RCRS patients247.  These patients also 
presented with a higher degree of severity in symptoms and signs428 on examination in 
comparison to those without biofilms.  
Chitogel has been proposed to be used as a wound healing agent in the sinus cavity after an 
extensive animal study
49
, followed by human clinical trial
44
 by Valentine et al. A follow-up 
study was designed and performed by Ha et al, where Chitogel was combined with a topical 
steroid solution (budesonide, Pulmicort®) or applied without steroid (Chitogel control) and 
applied in a similar manner following sinus surgery for similar patients
45
. Preliminary results 
of that study have shown reduced inflammation during the early postoperative period 
(compared to control) and even further improvements in ostial stenosis at 3 and 12 months. A 
previous study done using Mupirocin as a nasal irrigation flush was effective in the clearance 
of S. aureus infection in vivo and in patients with Saureus Chronic Rhinosinusitis
248,429
,
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following this Mupirocin 
429,430
and Budesonide in Chitogel gel showed goodresults in both
antibiotic activity and also wound healing properties with the gel
78
.
Having studied Chitogel as a carrier for targeted delivery of antibiotics, the proposal is  to use 
a novel drug combination discovered in our department to have synergistic antimicrobial 
properties (in-vitro & in-vivo)
96
 Deferiprone, a compound that is TGA-approved for oral use
to treat iron overload conditions such as Thalassemia, and Gallium Protoporphyrin, a haem 
mimetic. The combination of Deferiprone(Def) and gallium-protoporphyrin 
89
 has potent
synergistic anti-microbial properties for different bacteria in planktonic, biofilm and small 
colony variant form including bacteria that are resistant to multiple types of antibiotics
366
.
The combination Def-GaPP treatment is more efficient than first line antibiotic treatments to 
kill these bacteria. Gallium-protoporphyrin
89
 is a compound that targets the bacterial nutrition
by disturbing iron metabolism and eventually destroy it. Richter et al. reported on the in vitro 
activity of Def-GaPP against Staphylococcus aureus biofilms by interfering with bacterial 
iron metabolism. Def and GaPP can be incorporated into Chitogel and are efficiently released 
over a 2-week time period(in sheep studies)
97
. A second in vivo study was aimed to assess the
safety and efficacy of Def-GaPP-Chitogel as a topical treatment against S. aureus biofilms in 
our sheep model of sinusitis. Incorporating this experience will allow to confirm thesafety 
and efficacy of Chitogel in combination with Def and GAPP current standard of care post-
operatively, which is oral antibiotics and nasal saline douching and determine applicability in 
preventing adhesions and reducing post-operative pain and disability in endonasal surgery. 
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6.1.1 Aim and Scope of Study 
The specific aim of this study is 
1. to investigate the safety and efficacy of Chitogel combined with Deferiprone and
Gallium–Protoporphyrin, a novel formulation that acts on persistent infections and
prevents the formation of adhesions.
2. to study the effect of Chitogel with Deferiprone as an anti-fibrotic agent.
The purpose of this study is to further develop a dissolvable dressing (Chitogel) that is 
designed to improve outcomes in patients with chronic rhinosinusitis (CRS). The ultimate 
goal is to develop a product that will encompass all aspects of postoperative care which also 
involves good wound healing and elimination of infection following operation for patients 
with CRS and other surgical specialties. This is proposed to be achieved by the use of 
Chitogel as a vehicle and scaffold for a novel antimicrobial combination Deferiprone with 
Gallium Protoporphyrin 
365
. Furthermore, Chitogel has also been shown to have antibacterial
and pro-wound healing properties in its own, characteristics that may act in synergism or 
addition to the expected effects of Def and GaPP. 
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6.1.2 Chitogel™ improves post-operative wound healing and 
patient outcomes in recalcitrant Sinusitis after ESS: Adding 
Deferiprone and Gallium Protoporphyrin, does it make a 
difference? 
Phase 1 Human Clinical Trial conducted in the Department of Otolaryngology – Head and 
Neck Surgery, The University of Adelaide, Adelaide, Australia  
Financial assistance provided by The University of Adelaide, Commercial Accelerator 
Scheme.  
And supported by The Hospital Research Foundation and The University of Adelaide under 
Australian Government Research Training Program Scholarship 
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Background: Ostial stenosis and persistent inflammation are the main reasons for revision 
endoscopic sinus surgery (ESS). Post-operative (PO) dressings can improve PO wound 
healing and patient outcomes after ESS. This study aimed to determine the safety and 
efficacy of Chitogel, with and without Deferiprone (Def) and Gallium Protoporphyrin 
89
, as a 
promoter of wound healing to improve surgical outcomes.  
Methods: A double-blinded, randomized control human clinical trial was conducted in 
patients undergoing ESS as treatment for CRS. Participants were randomised to receive test 
product Chitogel, Chitogel in combination with Def or Def-GaPP versus no packing 
(control). Patients were followed up at 2-, 6- and 12-weeks PO, outcome scores such as 
SNOT-22, VAS and LKS, pre- and post-surgery (12 weeks) were compared.  
Results: 79 patients completed the study, there was a significant reduction in SNOT-22 score 
and improvement of VAS at 12-week in patients treated with Chitogel compared to control 
(p<0.05). In those patients, the mean ostium area for the Chitogel and the Chitogel + Def + 
GaPP groups were higher across all 3 sinuses compared to the no-treatment control group, 
without statistical significance. Sphenoid sinus ostium was significantly more patent in 
patients treated with Chitogel compared to control at the 12-week time point (p < 0.05). 
 
Conclusion: Chitogel is an excellent post-operative dressing after ESS and results in the best 
patient reported symptom scores and objective measurements. The combination of Def and 
GaPP to Chitogel though proving safe, had no effect on the ostium patency or mucosal 
healing. 
Clinical Trials Repository : 2018-01-28, CT-2017-CTN-04279-1-v1Trial Chitosan-dextran 
(Chitodex) gel with and without Deferiprone and Gallium-Protoporphyrin: wound healing 
(University of Adelaide (Department of Otorhinolaryngology / Head and Neck Surgery) 






Keywords: chronic rhinosinusitis; Chitogel™; absorbable packing; biomaterials; drug-
eluting stents; endoscopic sinus surgery; haemostasis; nasal packing; removable packing; 
rhinology; wound healing. 
 
Level of Evidence: Level 2 
 
Introduction:  
Endoscopic sinus surgery (ESS) is the standard of care for chronic rhinosinusitis (CRS) 
patients who do not respond adequately to appropriate medical therapy 
431-433
. The guiding 
principles of ESS are to improve aeration of the sinuses and to enable delivery of topical 
therapy to the sinuses 
200,434,435
. Surgical outcome depends not only on adequate surgical 
clearance of obstructing cells and disease, but also on the post-operative delivery of 
medication to promote mucosal wound healing 
251,252
.  Success of ESS is determined by 
patency of the sinus ostia, health of nasal mucosa and the absence of repeated infections 
253,436
.  Failure of ESS is usually marked by ostial stenosis, adhesions, repeated infections and 
excessive granulation formation 
214,437
. Adhesions occur in 10 – 30 % of patients undergoing 
ESS
214
; scarring and narrowing of frontal sinus ostia is seen in 60% of these patients leading 
to abnormal drainage patterns and persistent infections making this recurrent sinusitis  
difficult to treat 
215
.  
Traditionally, removable nasal packings were used to improve wound healing and control 
bleeding after surgery, but in recent years they have been replaced by absorbable nasal 
packings 
29,218,438,439
.  Some of these also provide drug delivery to promote wound 
healing
439,440
.  Of all the sinus ostia, the frontal sinus remains the most challenging to keep 
patent and healthy post-operatively. Currently standard middle meatal stents do not reach the 
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mucosa of the frontal ostium or frontal recess but are placed between the middle turbinate 
and the lateral nasal wall.   
Previous studies using Chitogel with and without steroid have shown significant benefit in 
both the preservation of the sinus ostia and improved wound healing
45
. Deferiprone (Def) is
an FDA-approved iron chelator for use in the treatment of iron overload in thalassemia 
patients
81
. It also has anti-bacterial activity, by chelating the iron in the bacteria‘s
environment which is required for metabolism and replication 
365
.  Another feature of Def is





 is a haem analogue.  Haem is the primary source of iron for bacteria in the
human environment. The structure of haem and GaPP is identical except that for GaPP the 
central ion is gallium, rather than iron. The bacteria recognise GaPP as haem, absorb it but 
are unable to metabolize it. The result is a release of reactive oxygen species and starvation 
leading to bacterial death
96
.
The aim of this study was to evaluate whether Chitogel alone or incorporating Def, with and 
without GaPP, was safe and could improve sinus ostium patency and mucosal healing in 
patients after ESS. 
Materials and Methods: 
This prospective, double blinded, randomised controlled trial was approved by the Human 
Research Ethics Committee of the Central Adelaide Local Health Network (32707-
HREC/17/TQEH/245; CALHN: Q20171012) and was conducted from February 2018 to 
December 2019. Patients over 18 years of age undergoing ESS with a diagnosis of CRS 
99
and not allergic to shellfish/drug, pregnant or breastfeeding, without history of hepatitis or 
blood disorders were recruited in the study after informed consent was obtained.  





Study Design: All participants underwent bilateral ESS with meticulous mucosal preserving 
technique using cold steel and powered instruments. Patients were separated into 2 main 
groups based on whether or not a frontal drillout (DO) procedure was planned in addition to 
the ESS. Patients in the full house FESS group (hereafter referred to as the FHF) were 
randomised to receive treatment on one randomised side of the sinuses in the form of 
Chitogel, Chitogel with Def (20 mM) and GaPP (250 µg/ml), Chitogel with Def (20 mM) or 
Chitogel with GaPP (250 µg/ml) and the opposite side was considered as control receiving no 
nasal packing as per Figure 1. Patients in the full house FESS +DO group (here after referred 
to as the drillout (DO) cohort) were stratified by block randomization to ensure equal 
numbers of patients in each of the treatment groups. Randomisation occurred in 4 groups: no 
packing control group, Chitogel, Chitogel with Def (20 mM) and GaPP (250 µg/ml) and 
Chitogel with Def (20 mM) (Figure 1).  
 





Figure 1: Schema of participant randomization (Rand) into FHF and FHF+DO groups (DO) 
for various treatments (10 patients in each group). FHF-Full House FESS; DO = drill-out 
+FHF; Chit = Chitogel; Def=Deferiprone; GaPP= Gallium Protoporphyrin; no Rx Ctl= no 
treatment control; R/L= right/left side.                                  
Statistical power calculations: Power calculations were based on the requirement that effects 
be assessed at the 5% alpha level with 80% statistical power. The outcomes were measured 
based on the wound healing in the sinus openings made during surgery. We determined that a 
clinically meaningful difference between the two closest treatment groups would be a 




 in the frontal ostial size at 12 weeks post-surgery. Based 
on available data, we expected the standard deviation to be approximately ½ the magnitude of 
the mean difference (i.e.: 1.5 mm). According to these values, 10 patients in each of the 
groups are needed to reach statistical significance. In this study, observations over time were 
correlated due to clustering and randomised by GraphPad Quickcalcs software 
(http://www.graphpad.com/quickcalcs/index.cfm). 
 
Details of the Active Compounds: 
Chitogel: Chitosan and dextran aldehyde components were supplied by Chitogel Pty Ltd 
(Dunedin, New Zealand) in sealed containers after sterilized during the production process. 
Deferiprone: (3-hydroxy-1,2-dimethylpyridin-4(1H)-one) was sourced from Sigma-Aldrich 
(St Louis, MO, USA) and used at a final concentration of 20mM in Chitogel.  
Gallium Protoporphyrin IX (Ga-PP IX) was sourced from Frontier Scientific (Logan, UT, 
USA) and used at a final concentration of 250 µg/ml in Chitogel.  
Def and GaPP were dissolved in 0.3% sodium hydrogen phosphate buffer solutions and 40% 
glycerol in sterile conditions. Once dissolved, the solution was filter sterilised in an aseptic 





environment using 0.22 micro syringe filters. Sterile Def and GaPP stock solutions were 
stored at room temperature, protected from light and used within 4 weeks. 
Application of treatment and post-operative care: At the end of the FHF procedure, 20 ml of 
gel (Chitogel or Chitogel + Def or Chitogel + GaPP or Chitogel +Def + GaPP) was instilled 
using the supplied malleable applicator into one side of the patient‘s sinuses selected by 
computer randomization. In the FHF plus drill out (DO) procedure group, patients received 
no treatment (control group) or 40ml Chitogel, Chitogel + Def or Chitogel + Def + GaPP. 
Post-operative care proceeded as per standard protocol for ESS surgery.  
 
Blood tests: Drug safety profilewasevaluated by adverse eventreporting and by testing total 
bloodcellcounts, liverfunctiontests and serumferritinlevels pre-surgery and 2 weeks after 
surgery.  
Follow up protocol and outcome measurements:  
Post-operatively, all participants received an empirical course of antibiotics as this is our 
routine standard of care.  Evaluation of both nasal cavities was performed at 2, 6 and 12 
weeks after surgery.  At review, cleaning of the sinuses and a recording of their endoscopic 
sinus examination was carried out and participants were instructed to perform steroid-saline 
douches daily on each side.  
 
Subjective and objective outcome measurements: Pre and post-operative questionnaire-based 
evaluation was done at 0 and 12 weeks post-operative. This included subjective symptom 
scores using the SNOT-22 score and Visual Analog Scale (VAS) patient reported scores (0-
10) for evaluating the facial pain/discomfort, bleeding, nasal obstruction and nasal secretions 
on both the left and the right side. At each visit, all participants underwent nasal endoscopy 
which was recorded, and these endoscopic videos were graded by blinded independent 





surgeons using the Modified Lund Kennedy Score (LKS)
136
. A consensus ordinal scale score 
was given for crusting, mucosal oedema, infection, granulations and adhesion.  During the 
post-operative visits, on evidence of persistent infection, a culture-directed course of oral 
antibiotic was given.  
Measurement of ostial openings:  Evaluation of ostial dimensions was performed by taking 
measurements from the 3 binary pairs of maxillaries, sphenoid and frontal sinus ostia at the 
end of the surgery just before the application of the gel. The measurements were repeated in 





The results of all variables were collected and compared between treatment groups at 2 time 
points: 0 weeks-intraoperative baseline and 12 weeks post-surgery. These were collated to 
produce a mean value with standard deviation for each post-operative time point. Data for 
SNOT-22, VAS and LKS were analysed using R statistical software (R Foundation for 
Statistical Computing, Vienna, Austria) through the Jupiter notebook interface. The R 
package "MASS" 
442
 was used for ordinal regression. Statistical significance was taken at the 
traditional < 0.05 level. Linear mixed model was used for t-tests Satterthwaite's method 
(longitudinal ANCOVA) and results are averaged over the levels of time factor and Degrees-
of-freedom method Kenward-roger using a Confidence level used: 0.95. P value adjustment 
was done by the Tukey method for comparing a family of 20 estimates was used with 
―treatment‖ defined as Full House FESS group were FHF Control - FHF no Rx Ctl, FHF 
Chitogel alone - FHF Chit, FHF Chitogel plus Def – FHF Chit +Def, FHF Chitogel plus 
GaPP - FHF Chit +GaPP, FHF Chitogel plus Def and GAPP - FHF Chit +Def + GAPP and 
similarly FHF + Drillout Control - DO no Rx Ctl, FHF + Drillout with Chitogel alone - DO 





Chit, FHF + Drillout with Chitogel plus Def - DO Chit +Def and FHF + Drillout  with 
Chitogel plus Def and GaPP - DO Chit + Def +GaPP (Table 1 and 2). Data for ostial 
measurements were collated in mm
2
 for original intra-operative measurements and as 
percentages at weeks-―0‖ intra-operative and 12 weeks Post-operative and analysed using 
Kruskal Wallis for DO and Wilcoxon for FHF group. Graphical representations are displayed 
in Figures 2-6.  
 
Results:  
From a total of 82 patients recruited into this trial, a total of 79 patients (47 male, 32 females, 
aged 18-80 years) completed the trial, of which 40 underwent FHF and 39 FHF with DO, 3 
patients failed to complete the study. Details of patient demographics are shown in 
Supplementary Table 1. The 40 patients in the FHF group were randomized to receive 
treatment on one side with the other side acting as a within patient control.  In the FHF+DO 
group, 39 patients were randomised to receive no treatment (control) or treatment – Chitogel 
only, Chitogel with Def and Chitogel with Def and GaPP.  There were no reported adverse 
events or complications during the trial. 
 
Comparison of patient symptom scores and SNOT 22 in Full House FESS (FHF) + 
Frontal Drill Out (DO) group 
Patients who underwent FHF with DO treated with Chitogel alone had a significant 
improvement in SNOT 22 scores compared to control patients at 12 weeks after surgery  
(p=0.048). A similar trend was observed in the Chitogel with Def group as compared to 
control, but the results were not statistically significant (p=0.13). Patients treated with 
Chitogel with Def and GaPP did not have any significant differences compared to control in 
SNOT 22 scores (p=0.39). Results are detailed in Table 1A and Fig 2. 





Table 1A. Patient SNOT-22 scores (mean and SEM) in each treatment group after FHF 
with Drill Out (FHF with DO) 
FHF with DO, 
treatments received  
Mean 
SNOT-22 Score  











no Rx Ctl 49.7 ± 4.25 38.2 ±5.30 - 
Chit 50.4 ± 4.51 17.1 ± 5.28 0.048 
Chit +Def 50.8 ± 4.25 20.5 ± 4.54 0.13 
Chit + Def + GaPP 50.4 ± 3.68  26.4 ± 5.86 0.39 
 
Table 1B. Patient VAS scores (mean and SEM) in each treatment group after FHF with 
Drill Out (FHF with DO) 
FHF with DO, treatments 
received  
VAS mean at 
Pre-Op 0 weeks  
VAS mean at 
Post-Op 12 
weeks visits 




control Vs treatment 
no Rx Ctl 36.2 ± 3.39 34.1  ± 3.5.3 - 
Chit 31.1 ± 3.45 21.7 ± 3.91 0.026 
Chit + Def 35.2 ± 3.92 31.6 ± 4.24 0.64 
Chit + Def + GaPP 36.2 ± 3.29 34.2± 3.77 0.98 
 





Table 1C. Average percentage of Area of Frontal, Maxillary and Sphenoid Ostium after 
FHF with drill out at 12 weeks post treatment relative to ostium size at time=0 






at 12 wks PO 
Mean 
Maxillary 
ostium area in %
 





at 12 wks PO 
DO no Rx Ctl 74 89 77 
DO Chit 96 100 80 
DO Chit +Def 78 78 42 
DO Chit +Def + GAPP 90 95 82 
 
 





Figure 2, SNOT-22 responses before surgery (0 wks) and 12 weeks after FHF and 
frontal drillout (mean and SEM). WKS-weeks, Def-Deferiprone, GaPP-Gallium 
Protoporphyrin, * p value<0.5 
Patient-reported VAS scores of facial pain/discomfort, bleeding, nasal obstruction, anterior 
and postnasal secretions and sense of smell after FHF with DO improved significantly over 
time across all groups (p<001) and were significantly better in patients that received Chitogel 





Figure 3. VAS responses before surgery and at 12 weeks after FHF with Frontal 
Drillout, WKS-weeks, Def-Deferiprone, GaPP-Gallium Protoporphyrin, * p value<0.5 
 





Comparison of surgeon reported ordinal scale of wound healing in the Full House FESS 
Group :  
Wound healing on both sides after FHF were assessed at each time point and untreated (no 
Rx Ctl) or treated with test product (Chitogel with or without Def and GaPP) was scored by 3 
blinded surgeons (RV, YS, JL) using modified LK scores. Even though Chitogel treated 
sinuses appeared to heal better (Fig 4 & 5), there was no statistically significant difference in 
LKS for any of the test treatment groups when comparing the control untreated side with the 
test treatment side for each of those patient groups. Comparing LK scores between patient 
groups for the test treatment side only was not significantly different between the groups.  
 
Comparison of sinus ostial size in the FHF + Drill out (DO) groups:  
The sinus ostial sizes were measured and compared at time = 0 (immediately after surgery) 
and at weeks 12 after surgery for each of the treatment groups (Fig 4 A & 5). In control 
patients (no treatment group), the mean frontal, maxillary and sphenoid ostium area reduced 
to 74, 89 and 77% of the original area measured at time=0. The mean ostium area for the 
Chitogel (96, 100 and 80% for the frontal, maxillary and sphenoid ostium respectively) as 
well as the Chitogel + Def + GaPP groups (90, 95 and 82% for the frontal, maxillary and 
sphenoid ostium respectively) were higher across all 3 sinuses compared to the no-treatment 
control group, however, those differences did not reach statistical significance (Table 1C ).  
 






Figure 4: Ostium size of Frontal, Maxillary and Sphenoid sinuses at 12 weeks relative to 0 
weeks (immediately after surgery) in patients receiving Full House FESS with Drill Out (A) 
or Full House FESS (B-D). Area of Frontal Ostium after FHF + Drill out (DO) in percentage 
at 12 weeks post treatment relative to ostium size at 0 weeks (A) for patients receiving no 
treatment (no Rx Ctl, blue line), Chitogel (Chit, red line), Chitogel + Def (Chit + Def, green 
line), Chitogel + Def + GaPP (Chit + Def + GaPP, orange line).Frontal (B), Maxillary (C) 
and Sphenoid (D) ostium size at the time of surgery (time= 0 weeks) and 12 weeks after 
surgery in control side and treatment side C. Maxillary Sinus ostium patency at surgery (0 
weeks) and 12 weeks after surgery in control side and treatment side, Wilcoxon normalised to  
ostium size at time zero, , * p<0.05 
  







A. DO no Rx Ctl, Frontal ostium Day 0 
 
 





B. DO no Rx Ctl, Frontal ostium, 




D. DO Chit, Frontal Ostium PO 12 wks 
Figure 5, Endoscopic images of the frontal sinus ostium after FHF + Drill out at week 0 ( 
A&C) and 12 (B &D) with and without Chitogel™,  showing a similar sized ostial opening 
with Chitogel treated sinus (d). * calibrated measuring ball probe, broken line representing 
area of ostium , Day O – immediately after completion of surgery, PO – post operative , 
wks- weeks, FHF + Drillout Control - DO no Rx Ctl, FHF + Drillout with Chitogel alone - 







Comparison of sinus ostial size in the full house FESS (FHF) group:  
The sinus ostial sizes were measured and compared at time = 0 (immediately after surgery) 
and at weeks 12 after surgery for each of the treatment groups and for each of the sides 
(treated or not with test formulation). Normalised to the ostium size at time zero, the frontal 
ostium size in control sides (no treatment) reduced to <89% for all 4 treatment groups. In 
contrast, the mean frontal ostium size for all treatment sides reduced to maximum 96% for 
Chitogel + Def and was >99% for the Chitogel, Chitogel + GaPP and Chitogel + Def + GaPP 
treatment groups (Fig 4B & 6). However, those differences did not reach statistical 
significance. For the maxillary and sphenoid ostia sizes, there seemed to be more variability 
with the Chitogel and Chitogel + Def + GaPP treatment groups having ostia sizes that did not 
reduce at the 12 weeks‘ time point compared to ostia sizes at time zero (Figure 4C). The 
difference between ostium size of control and treatment side reached significance for the 
treatment with Chitogel where the sphenoid ostium size remained 100% compared to the 
ostia size at time zero and was significantly larger than the no-treatment control side at 87% 
(p<0.05)(Fig 4D).  
 
 


















d. FHF no Rx Ctl , L Frontal ostium,  





d. FHF Chit Left Frontal PO 12 weeks 
Figure 6  Endoscopic images of the frontal ostium FHF at week 0 ( a & c) and 12 ( b & d) with 
and without Chitogel™,  showing well retained ostial opening with Chitogel treated sinus (d). * 
calibrated measuring ball probe, broken line representing the area of ostium, Full House FESS 





group -FHF,  FHF Control - FHF no Rx Ctl, FHF Chitogel alone - FHF Chit 
 
Blood tests for safety monitoring:  
 
All blood tests for markers of inflammation, serum ferritin levels and liver enzymes 
performed at 0 hours and 2 weeks post-operative visit were within normal limits and did not 
show any signs of toxicity. 
 
Discussion:  
One of the biggest challenges in sinus surgery is preservation of the sinus ostia such that 
adequate aeriation and drainage of the sinus can occur.  In recent years the importance of 
effective topical therapy delivery in the post-operative period to the sinuses through these 
ostia has also been recognized 
443
. In this study, we confirm the previously described benefits 
of Chitogel on preservation of sinus ostial size during the healing period
46
.  We also show 
that adding Def and GaPP to Chitogel provides little additional benefit to using Chitogel 
alone. However, the safety of utilizing Def and GaPP in the post-operative environment was 
confirmed with no side effects from their use seen. The dose of the Def used in this study was 
higher than the dose used in a recently published paper where lower Def concentrations were 
shown to have higher anti-adhesive properties 
367
. Further studies will need to be performed 
to better evaluate whether an inverse dose response can be seen for Def dosages lower than 
the 20 mM used in the present study. This study also demonstrates improved patient comfort 
and reduced symptom scores in patients who received Chitogel in the post-operative period 
as reflected by improvement in the quality of life and symptom scores (SNOT22 and VAS).  
Previous studies performed with Def and GaPP in combination 
85,96
 have shown synergistic 





antibacterial activity. Given the numerous confounding factors affecting infective status, 
including the presence of raw mucosal surfaces and blood and well as the use of antibiotics 
and corticosteroids before, during and/or after surgery and in view that the primary outcome 
of this study was to evaluate safety and tolerability, whereas antibacterial effects of the 
treatments and Def-GaPP in particular was not comprehensively analysed. A further study 
specifically evaluating this aspect will be needed to determine the effect of Def-GaPP in 
Chitogel to reduce infection rates in the context of CRS and/or after surgery.  
Sinus ostial patency post-surgery is dependent on creating the widest possible ostium with the 
maximal preservation of mucosa as well as limiting inflammation and blood clot within the 
ostium. Blood clot in itself creates inflammation so haemostasis is an important additional 
factor that needs to be addressed on completion of the surgery. One of the benefits of 
Chitogel over standard middle meatal stents is that it is applied into the sinus ostia thereby 
preventing blood clot formation within the ostium.  Chitogel has been shown to have good 
haemostatic properties which help to prevent bleeding and blood clot formation. Furthermore, 
promoting mucosal healing by reducing inflammation and controlling bacterial activity with 
the prevention of fibroblast migration, has been demonstrated for Chitogel 
80,444
 and is 
thought to further improve ostial patency.  The incorporation of Def and GaPP into Chitogel 
was intended to further improve wound healing in view of the known antibacterial, anti-
inflammatory and anti-fibroblast migration properties of Def and GaPP
22,23
. Although both 
these agents were shown to have good safety and tolerability profiles, little additional benefit 
was seen in ostial preservation.  A larger sample size is needed to comprehensively assess 
possible benefits with lower doses used in subsequent studies with good effect (paper under 
review) in terms of preservation of ostial size, mucosal healing and antibacterial effects.  
 





Conclusion: Chitogel was shown to be an effective post-operative nasal dressing with 
improved patient comfort and symptoms after surgery. In addition, it was effective in 
maintaining sinus ostial size during healing.  The addition of both Def and GaPP in the doses 
studied although safe showed no additional benefit. 
 
Supplementary table 1 Patient demography and randomization, M- male, F-female, FHF-




in FHF, Non treatment control in DO, L-left side nasal cavity, R-right side nasal cavity, Pos-
positive and neg-negative 
 
Clinical  
Trial No: Sex Age Surgery Trial Arm Randomization Asthma 
1 M 28 FHF C L neg 
2 M 44 FHF B R pos 
3 M 29 DO C   neg 
4 F 38 FHF A L neg 
5 F 23 FHF A R neg 
6 M 35 FHF A L pos 
7 F 54 DO B   pos 
8 M 58 FHF C R neg 
9 M 79 FHF B R neg 
10 F 48 DO B   pos 
11 F 36 DO C R neg 
12 M 49 FHF C L neg 





13 M 59 DO D   pos 
14 F 67 FHF B L neg 
15 M 23 FHF C R neg 
16 F 66 DO A   pos 
17 M 36 DO A   neg 
18 F 61 FHF C L pos 
19 F 39 FHF B L pos 
20 F 50 FHF C R neg 
21 F 76 FHF B L neg 
22 M 36 DO D   pos 
23 M 52 FHF B R neg 
24 M 78 FHF A R pos 
25 M 59 FHF A R neg 
26 M 39 FHF D L neg 
27 M 36 DO C   pos 
28 M 79 FHF D L neg 
29 F 63 FHF D R neg 
30 M 38 FHF A L neg 
31 M 61 FHF D L   
32 M 55 FHF D R neg 
33 M 30 FHF C L neg 
34 F 80 FHF C L neg 
35 M 50 FHF B R neg 
36 M 60 FHF D R neg 





37 F 33 DO D   neg 
38 M 69 FHF C R neg 
39 M 56 FHF D L neg 
40 F 51 FHF C L neg 
41 F 43 DO C   neg 
42 F 65 FHF D R neg 
43 F 29 DO B   pos 
44 F 68 FHF A L pos 
45 F 51 FHF B R pos 
46 F 55 DO B   pos 
47 M 29 FHF A R pos 
48 F 69 FHF B L pos 
49 F 51 DO D   pos 
50 M 49 DO D   pos 
51 F 49 DO A   pos 
52 M 66 DO B   neg 
53 F 72 FHF A R neg 
54 M 56 FHF A L neg 
55 M 64 DO C   neg 
56 M 56 DO A     
57 M 41 DO D   pos 
58 M 48 DO A   pos 
59 F 47 DO A   pos 
60 M 77 DO D   neg 





61 F 82 FHF D L neg 
62 M 62 FHF D R pos 
63 F 55 DO A   neg 
64 F 52 DO C   pos 
65 M 74 DO C   neg 
66 M 69 FHF B L neg 
67 F 60 DO A     
68 F 25 DO B   pos 
69 F 66 DO B   pos 
70 M 59 DO B   pos 
71 M 61 DO C   neg 
72 M 23 DO D   pos 
73 M 47 DO D   pos 
74 M 51 DO C   neg 
75 M 46 DO A   neg 
76 M 52 DO A   pos 
77 M 60 DO B   pos 
78 M 66 DO C   neg 
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7 Chitogel with Def - GaPP in Abdominal Surgery: 
Summary: Adhesion in the abdominal cavity after surgery is a result of natural process of 
wound healing that is either excessive or abnormal. The unwanted consequences of adhesion 
are Pain, Intestinal obstruction or infertility, with an overall burden of 2.3 billion on health  
expenditure
302
, with immeasurable human suffering and cost. Due to this there has been a
constant effort by surgeons and researchers to innovate surgical techniques and materials that 
could prevent adhesion formation
306
. Wound healing in the abdomen after surgery is unique,
after peritoneal injury there is a rapid fibrin matrix formation within 30 minutes of 
haemostasis, and there is  fibroblast migration within 2 hrs to 1 week
445
. There is a need for
anti-adhesive products or barriers which will be able to regulate the wound healing, of which 
haemostasis is the primary step followed by regulation of fibroblast activity. Associated with 
this is the accentuation of adhesion formation in the presence of infection due to 
contamination of the wound site either due to surgery or post-surgical complication
363
.
Hence, there is search for a product which has excellent anti-adhesive property and potent 
anti-microbial activity. Among many products in use, barrier system is the most effective, 
and there is no universally acceptable product available, which has led to search for an ideal 
barrier system. The team at TQEH have done preliminary experiments and have optimized 
murine and porcine models of abdominal surgery
332,362
 . The ideal volume, composition and
consistency of the Chitogel for intra-abdominal application was determined in these models. 
There is a further need to develop treatment regimens along with this for conditions  such as 
adhesions due to Intra-abdominal infections. One of the challenges in determining the 
usefulness of the anti-adhesive barrier effect is to have an animal model that will be mimic 
the human intra-abdominal condition and also be safely replicable in animals. We propose to 
use Kaolin as an adhesion inducing agent over a surgical gauze indued injury by rubbing over 
the caecum until bleeding. This novel technique is first of its kind and after validation we 





proceeded to use Chitogel with various combination  and concentrations of Deferiprone and 
Gallium Protoporphyrin to determine the safe and effective combination and their dose. 
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7.1.1 A Novel Rat Model to Test Intra-Abdominal Anti-Adhesive Therapy 
Conducted in the Department of Otolaryngology – Head and Neck Surgery  
The University of Adelaide, Adelaide, Australia,  
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Abstract: 
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Background: Adhesion formation after abdominal surgery is considered almost inevitable 
and a major cause of morbidity. Some novel treatments have been proposed however, there is 
a lack of suitable small animal models for pre-clinical evaluation, mainly due to 
inconsistency in adhesion formation in positive control animals. Here, we propose a new rat 
model of abdominal adhesions using Kaolin as adhesion-inducing agent at an optimised 
dosage.  
Materials and Methods. Twenty-five adult (8-10week old) male Wistar albino rats 
underwent midline laparotomy and caecal abrasion and were randomized to receive topical 
applications of normal saline or different concentrations and volumes of a Kaolin-based 
formulation. At day 14 rats were euthanized, and adhesions graded macroscopically by an 
investigator blinded to the treatment groups, using pre-determined adhesion scores and 
microscopically using histopathology.  
Results: Kaolin at 0.005 g/mL caused consistent adhesions without compromising 
rat viability. At higher doses significant morbidity and mortality was observed in the 
animals treated. 
Conclusions: Kaolin induced adhesion in a rat abdominal surgery model is reliable and 
can be safely used to test the efficacy of novel anti-adhesive formulations to prevent 
intra-abdominal adhesions. 
Keywords: Kaolin, abdominal adhesion, animal model, fibrosis, anti-adhesive agent 
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Introduction:  
Scarring or fibrosis is an inevitable manifestation of the wound healing process in the human 
body after surgery resulting in undesirable outcomes. Scarring after abdominal surgery often 
results in the formation of adhesions where scar tissue connects organs with each other, often 
resulting in post-surgical morbidity. Around 7 million open abdominal surgeries occur each 
year in the US and Europe 
446
with adhesions presenting in up to 90% of cases, costing the
health care system $USD 2.3 billion annually 
302
. Postsurgical adhesions are the largest single
cause of intestinal obstruction with a mortality rate of 10% and can cause female infertility 
274,447
. Numerous strategies have been recommended to prevent peritoneal adhesions 
however, none of those are widely adopted due to poor efficacy or risk of adverse events 
305
.
It is essential to have an animal model that could be used to test novel anti-adhesive strategies 
in abdominal surgery or to test substances that could prevent adhesions.  Different models 
have been proposed but a recurring problem is the high variability of adhesions in positive 
control animals and a better animal model is required. Kaolin is known to induce 
inflammation and foreign body reactions and has been used to induce adhesions in animal 
models, especially in pulmonary fibrosis 
448,449
, hepatic fibrosis 
450
, and subarachnoid dural
adhesion clinical models 
451
. This study tested the dose-dependent effects of kaolin to induce
adhesions in a rat colon abrasion model.   
Materials & Methods:  
The University of Adelaide and Central Adelaide Local Health Network/SA Pathology 
Animal Ethics Committees (AEC) approved the study to be conducted at The Queen 
Elizabeth Hospital Experimental Surgical Suite(The University of Adelaide AEC M-2017-
061 and CALHN/SA Pathology AEC 25-17). 
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Animals and materials: 
Male Wistar albino rats were purchased from Laboratory Animal Services   
Medical School (The University of Adelaide, SA, Australia), 8 to 10 weeks old, with an 
average weight between 350-500 grams. Rats were housed 1 week prior to surgery under 
standard laboratory conditions (temperature 21°C ± 2°C, humidity 55% ± 10%, 12:  12-hour 
light-dark-cycle). Rats were housed in groups of 3 per cage and food and water were 
provided in a standard manner. Kaolin (Aluminium silicate Hydroxide,Al2Si2O5(OH)4) was 
purchased from Sigma-Aldrich, St. Louis, Missouri, United States.  
Surgical procedure: 
Surgical procedures were performed by the same surgeons (RSV, CB) and a  
maximum group size of five animals per day was used to ensure close monitoring during the 
immediate post-operative period. Anaesthesia was achieved using a sealed chamber to deliver 
2%-3% Isoflurane after which the animal was positioned supine for surgery and 
anaesthesiamaintained with isoflurane over an open mask. Analgesia was provided 
preoperatively by subcutaneous injection of Buprenorphine (0.05mg/kg) and post-operative 
8hourly for 48hours. The surgery was conducted in aseptic manner and a prophylactic dosage 
of broad-spectrum antibiotic in the form of Amoxicillin Clavulanic acid5 mg/kg (Clavulox
*
Zoetis Australia, Rhodes, NSW, Australia) was also administered via subcutaneous injection. 
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A. Incision B. Identification of Caecum
C. Abrasion with Gauze D. Application of Kaolin.
Figure1: A. Incision over the Rat abdominal wall after preparation, B. Identification of 
Caecum (orange arrow), C. Abrasion over the caecum with gauze till bleeding spots appear, 
D. Application of Kaolin over the abrasion/enterotomy,
Rats then underwent a laparotomy and a colon abrasion
332
 or a colon abrasion with
enterotomy. Briefly, the abdomen was shaved and prepared with alcohol and after drying, a 3 
cm laparotomy was performed to gain access to the abdominal cavity (Fig 1A). In the caecal 
abrasion group, the caecum was delivered (Fig.1B) and kept moist with saline-soaked gauze 
whilst a dry gauze was used to rub the caecum repeatedly until sub-serosal bleeding occurred 
over an area of 1 cm
2
 (Fig. 1C). The caecum was then returned to the abdomen and the
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abdominal wall closed in layers with a 3-0Polyglactin suture. Prior to the placement of the 
final abdominal closure suture, rats were randomized to receive the following treatments: 
(1) 4 mL normal saline, n=5
(2) 4 mL 0.25g/mL mixture of Kaolin/normal saline, n=5
(3) 2 mL 0.1g/mL mixture of Kaolin/normal saline, n=5
(4) 2mL 0.005g/mL mixture of Kaolin/normal saline, n=5
The operation was limited to <20 mins each rat so as to avoid air drying of the organs. 
In a second stage, we used a colon abrasion with enterotomy model (n=5) to simulate a colon 
resection with anastomosis performed at a different site on the caecum to the abrasion. Rats 
underwent a laparotomy as above followed by a caecum incision to create a full thickness 
enterotomy over a length of 1 cm away from the abrasion site. The enterotomy defect was 
then closed with a continuous 4-0 PDS suture (resorbable, monofilament) and the repair leak 
tested with a simple pressure test. 2 ml 0.005g/mL Kaolin in saline was instilled over the 
abrasion (Fig.1D) and sutured site before closure of the abdominal wall. The rats in this 
group were monitored for 3 weeks as part of the larger experiment protocol. 
 Postoperative monitoring 
Post-surgery, the animals were housed individually in separate cages.  Animals were 
monitored postoperatively 8-hourly for the first 48 hours to observe their weight, behaviour, 
physical wellbeing and appearance by using the Clinical Record Sheet, as approved by AEC. 
Distress scores higher than 6 or weight loss greater than 15% required that animals be 
humanely killed.  
Outcome measures: 
The animals were humanely killed on post-operative day 14 and scored based on the presence 
and severity of adhesions using a previously validated adhesion scoring system as in Table 1 
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(36). The score takes into account the number, strength and distribution of adhesions formed. 
Pictures were taken by iPhone8 12mp ƒ/1.8 aperture camera and also evaluated by a blinded 
observer.  
Table 1. Adhesion Scoring Scheme 
Adhesion Scoring Scheme 
Adhesion Scoring Scheme Score Description 
0 No adhesions 
1 Thin filmy adhesions 
2 More than one thin adhesion 
3 Thick adhesion with focal point 
4 Thick adhesion with planar 
attachment 
5 Very thick vascularized 
adhesions or more than one planar 
adhesion 
Histology:  
The caecum, and adhesions between the caecal adventitia and adherent, adjacent  
intestinal serosal surfaces, and between the adventitial aspect of the caecum and the parietal 
peritoneum of the abdominal wall, were collected and immersion-fixed in 10% neutral 
buffered formalin.  These tissues were then paraffin-embedded, cut at 6μm, and stained with 
haematoxylin and eosin (H&E).  Duplicate sections were also stained by the Masson‘s 
trichrome technique to demonstrate collagen deposition in fibrous adhesions. 
Statistical Analysis: All statistics were performed using R statistical software (R Foundation 
for Statistical Computing, Vienna, Austria) through the Jupyter notebook interface. The R 
package "MASS"
442
was used for ordinal regression. The "polr" function from MASS was





used to fit a proportional odds logistic regression model for the ordinal outcome variable (the 
adhesion score as scored by the primary surgeons). A Likelihood ratio test (using the R 
function "anova") was used to compare the model with a null ordinal regression model. The 
means of the ordinal response (interpreted as a numeric value from 1 to the number of 
classes) were calculated and post-hoc pairwise contrasts for each pair of levels of the 
treatment variable were compared using the "emmeans" package. 
442
. Statistical significance 




Control rats receiving colon abrasion and saline and had variableadhesion scores with a mean 
adhesion score of 1(SD1) and 2/5having an adhesion score of 0 (no adhesions) (Figure 2A). 
Four rats died in the treatment groups with high Kaolindoses, 2 in the group treated with Four 
4ml 0.25 g/ml and 2 inthe group receiving 2ml 0.1 g/ml Kaolin (Figures 2B,C). Post-
mortemevaluation showed severe adhesions with complicationsof intestinal obstruction, 
thought to be the likely cause of demise.The remaining rats which lasted the full 14 days 
showed meanadhesiongrades of 4 (SD 0.44) (Figure 3A) and 4.6 (SD 0.6324) (Figure 3B) for 
4ml 0.25 and 2ml 0.1 g/mL respectively.  
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/
a. Saline (Grade 0) b. Kaolin 0.025g/ml (Garde 5)
c. Kaolin 0.1g/ml (Grade 5)
d. Kaolin0.005g/ml ( Grade 3)
Figure 2: a. Post euthanasia Caecum saline treatment showing minimal or no adhesion, b. 
Post euthanasia Caecum Kaolin 0.025g/ml showing Grade 5 adhesion, c. Post euthanasia 
Caecum Kaolin 0.1g/ml treatment showing Grade 5 adhesion, d. Post euthanasia Caecum 
Kaolin 0.005g/ml treatment showing Garde 3 adhesion. 









d. 0.25g/ml Kaolin H&E
//





g. MT stain Kaolin 0.25g/ml
//
h. MT stain Kaolin 0.1g/ml
//
i. MT stain Kaolin
0.005g/ml 
Figure 3: | (A) Macroscopic (A–C) and histopathological (D–I) evaluation of abdominal 
cavity of Rats treated with various concentrations of Kaolin. L, liver.C, caecum; A, adhesion. 
(A) 0.25 g/ml Kaolin causing very thick vascularized adhesions or more than one planar
adhesion (Grade 5), (B) 0.1 g/ml Kaolin causing very thick adhesions with planar adhesion 
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(Grade 4), (C) 0.005 g/ml Kaolin causing thick adhesion with focal point (red arrow) (Grade 
3) (D–I). Histopathology of rat caecum, 4X magnification using Haematoxylin & Eosin
staining (D–F) and Masson‘s Trichrome staining (G–I). 0.25 g/ml Kaolin treatment showing 
thick adhesions and polymorphonuclear cell infiltrates (D) with disorderly and dense collagen 
deposition (G). 0.1 g/ml Kaolin with polymorphonuclear cell infiltrates and foreign body 
reaction (E) and disorderly and dense collagen deposition (H). 0.005 g/ml Kaolin with 
minimal polymorphonuclear cells (F) and orderly and light collagen deposition (I). 
Five rats received 2ml 0.005 g/mL of Kaolin. These rats tolerated the procedure well with no 
significant morbidity or mortality at the end of 14 days recovery period. The resultant 
adhesions were mean grade 3.4 SD 0.54 (Figure 2D). The grade of adhesions was 
significantly greater in the 0.005 g/mL Kaolin treated rats compared to saline treated rats (p < 
0.0001). Similarly, the abrasion with enterotomy group, treated with Kaolin 0.005 g/ml 
showed much thicker and vascularized adhesions consistently over the enterotomy site in 
comparison to the abrasion site. These rats had mean adhesion grade of 4(SD 0.816) and was 
significantly higher than the Kaolin 0.005 g/ml treated abrasion. alone model with adhesion 
grade 3.4(SD0.54) (p < 0.0001). 
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FIGURE 4 | Laparotomy Adhesion score: Bar plot showing different dosages 
of Kaolin induced adhesion against Ordinal scale in Rats undergone laparotomy 
and abrasion. The Normal saline treated Rats had minimal, inconsistent 
adhesion. Rats treated with Kaolin 0.1 g/ml and 0.25 g/ml induced a high 
grade of adhesion. Rats treated with 0.005 g/ml of Kaolin showed a consistent 
grade of adhesion between 
Histopathology: 
Microscopic analysis of the various grades of adhesions formed in the presence of Kaolin 
showed classical foreign body (FB) reaction with granular activity at the epicentre of 
inflammation (Supplementary Figure 1-I) which was not seen in the saline treated caecum. 
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I. II. III. 
IV. V .  VI. 
VII. VIII. IX. 
Supplementary Figure 1 | Illustrates the temporal development of adhesion.(I) Formation of 
an active adhesion projecting from the caecal adventitial surface and comprised of 
fibrovascular granulation tissue and collagen deposition (arrow)H&E. (II) Higher power view 
of a similar adhesion to that shown in this figure. There is robust fibrovascular proliferation 
and invading macrophages containing phagocytosed administered exogenous material 
(arrow) H&E. (III) An early adhesion showing active fibroblastic proliferation, with loosely 















More mature adhesions showing abundant collagen deposition. H&E. (V) Adhesion 
projecting from the abdominal wall (abdominal wall) H&E. (VI,VII) Adhesion composed of 
numerous bundles of collagenous connective tissue, admixed with invading macrophages 
(arrows). Masson‘s trichrome. (VIII) Well-developed fibrous adhesion between two loops of 
bowel. Masson‘s trichrome (A in box Adhesion, C-caecal serosa wall). (IX) Diffuse adhesion 
projecting from the caecal serosa wall. 
 
The FB reaction was in the form of numerous invading macrophages(Supplementary Figure 
1III), which contained phagocytosed kaolin, with active fibrovascular granulation tissue 
formation with numerous proliferating fibroblasts and supportive micro 
vessels(Supplementary Figure 1II). There were mature adhesions with abundant compact 
collagen and fewer fibroblasts in the 0.1 and 0.25 g/ml kaolin treated rats. The presence of 
adhesions was predominantly confined to the abrasion site and one rat to the abdominal wall 
at the suture site (Supplementary Figure 1V). Masson‘s trichrome stain (MT stain) 
demonstrated a clear pattern of adhesion formation due to fibroblastic activity at various 
stages(Supplementary Figures 1VI–IX). The adhesions from threats that were treated with 
higher concentrations of Kaolin(0.25 and 0.1 g/ml) showed a very irregular pattern of 
collagen distribution (Supplementary Figure 1VI) compared to the uniform nature in the 
lower dosage group of Kaolin 0.005 g/ml(Supplementary Figure 1IX). 
 
Discussion:  
This study showed that Kaolin at low dosage of 0.005g/ml induced thick peritoneal adhesions 
in the abdominal cavity, consistent and non-lethal in a rat colon abrasion and colon 
enterotomy model. This model produced consistent moderate to severe grade adhesions with 
a uniform distribution of collagen fibres on microscopic examination.  
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Creating an animal model for abdominal adhesions with consistent, reliable and  
reproducible findings for the positive control is a challenge. Unlike humans, where adhesions 
are almost inevitable after abdominal surgery, in the rat model, no or only low-grade 
adhesions are commonly found after laparotomy alone. Also, in this study, no or limited 
adhesions were found in the saline control animals. Several types of animal models have been 
used, small (mice, rat and rabbit) and large (sheep, pig, monkey and horse)
368
. Models do
stimulate adhesion-formation in different ways, including colon and side wall abrasion, 
crushing, desiccation, incision, excision, electrocautery, laser injury, thermal injury, chemical 
injury, radiation injury, and foreign body-tissue irritation 
445
. However, the usefulness of
those models is hampered by the variability of adhesion formation in the positive control 
animals. This reduces the power of those studies increasing the number of animals that is 
required to test the anti-adhesive properties of test compounds and takes a longer period to 
replicate. Indeed, the strength of a model lies in the ability to replicate a similar injury 
process as in human conditions producing similar uniform non-lethal forms of adhesions in 
positive control animals. Kraemer et al
452
 compared 5 different types of injury models and
demonstrated good adhesion formation but they were performed on the parietal wall of the 
abdomen which does not mimic the laparotomy model and does not cause the serosal or 
mesothelial injury. diZeerga et al describes that clean-cut incisional wounds are not enough to 
stimulate fibrin deposition and in contrast, cautery and thermal injury causes excessive tissue 
necrosis with formation of mature fibrotic bands after more than 21 days
445
. Özel et al
453
discusses the chemical injury model using alcohol and iodine which are inherently 
disinfectants and are not suitable for an infective (enterotomy) model. Hence a chemical 
which is potent enough to create a foreign body reaction at the site of mechanical injury 
caused by abrasion and limited in its role as a general irritant is ideal. Kaolin or commonly 
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called ‗chalk‘, is a mixture of different minerals and is a naturally occurring aluminium 
silicate mineral derived from clay. It contains quartz, mica, feldspar, iolite and 
montmorillonite. Kaolin is used in paper production, in paints, rubber, plastic, ceramic, 
chemical, pharmaceutical and cosmetic industries
454
.  Jaurandand  Pairon
455
 in 1990 studied
the interaction of Kaolin with cell lines and found a variety of membrane interactions and 
metabolic impairments. Kaolin in the recent past has been of interest in clinical studies due to 
its role in achieving haemostasis in Oculoplastic Surgery as a local application 
456
 or intra-
abdominal surgery with Kaolin impregnated gauze as a leave-in substance for rapid 
haemorrhage control in critically injured patients in combat
457
.
 Kaolin has the universal property of causing a foreign body reaction and inducing an 
inflammatory response that induces adhesion formation
458,459
. The injury is similar to the
mesothelial injury in abdominal adhesion by foreign body reaction and setting up a wound 
healing process resulting in fibrosis/adhesion as seen in pulmonary fibrosis
448
.
The pathology thus generated could replicate the human condition of tissue handling, glove 
powder, mechanical injury due to clamps and electrocautery. A rat model is relatively easy to 
use and replicate in terms of the experiment and also the ratio of the peritoneal surface area 
relative to the body weight and height is comparable to human
368
. The volume of adhesion
inducing agent also matters when we test an anti-adhesive substance, hence refinement of 4 
mL to 2 mL is significant in terms of animal discomfort post-surgery. The surface area in the 
rat abdomen is high but the volume of chemical used to induce injury has to be titrated 
sufficient enough to cause injury and provide space for the anti-adhesive agent. The dosage 
of Kaolin that‘s ideal in both the laparotomy with abrasion alone and abrasion with 
enterotomy model was 0.005g/ml and this produces consistent adhesion without being 
harmful to the rat. Interestingly as expected there was higher grade of adhesion seen with the 





enterotomy model in compared to the laparotomy group, but the rats were able to tolerate the 
insult and recovered without any morbidity or weight loss.  
One of the limitations in this model is the anti-coagulant property of Kaolin which may 
inhibit adhesion formation
457
. In spite of which, the overall ability of its property to induce 
chemical injury has resulted in a controlled amount of adhesion formation using a low 
dosage.  
 
In conclusion, our rat model for abdominal adhesion prevention experiments using Kaolin 
















7.1.2 Prevention of  adhesions post-abdominal surgery: Assessing the 
safety and efficacy of Chitogel with Deferiprone in a Rat Model 
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Introduction: Adhesions are often considered to be an inevitable consequence of abdominal 
and pelvic surgery, jeopardizing the medium and long-term success of these procedures. 
Numerous strategies have been tested to reduce adhesion formation, however, to date, no 
surgical or medical therapeutic approaches have been successful in its prevention. This study 
demonstrates the safety and efficacy of Chitogel with Deferiprone and/or antibacterial 
Gallium Protoporphyrin in different concentrations in preventing adhesion formation after 
abdominal surgery. 
 
Materials and Methods: 112 adult (8-10 week old) male Wistar albino rats were subjected 
to midline laparotomy and caecal abrasion, with 48 rats having an additional enterotomy and 
suturing. Kaolin (0.005g/ml) was applied to further accelerate adhesion formation. The 
abrasion model rats were randomized to receive saline, Chitogel, or Chitogel plus 
Deferiprone (5, 10 or 20 mM), together with Gallium Protoporphyrin (250μg/mL). The 
abrasion with enterotomy rats were randomised to receive saline, Chitogel or Chitogel with 
Deferiprone (1 or 5 mM). At day 21, rats were euthanised, and adhesions graded 
macroscopically and microscopically; the tensile strength of the repaired caecum was 
determined by an investigator blinded to the treatment groups. 
 
Results: Chitogel with Deferiprone 5 mM significantly reduced adhesion formation (p<0.01) 
when pathologically assessed in a rat abrasion model. Chitogel with Deferiprone 5 mM and 1 
mM also significantly reduced adhesions (p<0.05) after abrasion with enterotomy. Def-
Chitogel 1mM treatment did not weaken the enterotomy site with treated sites having 
significantly better tensile strength compared to control saline treated enterotomy rats.  
 





Conclusions: Chitogel with Deferiprone 1 mM constitutes an effective preventative anti-
adhesion barrier after abdominal surgery in a rat model.  Moreover, this therapeutic 
combination of agents is safe and does not weaken the healing of the sutured enterotomy site.  
 
Key words: Chitogel, Deferiprone, Abdominal adhesion, Animal model, fibrosis 
 
Introduction:  
Seven million open abdominal surgeries occur each year in the US and Europe 
446
, costing the 
health care system $USD 2.3 billion annually 
302
. However, postsurgical adhesions are an 
almost inevitable consequence of abdominal surgery and are the largest single cause of 
intestinal obstruction
288
. Occurrence of adhesions after upper and lower abdominal surgery 
ranges from 67-93% 
24,273
. The mortality rate due to postsurgical adhesions can be high, 
especially among the elderly 
460
, and these complications can cause chronic pain and female 
infertility 
274,447
 . Prevention of adhesions aims to reduce inflammation and infection, which 
are the main triggers of their formation.  After surgery, inflammation results in extravasation 
of a fibrinogen-rich fluid, the resulting fibrin clot promoting adhesion formation, a process 
accentuated by microbial contamination from leaked intestinal contents. 
 
Numerous strategies have been devised  to prevent peritoneal adhesions, such as hydro 
flotation, barrier agents such as anti-adherence  hyaluronic acid/carboxymethylcellulose, 
regenerated and expanded oxidised cellulose 0.5% in ferric hyaluronate and chlorine dioxide 
273
. However, none of these strategies have been widely adopted due to poor efficacy or risk 
of adverse events 
305
. An ideal barrier agent should be a biocompatible substance that is 
sufficiently flexible to conform to the abdominal cavity and able to be used during 
laparotomy or laparoscopy. It should also be able to adhere to the peritoneal surface and 





remain in-situ for 5 to 7 days after the surgery. Moreover, it should prevent thrombin 
formation and hydrolyse, without leaving degraded residue that is pro-inflammatory in 
nature.  
Chitogel  has been identified as an ideal candidate for this role. It is a dissolvable gel that 
can carry Deferiprone (Def), an iron chelator, and Gallium-Protoporphyrin 
89
 an anti-bacterial 
haem analogue. Chitogel has been used extensively in the nasal cavity and sinuses as a 
haemostatic and adhesion prevention agent with considerable success. It has good 
haemostatic
44,49
 and anti-adhesive properties 
44,80,252
, and an anti-microbial action 
80
. Chitogel 
is biocompatible, non-toxic 
42,444
, an excellent drug delivery device, and is currently a Food 
and Drug Administration (FDA) approved postoperative dressing in sinuses post-surgery. 
Previous in vivo studies conducted in small and large animal models of abdominal surgery 
support Chitogel‘s anti-adhesive properties within the abdominal cavity 
332,362
. Def is an 
FDA-approved drug for the treatment of iron-overload conditions such as Thalassemia Major, 
which has also been shown to reduce reactive oxygen species (ROS), an important 
contributor to the inflammatory process in wound healing. In vitro Def has also been shown 
to reduce the migration and proliferation of fibroblasts in a time and dose-dependent manner 
85
. Importantly, Def is released from Chitogel within 48 to 72 hours, a critical timeframe for 




GaPP has a similar structure to haem, with Gallium complexed in its center rather than iron. 
Bacteria require iron for their metabolism and actively absorb GaPP. When used in 
combination with Def, Def-GaPP has demonstrated potent synergistic anti-microbial effects, 
killing both Gram-positive and Gram-negative bacteria, including Multi Drug Resistant 
(MDR) bacteria 
461
. GaPP is released from Chitogel for up to 460 hours in vitro and in 
vivo
365
, making it available to bacteria  long term.  





This study sought to determine the lowest therapeutically relevant dose of Def required to 
effectively reduce adhesion formation after abdominal surgery. 
 
Materials & Methods:  
The University of Adelaide and Central Adelaide Local Health Network/SA Pathology 
Animal Ethics Committees (AEC) approved the study to be conducted at The Queen 
Elizabeth Hospital Experimental Surgical Suite (The University of Adelaide AEC M-2017-
061 and CALHN/SA Pathology AEC 25-17) and the AHMS Biomechanics Laboratory. 
 
Animals: 
Male Wistar albino rats were purchased from Laboratory Animal Services   
Medical School (The University of Adelaide, SA, Australia), 8 to 10 weeks old, with an 
average weight between 350 and 500 grams. Rats were housed 1 week prior to surgery under 
standard laboratory conditions (temperature 21°C ± 2°C, humidity 55% ± 10%, 12:  12-hour 
light-dark-cycle). Rats were housed in groups of 3 per cage and food and water were 
provided in a standard manner.  
Materials 
Kaolin (Aluminium silicate Hydroxide, Al2Si2O5(OH)4) was purchased from Sigma-Aldrich, 




The Chitogel is made up of a combination of three components:1% succinyl chitosan, 0.3% 
phosphate buffer +/- 40% glycerol and 3% dextran aldehyde (Chitogel, Wellington, NZ), 
462 






 . The components are manufactured and sterilized by Chitogel. All stocks were stored 
at room temperature. 
 
Deferiprone and Gallium Protoporphyrin 
 
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4(1H)-one) (Sigma-Aldrich, St Louis, USA)          
(Lot # STBG8424) and Gallium Protoporphyrin IX (Ga-PP IX) (Frontier Scientific, Logan, 
USA) ( Lot # JB18-12460) were stored at room temperature. 
 
Preparation of Chitogel 
Dextran aldehyde (0.3 g) was dissolved in 10 mL of phosphate buffer +/- 40% glycerol then 
mixed with 10 mL 1% succinyl chitosan. 
 
Preparation of Chitogel-Deferiprone-Gallium Protoporphyrin 
Deferiprone (80 mM, 40 mM, 20 mM or 4mM) and Gallium Protoporphyrin (1 mg/mL) were 
dissolved in 5 mL phosphate buffer (+/- 40% glycerol) under sterile conditions. For 
Def/GaPP combination gel, 5 mL of each were added to dissolve dextran aldehyde prior to 
mixing with 10 mL of 1% succinyl chitosan. For Def gel, 5 mL Def solution plus 5 mL buffer 
were added to dissolve dextran aldehyde prior to mixing with 10 mL of 1% succinyl chitosan. 
Surgical procedure: 
Surgical procedures were performed by the same surgeons (RSV, CB) and a  
maximum group size of five animals per day was used to ensure close monitoring during the 
immediate post-operative period. Anaesthesia was achieved using a 
sealed chamber to deliver 2-3% Isoflurane, after which the animal was positioned supine for 
surgery and anaesthesia maintained with isoflurane over an open mask. Analgesia was 





provided preoperatively by subcutaneous injection of Buprenorphine (0.05 mg/kg) and post-
operative 8 hourly for 48 hours. The surgery was conducted in aseptic manner and a 
prophylactic dosage of broad-spectrum antibiotic in the form of Amoxycillin Clavulanic acid 
5 mg/kg (Clavulox
*
 Zoetis Australia, Rhodes, NSW, Australia) was also administered via 
subcutaneous injection. 
 
Rats underwent a laparotomy and a colon abrasion 
332
 or a colon abrasion  
with enterotomy 
463
. Briefly, the abdomen was shaved and prepared with alcohol. After 
drying, a 3 cm laparotomy (Fig 1a) was performed to gain access to the abdominal cavity. 
The caecum was delivered and kept moist with saline-soaked gauze whilst a dry gauze was 
used to rub the caecum repeatedly until sub-serosal bleeding occurred over an area of 1 cm
2 
(Fig 1 b & c). 2 ml 0.005 g/mL Kaolin in saline was instilled over the abrasion
463
. The 
caecum was then returned to the abdomen and the abdominal wall closed in layers with a 3-0 
Polyglactin suture. Prior to the placement of the final abdominal closure suture, rats were 
randomized to receive the following treatments into the abdominal cavity: 
(1) 4 mL normal saline, n=12 
(2) 4 mL Chitogel, n=12 
(3) 4 mL Chitogel + Def 20 mM + GaPP 250 μg/mL, n=12 
(4) 4 mL Chitogel + Def 10 mM + GaPP 250 μg/mL, n=12 
(5) 4 ml Chitogel + Def 5 mM + GaPP 250 μg/mL, n=12 
 
In the Caecal abrasion + enterotomy group rats, colon abrasion (dry rubbing of the caecum 
wall over an area of 1 cm
2
 with gauze until bleeding occurs) and a full thickness enterotomy 
of the caecum over a length of 10 mm at an adjacent site of Caecum was performed. The 
enterotomy was then closed with 4-0 PDS suture (resorbable, monofilament) ( Fig 1d) and 





the repair leak tested with a simple pressure test. 2 ml 0.005 g/mL Kaolin in saline was 
instilled over the abrasion and sutured site, followed by application of 4 ml of the test 
treatments without glycerol into the abdomen by randomization before closure of the 
abdominal wall as follows: 
(1) 4 mL normal saline, n=12 
(2) 4 mL Chitogel, n=12 
(3) 4 mL Chitogel + Def 5 mM n=12 
(4) 4 mL Chitogel + Def 1 mM n=12 
The operation was limited to <15-20 mins each rat so as to avoid air drying of the organs.  
Postoperative monitoring 
Post-surgery, the animals were housed individually in separate cages at a constant room 
temperature with a 12 h light and dark cycle. In the immediate post-operative period animals 
were given Lectade Oral Rehydration Therapy (Lectade, Jurox Pty Limited, Australia) until 
they were able to eat standard rodent food and drink water that were provided ad libitum. 
Animals were monitored every 8-hours for the first 48 hours post-surgery. Their weight, 
behaviour, physical well-being, and appearance were documented using the Clinical Record 
Sheet, as approved by AEC. Adequate pain relief was maintained until 72 h post-surgery, and 













 Outcome measures: 
 
a.Midline Laparotomy  
 
 








e.Adhesion after abrasion  
 
f.Adhesion after enterotomy  
Figure1: a. Incision over the Rat abdominal wall after preparation, (orange arrow) 
b. Identification of Caecum, c.  Abrasion over the caecum with gauze till bleeding spots 
appear, d. Enterotomy sutured, e. Adhesion induced by Kaolin at dosage of 0.005g/ml at day 
21, f. Adhesion over the enterotomy site at day 21 
 





The animals were humanely killed using a CO2 gas inhalation chamber after 21 days post-
operative observation. Post-mortem laparotomy was performed to assess adhesion formation 
based on the presence and severity of adhesions using a previously validated adhesion 
scoring system (Table 1)
332
. The score takes into account the number, strength and 
distribution of adhesions formed. Pictures were taken with an iPhone 8 12mp ƒ/1.8 aperture 
camera (Fig 1 e & f) and a macroscopic grade was assigned to each rat by an abdominal 
surgeon who was blinded to treatment. The intra-abdominal cavity was examined for any 
residual gel and contents were examined for any gross changes.  
Table 1. Adhesion Scoring Scheme 
Adhesion Scoring Scheme Score Description 
0 No adhesions 
1 Thin adhesion strands 
2 Multiple thin adhesions 
3 Thick adhesion with focal 
attachment 
4 Thick adhesion with more broad-
based planar attachment 




The caecum with adhesion(s) was collected and the tissue between the caecal adventitia and 
adherent adjacent intestinal serosal surfaces, and between the adventitial aspect of the caecum 
and the parietal peritoneum of the abdominal wall, were collected and immersion-fixed in 
10% neutral buffered formalin. These tissues were then paraffin-embedded, cut at 6 μm, and 





stained with haematoxylin and eosin (H&E).  Duplicate sections were also stained by the 
Masson‘s trichrome technique to demonstrate collagen deposition in fibrous adhesions. The 
slides were examined, and scored, independently by two observers, blinded as to the 
treatment groups. 
In order to assess the nature of the intestinal adhesions produced by our experimental 
paradigms, we attempted to grade these adhesions with respect to the stage of foreign body 
inflammatory reaction and degree of fibrosis. 
  
Since there was some variability in the stage of these pathological processes between 
different intestinal sites in a given animal, the adhesions were initially scanned at low 
magnification (x4) and 3 sites selected for further analysis (at x20 magnification), these being 
areas of adhesions most representative of the overall pathological reaction in each case (Fig 
2). 
  
In routine H&E - stained sections, the 3 sites selected were scored for inflammation and 
wound healing according to an internally validated scoring system (Table 2):  
Table 2, Grade of Inflammation and cellular proliferation in Adhesion (H&E) 
Grade Description 
Grade 1+ predominantly epithelioid macrophage infiltration, with phagocytosed 
adhesion-inciting material, and fewer multinucleated giant cells, 
lymphocytes and plasma cells 
Grade 2+ fibrovascular granulation tissue formation, with fibroblastic proliferation 
and supporting microvascular angiogenesis, and a relatively small quantity 
of loosely arranged collagen 
Grade 3+ more mature fibroplasia with abundant collagen deposition 





These 3 sites were also evaluated in sections stained by the Masson‘s trichrome technique for 
quantity and quality of collagen deposition (Fig 3), and the Grades are shown in Table 3: 
1+ 
 predominantly epithelioid 
macrophage infiltration,  
 phagocytosed adhesion-inciting 
material 
 fewer multi-nucleated giant 
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Figure 2: H & E grading of Caecal scar tissue 20X 
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 mature collagenous connective 
tissue with compact,  
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Table 3, Grade of Fibroblastic activity in the Adhesion (Masson‘s Trichrome) 
 
A 






Grade1+ minimal and loosely arranged collagen fibrils with numerous fibroblastic 
nuclei 
Grade 2+ more abundant and compactly arranged collagen deposition 
Grade 3+ mature collagenous connective tissue with compact collagen and markedly 
fewer fibroblastic nuclei 
 
Tensile strength testing:  
After separation for histology, the caecal tissue was laid open and cut into a rectangular 
specimen (nominally 40 mm long and 9 mm wide) centred about the suture site (for the 
treatment groups).The ends (5 mm) of each specimen were attached to custom plastic 
gripping tabs (20×20 mm) using cyanoacrylate adhesive (Loctite 401, Henkel, Düsseldorf, 
Germany), giving a gauge length of approximately 30 mm (Fig 4 a). These gripping tabs 
assisted with fixing the specimen into an electromechanical tensile testing machine (5543, 
Instron, High Wycombe, UK) via pneumatic grips (2712-019, Instron, High Wycombe, UK; 
5 bar compressed air pressure). Specimens were consistently placed in the grips with thicker 
colonic wall superiorly. Prior to testing, a tensile pre-load of 0.01 N was applied; the 
specimen width above, below, and at the suture site (middle for naïve tissue group), and 
specimen gauge length, were measured using Vernier callipers (make, model etc). Tensile 
loading was applied at 0.1 mm/s until complete failure occurred (Fig. 5 A). Loads and 
displacements were recorded at 100 Hz using a uniaxial load cell (range ±10 N, Instron, High 
Wycombe, UK) and linear variable differential transducer(position accuracy ± 0.02 mm), 
respectively. All tests were video recorded in high-definition using a mobile-phone camera 
for qualitative analysis of the failure region. 





Custom MATLAB code (R2015a, MathWorks, Massachusetts, USA) was developed to filter 
the load and displacement data using a second-order, two-way Butterworth low-pass filter 
with a cut-off frequency of 10 Hz, and load-displacement plots were generated. The peak 
load and extension (displacement) at peak load were calculated. Stiffness (N/mm) was 
determined from the linear region, the bounds of which were determined by a single operator, 
and a linear regression line was fitted to the data points within this region to determine the 
slope. 
 
 Statistical Analysis:  
Statistics of adhesion grades and histology were performed using R statistical software (R 
Foundation for Statistical Computing, Vienna, Austria) through the Jupyter notebook 
interface. The R package "MASS" 
442
 was used for ordinal regression. The "polr" function 
from MASS was used to fit a proportional odds logistic regression model for the ordinal 
outcome variable (the adhesion score as scored by the primary surgeons). A Likelihood ratio 
test (using the R function "anova") was used to compare the model with a null ordinal 
regression model. The means of the ordinal response (interpreted as a numeric value from 1 
to the number of classes) were calculated and post-hoc pairwise contrasts for each pair of 
levels of the treatment variable were compared using the "emmeans" package. 
442
. Statistical 
significance was taken at the traditional < 0.05 level. 
 
 Statistical analyses for the mechanical testing were performed using SPSS v22 (IBM, 
Illinois, USA). Three linear regression models were developed to identify if treatment (naive, 
control, gel alone, Chitogel with 1 mmol or 5 mmol of Def) was significantly associated with 
the following outcome measures: 1) peak load, 2) extension at peak load, and 3) linear region 
stiffness. Each model was developed as follows: Firstly, Shapiro-Wilk and Levene tests were 





performed to assess normality and homogeneity of variance of the dependent variables, 
respectively. If required, statistically significant outliers were removed to meet these 
criteria. The effect of treatment was assessed in all models, and this effect was adjusted for 
the geometric measurements taken of the specimens when under 0.01 N preload: thick-end 
width, middle (or suture site) width, thin-end width, and length. Each model was refined 
using a manual backward stepwise approach until only significant predictors remained 
(α=0.05). Bonferroni-adjusted post-hoc comparisons were used to determine differences 
between treatment group. 
 
Results:  
Macroscopic Adhesion Scores 
One hundred and eight rats underwent either colon abrasion (n=60) or colon abrasion with 
enterotomy (n=48). Post-operative follow-up was uneventful for all rats with no major 
complications up to day 21 after surgery. All 108 rats were recovered and at day 21 humanely 
killed and observed for adhesions. All major organs were un-affected, and the abdominal 




The mean adhesion score in control rats treated with only saline was 3.98 (CI 3.33, 4.63), and 
there were thick adhesions present over the site of abrasion in most of the rats (Fig. 4A, IV). 
Some were vascularized and had planar attachments between the abdominal wall and the site 
of injury (Fig. 4A III). The rats treated with Chitogel and Deferiprone 5 mM showed a 
significant reduction of the intra-abdominal adhesion scores macroscopically with a mean 
adhesion score of 2.77 (CI 2.19, 3.4) (p<0.01) (Fig 4 B). Some of these rats had a few very 





thin adhesion strands and in some there was more than one adhesion strand (Fig. 5, II). Rats 
treated with Chitogel alone had a mean adhesion score of 3.51 (CI 2.95, 4.08) and higher 
dosages of Def 10 mM and Def 20 mM had similar mean adhesion scores of 3.33 (CI 2.6, 
4.06) & 3.64 (CI 2.77, 4.51) respectively.  
 



























































Figure 4 D Blinded grading of Grade of Fibrosis on Masson‘s Trichrome staining 
 



























































Figure 4 E Blinded Grade of Fibrosis on Masson‘s Trichrome staining 
 
 Figure 4A; Photographs of rat abdomen at end point depicting different grades of adhesion. I 
- No adhesions, II - Thin adhesion strands, III - Thich adhesions with focal attachment, IV  - 
Thick adhesion with more broad-based planar attachment, 4B Bar graph of blinded 
macroscopic grading of adhesion in a rat colon abrasion model 
Mean grade of adhesion after colon abrasion in rats treated with saline (n=12), Chitogel (CD, 
n=12), Chitogel with 5mM Deferiprone (Def_5mM, n=12), Chitogel with 10mM Deferiprone 
(Def_10mM, n=12), Chitogel with 20mM Deferiprone (Def_20mM, n=12). ** p<0.01 
compared to saline control, 4C; Bar graph of blinded macroscopic grading of adhesion in 
an abrasion + enterotomy model, mean grade of adhesion after colon abrasion + 
enterotomy in rats treated with saline (n=12), Chitogel (CD, n=12), Chitogel with 1mM 
Deferiprone (Def_1mM, n=12), compared to saline control and Chitogel with 5mM 
Deferiprone (Def_5mM, n=12), *p<0.05, 4D; Bar graph of Masson’s Trichrome staining 
grading of caecal scars based on table 3 





Mean grade of fibrosis after colon abrasion in rats treated with saline (n=12), Chitogel (CD, 
n=12), Chitogel with 20mM Deferiprone (Def_20mM, n=12), Chitogel with 10mM 
Deferiprone (Def_10mM, n=12), Chitogel with 5mM Deferiprone (Def_5mM, n=12). 
 
Colon Abrasion with Enterotomy Model 
Adhesions seen in this group of rats as compared to the abrasion model were thicker and 
more abundant at the suture site. The mean adhesion score of the control rats treated with 
saline in the colon abrasion with enterotomy group was 4.87 (CI 4.36, 5.38). Rats treated with 
Chitogel alone had similar adhesion scores of 4.43 (CI 3.88, 4.9) compared to control 
(p>0.05). The rats treated with Chitogel in combination with 2 low dosages of Deferiprone of 
5 mM and 1 mM, showed significant reductions of abdominal adhesions macroscopically 
with mean adhesion scores of 3.66 (CI 3.12, 4.21) and 3.69 (CI 3.06, 4.32) respectively 
(p<0.05) (Fig. 4C).  
 
Histopathology:  
Caecal adhesions and scar tissue from control rats in both the abrasion and abrasion with 
enterotomy models showed inflammation and mature adhesions with abundant compact 
collagen and few fibroblasts. The caecal scar tissue from rats treated with Chitogel and Def 
showed predominantly epithelioid macrophage infiltration, with phagocytosed adhesion-
inciting material, with fewer multinucleated giant cells, lymphocytes and plasma cells. 
Masson Trichrome staining of adhesions showed a significant reduction in fibroblastic 
activity with reduced collagen deposition in rats treated with Chitogel with lower dosages of 
Def in the rat abrasion model (Def 5mM p<0.05and Def 10mM P<0.05) (Fig. 4D). There was 
similar reduction of fibroblastic activity in the enterotomy model (Def 5mM & 1mM) but this 
was not statistically significant (Fig. 4 E).  
Modifying wound healing and PO outcome 
185 
Tensile strength Testing: 
Electromechanical tensile strength testing revealed differences between samples of the 
localisation of tissue rupture (Supplementary Table 2). Naïve caecum colon mucosa ruptured 
7/12 mid-specimen (58.3%) and 5/12 (41.7%) in the lower, thinner part of the mucosa and 
none in the upper, thicker part of the mucosa (Figure 5A I). In contrast, in control colon 
anastomosis samples, colon mucosa ruptured 2/11 mid-specimen (18%), 3/11 (27%) in the 
upper, thicker part of the mucosa and 6/11 (54%) in the lower, thinner part of the mucosa. 
Chitogel with Def 1mM and Def 5 mM treated colon anastomosis never failed within the 
repair zone and rupture sites were similar with 0/22 ruptures occurring mid-specimen (0% of 
all ruptures), 8/22 (36%) in the upper, thicker part of the mucosa and 14/22 (64%) in the 
lower, thinner part of the mucosa, whereas 1/12 (8%) failed at the repair zone in Chitogel 
alone treated wound,  All enterotomy groups (i.e. control, Chitogel and Chitogel with Def 
5mm), except the Chitogel with Def 1 mM group (p=0.142), had significantly lower peak 
loads than the naïve tissue (p<0.05). Def 1mM and Def 5 mM had significantly larger peak 
loads than Chitogel Only (p<0.001 and p=0.049, respectively) (Fig 5 C). All ―repaired‖ 





 Electromechanical tensile testing 
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Figure 5: Electromechanical tensile strength testing 
 
(A) Experimental set up showing specimen caecum split open and fixed to the 
Instron pneumatic arms with sutured area at its centre before being stretched 
(thick white arrow indicates direction of pull) for electromechanical tensile 
testing. (B) Load displacement graph showing value of tensile force [in 
Newton(N)] vs displacement [in millimetre(mm)]. The red line represents the 
linear region, from which the stiffness was calculated, and the red circle indicates 
the peak load location. (C) Bar graph of peak axial force [in Newton (N)] for the 
different treatment groups ***p<0.001, * p<0.05, (D) Bar graph of Linear region 
stiffness [in Newton/mm (N/mm)] of caecum in different treatment groups 










Supplementary Table 1: 
Table of Adhesion Grade with Abrasion alone and Abrasion with Enterotomy 
Macroscopic Grading of Adhesion 




Saline(Control) 3.98 0.33  
Chitogel  3.51 0.29 0.20 
Chitogel + Def 20mM 3.64 0.44 0.53 
Chitogel +Def 10mM 3.33 0.37 0.19 
Chitogel +Def 5mM 2.77 0.29 0.001 





Saline(Control)  4.87 0.26  
Chitogel  4.43 0.28 0.9174 
Chitogel + Def 5mM 3.66 0.28 0.042 
Chitogel + Def 1mM 3.69 0.32 
0.018 
 
Microscopic Grading of Fibrosis by Masson‘s Trichrome staining  
 Treatment mean SE  






Saline(control) 2.450602 0.197389  
Chitogel 2.161037 0.205117  
Chitogel + Def_20mM 2.085894 0.213718  
Chitogel + Def 10mM 1.854784 0.195241  
Chitogel + Def 5mM 1.819321 0.216551  
Chitogel + Def 1mM    
Abrasion + 
Enterotomy 
_saline 2.476377 0.163667  
cd 2.562720 0.157606  
def_1mM 2.429625 0.173113  
def_5mM 2.617976 0.158781  
 
 
Supplementary Table 2: Number of failures at each site for each treatment group. 
Thin/thick refers to the region of the specimen in which failure occurred.  
Middle Thin Thick Middle Thin Thick Middle Thin Thick Middle Thin Thick Middle Thin Thick
7 5 0 2 6 3 1 3 8 0 7 4 0 7 4












While Chitogel has well documented anti-adhesive properties 
332,362,415
, this study 
demonstrated that the addition of Deferiprone at lower concentrations of 5 mM and 1 mM to 
Chitogel further improved Chit gel‘s anti-adhesive properties. This resulted in a significant 
reduction in adhesions in the abdominal cavity post abdominal surgery when assessed 
macroscopically and microscopically. Moreover, although the adhesions produced in the 
positive control animals were robust due to the presence of an inducing agent, 
histopathological data showed reduced collagenous connective tissue in Def-Chitogel treated 
animals. Importantly, the addition of 1 mM and 5 mM Def to Chitogel did not reduce the 
strength of the scar tissue. Def 1mM and Def 5 mM treated sites never failed at the repair site 
and an increase in peak load was observed when compared to Chitogel alone. In fact, peak 
load, indicative of wound healing of enterotomy sites, was significantly higher when Def 
1mM-Chitogel was applied compared to control saline treated enterotomy sites and was 
similar to naïve, non-operated tissue. Together, these results indicate that Def 1mM-Chitogel, 
apart from reducing post-operative adhesions, actively promotes wound healing of the 
enterotomy site. This data supports the excellent potential of Def 1mM-Chitogel as an anti-
adhesion device for use after open abdominal surgery with and without enterotomy. 
 
Wound healing after abdominal surgery is a complex process and, to a large extent,  
depends on the site and organs involved  
25
. Adhesions are common after surgery on the 
abdominal wall, abdominal viscera, and the urogenital system 
288
.  While adhesions formed 
after peritoneal injury are uniquely formed by sheets of mesothelium 
464
,  most abdominal 
adhesions are formed by organisation of a fibrin-rich haematoma and characterised by 
infiltration of fibrovascular granulation tissue, the fibroblastic component laying down 
collagen, which forms the healed scar tissue. This process of post-surgical blood clot 





organisation is further complicated and impeded by inflammation and infection. To date, 
there have been various strategies devised to prevent adhesions, mainly in the form of 
peritoneal irrigates, instillates or barriers
278
. The application of silastic sheets within 36 hours 
of surgery, for example, is able to reduce adhesion formation from 100% to 0%
278
. 
However, although barrier systems have proven to be useful in reducing adhesions, no agent 
has progressed to widespread clinical use, in large part due to the lack of clinical efficacy or 
undesirable side effects
465
.  Adhesion-reducing liquid barriers, such as icodextrin solution or 
polyethylene glycol, rely on the principle of hydro-flotation, but have not been proven useful 
in all situations 
24
. Films such as oxidised regenerated cellulose 
278
 or hyaluronate 
carboxymethylcellulose act as a mechanical barrier, separating the operative surfaces within 
the abdomen. While  these are solid barriers, their solubility and longevity in the abdomen 




Chitogel has been extensively studied in ENT surgery as a post-operative dressing in the 
nasal and sinus cavities 
44-46,60,252,467
. The viscous nature of Chitogel enables it to conform to 
narrow spaces
4,77,252
 and deliver anti-adhesive and anti-microbial drugs in chronic sinusitis 
surgery
78,97
. In order to prevent intra-abdominal adhesion formation, post-surgical 
haemorrhage, inflammation and inhibition of inflammatory cytokine-driven fibroblastic 
infiltration are required 
445
. Chitogel has haemostatic
44
, anti-inflammatory and anti- 
proliferative properties 
80
. Deferiprone‘s potent anti-inflammatory and inhibitory effects on 
fibroblast migration potentiate Chitogel‘s anti-adhesive properties
85
. Def also has inhibitory 
effects on Reactive Oxygen Species (ROS) generation and collagen secretion by primary 
fibroblasts 
85
. This combined effect results in reduced fibrosis in the rat abdomen treated with 
Chitogel and Deferiprone when compared to Saline and Chitogel alone in both our abrasion 
and enterotomy with abrasion models. The Def release profile from Chitogel has shown that 





the complete release of Def occurs within 72 h
365
 and maximum serum levels are reached 
within 24 h
97
. These findings indicate that Def affects wound healing in the early stages of 
wound repair, a time when the production of ROS and associated inflammation is maximal 
85
 
. Histological findings in the present study are concordant with these actions in the form of 
reduced fibroblastic proliferation and attenuated collagen deposition.  
While the anti-fibrotic effect of some interventions such as hyaluronic acid–based films, 
reduce the quality of wound healing
468
 and promote fistula formation
469
, the tensile strength 
of caecal tissue treated with Def-Chitogel in the present study was not compromised.  
 
In the enterotomy part of this study, the antimicrobial GaPP was omitted as no 
microorganisms were cultured from the abdominal cavity in the control animals at day 21.  
Without a positive bacteriological swab at day 21, we would have been unable to show any 
benefit of adding GaPP. Moreover, lower Def dosages of 5 mM and 1 mM were used in this 
cohort because our results indicated an inverse dose response when using Def dosages of 
10mM and above. A previous sheep laminectomy study similarly showed reduced anti-
adhesive capacity of Def-Chitogel when Def concentrations above 20 mM were used
367
. The 
reason for this reduced anti-adhesive capacity at high-Def concentrations in Chitogel is 
unclear. Ramezanpour et al showed no significant toxicity when 10 mM Def was applied to 
primary fibroblasts and primary human nasal epithelial cells for up to 48 hours
85
. In that 
study, Def at higher concentrations of 10 and 20 mM had stronger anti-inflammatory 
properties than corticosteroids at clinically relevant concentrations. Whilst excessive 
inflammation can induce adhesions, it is well known that a low degree of inflammation is 
needed as part of the normal healing process after surgery 
19
. Therefore, Def concentrations in 
excess of 10 mM might deregulate this balancing act resulting in a loss of beneficial anti-
adhesive and wound healing properties. Reducing inflammation may also delay healing at the 





level of suture lines or anastomotic sites therefore demonstration of conserved tissue-holding 
strength of sutures and anastomotic sites is critical for abdominal adhesion barrier devices in 
particular if those are to be used in indications of enterotomy. The enterotomy part of our 
study replicates the clinical indication of open invasive abdominal surgery, e.g., involving the 
removal or opening of the gut with the associated intra-abdominal bacterial contamination 
that occurs with such an enterotomy. The tensile strength tests performed demonstrated that 
Chitogel with Def concentrations of 5mM and 1 mM was safe and allowed for a normal 
caecal  wound healing to occur. In fact, Def-Chitogel at 1 mM Def concentration resulted in 
anastomotic sites that had superior tissue strength than Chitogel treated animals without any 
significant difference with naïve rats that did not undergo abrasion/enterotomy. These results 
indicate that Chitogel with 1mM Def not only prevents adhesion formation but also promotes 
efficient healing of the enterotomy site, setting this product apart from all other marketed 
adhesion barrier devices. Whilst further research is needed to confirm these promising 
findings in large animal models of abdominal surgery, our results support the potential 
beneficial properties of Chitogel incorporating 1mM Def for use to prevent adhesions after 
abdominal surgery with enterotomy. 
 
In conclusion, the results of this rat study demonstrated that Chitogel with 1mM Deferiprone 
is a safe and effective product significantly reducing abdominal adhesion formation. 
Confirmation of safety and anti-adhesive properties in large animal models are required prior 




Modifying wound healing and PO outcome 
8 Chitogel with Def in Spine Surgery 
Summary: Failed Back Syndrome is a painful condition that arises out of abnormal scaring 
in the spinal foramina or canal region after spinal surgery, performed to relieve pain. Pressure 
on the nerve roots have debilitating effect on the patients, innovative therapeutic models and 
regimens have been espoused to avoid scar formation and inhibit excessive tissue deposition 
in the narrow-confined spaces of the spinal cord. Recommended anti-adhesion regimens are 
based on principles of - reduction of inflammatory reaction, quick clot formation, and limited 
fibrin deposition 
470
. Most of these are designed to implant a synthetic or organic material 
into the laminectomy site as a barrier between the exposed dura mater and surrounding 
muscles - Silastic, Dacron, methacrylate, bone graft, synthetic membranes and foams, free 
and pedicle fat grafts, and steroid agents
387
. There is, however, no consensus amongst spine 
surgeons as to the best and most effective option. Recently, surgical hydrogels have been 
developed and specifically marketed for their use to improve the clinical outcomes and 
prevent adhesions after spine surgery. FzioMed‘s surgical hydrogel for spine surgery
471
, is 






. It is serving as a 
protective physical barrier and is specifically marketed for reducing pain, lower extremity 
weakness, and the incidence, extent, and severity of postoperative adhesions after 
laminectomy. Clinical trials have shown that coating the surgical site with Oxiplex improves 
clinical outcomes after spine surgery
377
. However, due to efficacy data being discrete 
compared to control, no FDA approval has been granted to date despite FzioMed‘s repeated 
filings and appeals to the FDA for more than a decade. 
Chitogel has demonstrated many properties that result in improved wound healing.in vitro 
and in vivo (animal and human studies) proof-of-concept data previously
417
. These include 
haemostasis
44
 and anti-adhesive properties
49
, biocompatibility, non-toxicity and also as an 
excellent drug delivery device in particular for hydrophilic compounds.   
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Abstract: 
Introduction: Spinal laminectomy is a common procedure performed to relieve neural 
compression in patients suffering from myelopathy or radiculopathy. However, up to 40% of 
patients suffer from persistent post-operative pain and disability, a condition known as Failed 
Back Surgery Syndrome (FBSS).  Excessive scarring in the surgical bed is implicated as a 
cause. Hydrogels have been proposed to prevent adhesion formation post-laminectomy; 
however, their efficacy has not been proven. This study uses Chitogel complexed with the 
iron chelator Deferiprone (Def) to prevent adhesion formation in a sheep laminectomy model.  
Material & Methods: Fifteen Adult Merino sheep (Ovis Aries, 1-5 yrs old) 
underwent laminectomy at lumbar levels 1-5 and had hydrated aluminium silicate (kaolin) 
applied to promote adhesion formation. Subjects were randomised to receive at each 
laminectomy level no-treatment control, Chitogel, Chitogel with Def at 20mM or 40mM or 
Carboxy-methylcellulose and Polyethylene oxide (CMC/PEO) gel. The animals were 
recovered for 3 months post- surgery, followed by assessment with Magnetic Resonance 
Imaging (MRI) and histopathology of the spinal tissues for evaluating the presence and extent 
of adhesions.  
Results:  MRI and Histology assessment indicated that Kaolin induced severe inflammation 
with adhesion formation. Chitogel with and without 20 mM Def decreased inflammation 
(p<0.01) and trended to reduce adhesions (p<0.1). Chitogel with Def 40mM was not 
significantly dis-similar to CMC/PEO and did not reduce inflammation or adhesions 
compared to no-treatment control. 
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Conclusion: Chitogel in combination with Def 20 mM is safe and effective in decreasing the 
inflammatory process and may possibly reduce post-operative adhesions following 
laminectomy. 
Key words: Back pain, Epidural adhesion, Fibrosis, Chitogel , Sheep laminectomy and Failed 
Back surgery syndrome  
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Introduction:  
The prevalence of herniated disc associated with back pain and/or radicular leg pain is 1-3% 
in western societies requiring laminectomy with decompression of neural elements in 10% of 
patients
472
. More than 800,000 spine surgeries occur annually globally to provide relief,
however in up to 40% of patient‘s significant post-operative back pain occurs 
387,473
. This is
sometimes referred to as failed back surgery syndrome (FBSS). Based on Australian Bureau 
of Statistics data, FBSS occurs in up to 6,660 of the 22,200 patients undergoing spinal 
surgery each year in Australia 
382
. Epidural adhesions, formed after surgery, contribute to this
pain through tension on neural elements in more than 80% of FBSS patients with a direct 
relationship between the severity of adhesions and pain scores
383
. Wound healing after tissue
injury involves 4 major coordinated and regulated steps: haemostasis, inflammation, 
proliferation, and remodelling. Different factors can interfere with these steps, causing 
improper or impaired wound healing. Central to this is an increased inflammatory response 
with recruitment of polymorphonuclear neutrophils 
54
 to the injury site. These cells help in
the clearance of pathogens and foreign particles but also lead to tissue injury with the 
generation of Reactive Oxygen Species (ROS) 
474
, excessive migration of fibroblasts and
collagen deposition. These processes may result in excessive scarring or adhesion formation 
and can be exacerbated by pathological processes such as infection, inflammation and 
hematoma formation
391
. The extent of adhesion formation is determined mainly during the
first week, and in particular the first 48 hours after the initial injury 
25
. Numerous strategies
have been tested to reduce adhesion formation post spinal surgery, however, to date, no 
therapeutic approaches have been wholly successful and there are no Food and Drug 
Administration (FDA) approved marketed devices available for this indication
381,386,387
.
Chitogel is proposed to reduce adhesions by acting not only as a barrier between adjacent 
surfaces, but also a haemostatic material and carrier for Deferiprone (Def). 





Chitogel is a hydrogel product of naturally occurring Chitin in succinyl form cross-linked 
with dextran aldehyde powder that has been dissolved in sodium phosphate buffer solution. It 
has proven effects on enhancing haemostasis
44





 and is  FDA approved as haemostatic adhesion preventing post-
operative dressing in sino-nasal surgery
46,475
. It has also been shown to have protective 
properties in epidural spinal surgery and is safe when applied to brain tissue
417
. Hydrogels 
have controlled degradation rates and optimal biocompatibility with living tissues chemically, 
mechanically and electrically
476
. This property along with their ability to concurrently act as 
scaffolds to carry and deliver drugs, allows optimal promotion of regeneration of tissues and 
progressive wound healing.
477
 .  
 Deferiprone, an iron chelator used for the treatment of thalassemia
81
, has been shown to 
reduce inflammation and reactive oxygen species with a reduction in the migration and 
proliferation of primary fibroblasts in vitro in a time and dose dependent manner
85
. 
Deferiprone is released from Chitogel within 48 to 72 hours and has the potential of localized 
therapeutic effects when applied topically at this crucial time point in wound healing
365
. 
Hence, this study aimed to investigate the combined effects of Chitogel and Deferiprone to 
prevent epidural adhesions after laminectomy as well as determining its safety in a multilevel 
sheep laminectomy model.  
 
Materials and Methods:  
 
Study design:  
The University of Adelaide and South Australian Health and Medical Research Institute 
(SAHMRI) Ethics Committee approved the study to be conducted at the Large Animal 
Research & Imaging Facility Node (LARIF) (SAHMRI: SAM300).  
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This was a prospective double-blinded, randomised controlled study using a sheep 
laminectomy model, where all sheep underwent a 5-level laminectomy procedure.  
Animals and Materials: 
15 male merino sheep, 1-5 years of age were used. Following acclimatisation and fasting 
overnight, sheep underwent general anaesthesia (GA) with intravenous Ketamine and 
Diazepam for induction and Isoflurane for maintenance. Each animal was placed prone with 




Chitogel was made up of a combination of three components: 5% succinyl-chitosan, 0.3% 
phosphate buffer and 3% dextran aldehyde (Chitogel, Wellington, NZ). The components are 
manufactured and sterilized by Chitogel. All stocks were stored at room temperature. To 
prepare Chitogel, dextran aldehyde (0.3 g) was dissolved in 10 mL of phosphate buffer then 
mixed with succinyl chitosan solution (0.5 g in 10 mL buffer) using sterile technique. 
Deferiprone  
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4(1H)-one) (Sigma-Aldrich, St Louis, USA) 
was stored at room temperature. 
Preparation of Chitogel-Deferiprone 
Deferiprone (Def, 20 mM or 40mM) was diluted in 10 mL of 0.3% phosphate buffer under 
sterile conditions the day prior to use. This prepared solution was then used to dissolve 
dextran aldehyde (0.3 g) prior to mixing with succinyl chitosan solution (0.5 g) using sterile 
techniques. 
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Preparation of CMC/PEO (Carboxymethylcellulose and polyethylene oxide) 
There is only one product (not FDA-approved) that is used for the prevention of adhesions 
worldwide.  This is a gel and is available commercially and sold as Oxiplex (Oxiplex, 
FzioMed, San Luis Obispo, CA, USA) 
Surgical procedure: 
In an aseptic manner, 20 cm long posterior spinal approach midline incision was made over 
the spinous processes of each sheep and a sub-periosteal midline dissection made to expose 
the laminae by monopolar electrocautery. The spinous processes were removed at L1-L5 
levels in an intersegmental pattern and laminae removed with combination of high-speed drill 
and rongeurs. The dorsal surface of the spinal dura was exposed approximately 2 cm X 1 cm 
wide and 0.5 g Kaolin (Aluminium Silicate Hydroxide, Al2Si2O5(OH)4, Sigma-Aldrich, St. 
Louis, Missouri, United States), an adhesion-inducing agent 
451
, was mixed with 2 ml normal
saline and placed on the intact dura. Following Kaolin application, each site was randomized 
to receive nothing (control) or 2ml of Chitogel, Chitogel with Def 20 mM, Chitogel with Def 
40 mM or CMC/PEO. The wound was then closed in a multilayered fashion to eliminate 
surgical dead-space with 3-0 Polyglactin sutures. Pain relief was given in the form of 
Bupivacaine with adrenaline 0.5% as tissue infiltration immediately post-operatively and 
with Carprofen1ml/25mg intraoperatively, immediately post-operatively and further as 
required following veterinary advice. Additionally, a transdermal Fentanyl patch 
(2mcg/kg/hr) was placed on the sheep 24 hours prior to surgery and then replaced after 
surgery on the 3rd day as needed. Antibiotic cover in the form of subcutaneous infiltration of 
Cephalosporin (Excenel 
®
 RTU EZ, Zoetis, Parsippany, NJ, USA) 0.3mL/10kg once daily
was given pre-operatively and post-operatively for 48hrs. 
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Post-operative monitoring:  
Animals were recovered, and post-operative follow-up done for 48 hrs inside pens  
and monitored with CCTV every 2 hrs. Neurological examinations were carried out to assess 
the general condition of the sheep (food/fluid intake, temperature, teeth grinding, ground 
pawing and bleeding or other discharge at the wound). Basic neurological function 
assessment (pupillary response, circular walking, knuckling of the hind limbs and head 
movement to sound) were looked for every 2 hours after surgery. At the 48h post-operative 
mark, the animals were moved to the post-operative yards for 1 week, where they underwent 
once daily blood test (to determine Def levels) and observations 4 times per day. Animals 
were moved to a small open paddock for free roaming after 1 week for the remainder of the 
three months with twice daily monitoring as per scheduled blood testing, daily for the first 
week and then weekly for the next 3 months. After three months, the animals were brought 
back to the holding pens for 2 days acclimatisation with a partner at all times. Under general 
anaesthesia MRI of the spine was done for assessing adhesions after which the animals were 
humanely killed. 
Blood examinations: 
Blood examinations included Full Blood Examination (FBE), Urea Electrolytes and 
Creatinine (UEC), Liver Function Tests (LFT) and Iron studies at24h, 1 week and 1 month 
post op. High performance liquid chromatography (HPLC)  analysis was used to determine 
Def levels in plasma as follows: Baseline (time of induction, T0) Deferiprone levels at T0, 
T0.5 hrs, T1 hrs, T2 hrs, T4 hrs, T8 hrs, T12 hrs, T24 hrs then daily for 1 week, then weekly 
for weeks 2, 3 and 4. 
Quantification of Deferiprone in sheep plasma samples 
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Plasma samples were analysed for Def using HPLC on a Shimadzu UFLC XR (Shimadzu 
Cooperation, Kyoto, Japan) as previously described
97
. For the quantification of Def, 250 µl
plasma was mixed with 750 µl methanol (HPLC grade, Merck, Darmstadt, Germany). 
Following vortexing for 1 min, the samples were centrifuged for 4 min at 14,800 rpm at room 
temperature (Eppendorf 5804R, Eppendorf, Hamburg, Germany). A Phenomenex Synergi 4 
µm Fusion-RP LC column coupled to a security guard cartridge (Phenomenex, Lane Cove, 
NSW, Australia) was used to quantify 50 µl of the clear supernatant using methanol/0.1 M 
orthophosphate buffer pH 7.2 (15%: 85%) as mobile phase at a flow rate of 2.0 ml/min. The 
concentration of Deferiprone was detected at 280 nm and calculated against a standard curve 




At the end of three months, animals underwent Magnetic Resonance Imaging of the spine 
(MRI) using a Siemens Skyra 3T (Erlangen, Germany). T1 sagittal and transverse spin echo 
and T2 fast spin echo of the whole spine was made.  
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Fig. 1. Radiological scheme for grading of Adhesions on Magnetic Resonance Imaging 
(MRI). (A) MRI images of the dorsal spine of sheep in sagittal view. Spinal cord seen as 
railroad appearance (S), post laminectomy scar X 5 (*), (B) Axial images of the spinal 
column with spinal cord represented as (S) and the scar over the epidural layer indicated 
by the arrow. Grade 1 – no abnormalities, Grade 2 – abnormalities on < 8 slices, Grade 3 – 
abnormalities on > 8 slices but less than 1 mm thick, Grade 4 – abnormalities on > 8 
slices and > 1 mm thick. 
The spine sequences are as followed: 
a. T2_Space_Sagital (T2 anatomy); Voxel size: 0.9x0.9x0.9 mm
b. T2_Space_STIR_Sagital (T2 anatomy, fat suppressed); Voxel size: 0.9x0.9x0.9 mm
c. T1_Vibe_Axial (T1 anatomy); Voxel size: 0.6x0.6x2.0 mm
d. T2_Space_Axial (T2 anatomy); Voxel size: 0.6x0.6x2.0 mm
e. T2_Vibe_Axial (T1 anatomy); Voxel size: 0.6x0.6x2.0 mm
f. T2_me2d_Axial (Bleed Sequence); Voxel size: 0.4x0.4x3.0 mm
Fibrosis was scored by assessing the hypo-intense area (granulation tissue) in the epidural 
region utilizing the scoring system used by Rajiv et al 
417
. Each level was divided into 15
slices, Grade 1 – no abnormalities, Grade 2 – abnormalities on <8 slices, Grade 3 – 
abnormalities on > 8 slices but less than 1mm thick, Grade 4 – abnormalities on > 8 slices 
and > 1mm thick (Fig 1 A & B). Following MRI, the sheep underwent euthanasia at 12 
weeks. 
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Fig. 2. Results of radiology grading of epidural scars on MRI. Graph showing the 
radiological score of adhesions assessed via MRI. Fibrosis was scored by assessing 
the hypo-intense area (granulation tissue) in the epidural region utilizing the 
scoring system used by Rajiv et al (16). 
Histopathology examination:  
The sheep spines were removed en bloc and separated at each treatment level before fixation 
in 10% formalin. The vertebral bodies were mechanically removed prior to decalcification in 
a solution of 9.5% nitric acid in 1% EDTA. 
A representative section of each laminectomy site was embedded in paraffin wax and at least 
two 4 μm sections per defect were assessed with haematoxylin and eosin (H&E) and 
Masson‘s Trichrome (MT) stains. Each level was assessed by 1 pathologist and 1 pathology 
registrar who were blinded to the treatment given.  
Parameters assessed included a descriptive, qualitative assessment of the epidural scar and 
extent of inflammation. The method used to describe the quality of adhesions was based on a 
modified version of a method described by Richard et.al 
478
 using MT stains (Fig 3 A-E),





A. No treatment sheep 
 
 


























D. Score 3 fibrosis (moderate to dense) – 100% adhesion 
 
E. Score 4 fibrosis (dense) – 100% adhesion 
 
 
Fig 3. Histological scheme for Grading Adhesion. H&E (left) and MT (right) stained sections 
demonstrating the density of fibrosis corresponding to each grade. (A) Spine from a normal 
sheep for comparison, showing the posterior spinous process at the top and spinal cord at the 
bottom, with the loose dura mater in between. (B) Grade 1 fibrosis  
the adhesions are loose and delicate. (C) Grade 2 fibrosis – the scar is more established but 
still loose to moderate in density, with a pale quality on MT. (D) Grade 3 fibrosis – 
moderate to dense fibrosis; note the presence of chronic, foreign-body type inflammation 
within the scar (pink on MT). (E) Grade 4 fibrosis – the fibrosis is more dense 
compared to (D). S - Spinal cord, D -dura, * - adhesion & I – inflammation. 
 
where the epidural scar was characterised as mostly loose (score 1), loose to moderate (score 
2), moderate to dense (score 3), and dense (score 4). Assessment of the post-surgical 





















percentage of that area that was occupied by a chronic, foreign body-type inflammatory cell 
infiltrate. 
 
Statistical Analysis:  
All statistics were performed using R statistical software (R Foundation for Statistical 
Computing, Vienna, Austria) through the Jupyter notebook interface. The R package 
"ordinal" was used for ordinal regression. The "clmm" function was used to fit a Cumulative 
Link Mixed Models with the Laplace approximation. The semi-quantitative adhesion scores 
both on MRI and on H&E staining, were specified as the ordinal outcome variables. To 
control for the sheep variable, and the Radiology scorer variable when appropriate, they were 
assigned as random-effects covariates in the model. The means of the ordinal response 
(interpreted as a numeric value from 1 to the number of classes) were calculated and post-hoc 
pairwise contrasts for each pair of levels of the treatment variable were compared using the 
"emmeans" package
442




Of the 15 sheep that underwent surgery, 13 recovered, completing 12 weeks without any 
neurological deficit. 2 sheep developed neurological deficits in the hind limbs within 6-12 hrs 
after surgery. They were unable to recover with systemic steroid treatments and observation 
for 48 hrs and were subsequently euthanized. On emergency post-operative MRI, both sheep 
showed the presence of intrathecal blood, which was thought to be due to surgical trauma. 
The 13 remaining sheep had normal neural functions for 12 weeks and underwent euthanasia 
after MRI under general anaesthesia.  
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Blood examination 
FBE, UEC, LFT did not show any significant changes from baseline in any of the sheep 
tested. HPLC analysis showed trace amounts of plasma Def concentrations; the maximum 
Def concentration was reached after 12 hours (0.62 µg/ml Def). After 7 days the Def plasma 
concentration decreased to 0.16 µg/ml and after 3 weeks Def was not detected anymore 
(Supplementary Fig 1).  
Adhesion Scores by MRI 
MRI results were scored by 2 radiologists and 2 neurosurgeons for each of the individual 
laminectomy sites for 13 sheep. Assessors were blinded to the treatments given. Control sites 
had the highest mean adhesion grade of 3.74 [CI 3.09, 4.39]. A reduction in adhesion scores 
was seen for the treatment with Chitogel with a mean adhesion grade of 3.364 [CI 2.74, 3.98] 
and for the Chitogel + Def 20 mM treatment with a mean adhesion grade of 3.364 [CI 2.74, 
3.98] respectively in comparison to no-treatment control (p=0.0525 and P= 0.0534 
respectively). Mean adhesion scores were not significantly dis-similar for Chitogel + Def 40 
mM (3.53, [CI 2.9, 4.1]) and CMC/PEO (3.484, [CI 2.8, 4.1]) and were similar to control 
(P>0.1). 
Adhesion scores by histology 
The histological evaluation was performed by 1 consultant pathologist and 1 pathology 
registrar blinded to the treatment. Parameters assessed included a qualitative description of 
the epidural scar graded as ordinal scale (histopathology adhesion score) and extent of 
inflammation as percentage within the surgical site. Mean histopathology adhesion scores in 
the no-treatment control sites were 2.4 [CI 2.1, 2.7]. Chitogel with Deferiprone 20 mM (2.15 
[CI 1.94, 2.52]) and Chitogel with Deferiprone 40mM (2.06 [CI 1.8,2.3]) treated sites had the 
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lowest mean adhesion score, however, this reduction compared to control was not significant 
(P>0.05). Mean adhesion scores were similar for Chitogel (2.23 [CI 1.94, 2.52]) and 
CMC/PEO (2.23 [CI 1.94,2.52]) and not statistically different to control or to Chitogel with 
Deferiprone 20 mM or 40 mM (p>0.05).  
Fig. 4. Histological grading of inflammation in the adhesion and surrounding area. 
Foreign body-type chronic inflammation within the epidural scar was expressed as 
a percentage values. Graph showing the histological grading of inflammation in the 
post laminectomy site treated with Chitogel (CD), Chitogel with 20 mM Def 
(CD + Def20 mM), Chitogel with 40 mM Def (CD + 40 mM) and CMC/PEO in 
comparison to Control – Kaolin alone. 
Grade of inflammation 
Control sites showed an inflammation grade of 53.8% [CI 36%, 69%]. There was evidence of 
foreign body (FB) type reaction characterised by dense infiltrates of predominantly late 
inflammatory cells, especially macrophages with engulfed FB material.  
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Application of Chitogel significantly reduced this inflammation by 18.1 % compared to 
Control, with a mean inflammation grade of 35.7% [CI 21%, 51%], p=0.0398 (Fig 4). From 
all test treatments, Chitogel + Def 20mM appeared to have the strongest effect, reducing the 
inflammation by 23.1% compared to Control with a mean inflammation grade of 30.7% [CI 
16%, 46%], p<0.0096. Whereas Chitogel + Def 40 mM and CMC/PEO (52.69% [CI37.46, 
67.91]) was unable to reduce inflammation (47% [CI 32%, 62%]) compared to no treatment 
control (p>0.05)). 
Discussion:  
The current study shows Chitogel (a product of naturally occurring chitin) combined with 
Deferiprone 20 mM has significant anti-inflammatory properties and trends to reduce 
adhesions after laminectomy in comparison to no-treatment control and to commercially 
available CMC/PEO 
377,479
. Even in the background of extensive inflammation and fibrosis
caused by Kaolin, which promoted an environment for adhesion formation above and beyond 
what one would normally see in humans‘ post-surgery. Deferiprone-Chitogel could 
effectively reduce the inflammation and associated fibroblastic activity in the epidural region 
after surgery. All detected Def concentrations in plasma were substantially below the 
maximum Def plasma concentrations considered to be safe by the FDA
480
. This makes Def-
Chitogel a promising agent to reduce the morbidity associated with Failed Back Surgery 
Syndrome.  
Current strategies to prevent epidural fibrosis include modifications to surgical technique, 
radiation lysis, using medications and physical barrier materials
387
. Each of these techniques
has its limitations, yet barrier devices appear to be the preferred option with several products 
in preclinical and clinical development. Even though this appears to be among the more 
promising techniques, an ideal barrier or scaffolding material is still elusive.  Autologous fat 





has been used as a physiological barrier for a long time with limited long-term benefit
387
. 
Natural polymers and synthetic polymers have been tried as combined barriers, where 
scaffolds are incorporated with drugs that could give an added benefit. The polymers that 





 and silk-polythene glycol
388
. All these have a limited bioavailability 
and hence limited clinical use. Synthetic barriers are often combined with drugs such as 
Gelatine sponge with dexamethasone
417
, polyethylene glycol (PEG) with mitomycin-C, poly 
galacturonic acid gel (PGA) with Ibuprofen and Fibrin glue with methyl acrylate, but none 
have been recommended for standard practice. Scaffolds like Gelatine an inert spacer takes a 
long time to disintegrate and fibrin glue degrades faster than needed
387
. Pharmacological 
agents have had some limited benefit such as steroids, but some remain toxic to tissues like 
mitomycin, hence there is still an ongoing search for a better alternative
473
. Chitogel, a 
natural occurring biomaterial as an hydrogel barrier with its beneficial properties can be used 




Haemostasis being the first step in wound healing, optimal haemostasis is essential in 
promoting a balanced healing process. Chitogel is a rapid haemostatic agent when applied in 
the surgical bed and is thought to reduce scarring in part by promoting haemostasis
44
. 
Inflammation is the second step wherein the chemokines released from hematomas
388
 lead to 
recruitment of neutrophils and macrophages, producing inflammatory cytokines and reactive 
oxygen species (ROS) followed by fibroblast migration and proliferation into the wound, 
which are critical factors in the third step of the healing process. 
This fibroblastic activity in the extracellular space is regulated by various cytokines, such as 
transforming growth factor (TGF)-b1, interleukin-6 (IL-6) and fibroblast growth factor 
(FGF)
387
. Chitogel has previously been shown to have inherent anti-inflammatory effects and 





can reduce fibroblast migration in vitro, potentially contributing to its anti-adhesive 
properties 
80
. These properties could be further enhanced by adding Deferiprone to the gel. 
Indeed, in vitro studies have shown potent anti-inflammatory and inhibitory effects on 
fibroblast migration, proliferation and collagen secretion with inhibition of IL-6, a 
proinflammatory cytokine
85
. Hence, the enhanced anti-inflammatory property of Chitogel 
+Def 20mM is noticed in comparison to Chitogel alone as evidenced in the present study, 
indicating Deferiprone exerts anti-inflammatory effects also in vivo. The peak concentration 
of plasma Deferiprone was seen at 12 hrs with Deferiprone levels further decreasing up to 
day 7 after which Deferiprone was barely detected anymore. Similarly, a gradual drug release 
from Chitogel was seen in vitro over 10 days with a maximum release reached after 24-48 
hours. Importantly, the initial burst release of Deferiprone and continued release of 
Deferiprone in the first week after surgery matches the time frame of the wound healing 
process that is critically important to control at the second and third stages of wound healing 
85,365
. 
A previous 3-level sheep laminectomy study compared the anti-adhesive properties  
of Chitogel, Gelfoam and saline using MRI scan, ―Peel test‖ and histopathology. Whilst the 
peel test showed reduced adhesions in the Chitogel treated sheep compared to control, there 
were no significant differences in adhesion scores on MRI scan or histopathology
417
.  This 
current study also evaluated the nature of scar formed in the surgical bed using MRI images, 
―the gold standard‖ for evaluating FBSS 
473
. Peel test was not used to keep the fibrosis intact 
for histology which showed extensive fibrosis associated with manifest inflammation induced 
by Kaolin. This was further confirmed using MRI where Kaolin control sites consistently 
showed evidence for adhesion formation and this may in part explain why statistical 
significance was not achieved in the Chitosan with Def groups in this study. Whilst Kaolin 
can thus be used to induce adhesions, providing a consistent positive control lesser dosage of 
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Kaolin might be preferable in future studies to elucidate the beneficial effects of the gel and 
its combination with Deferiprone. The histological evaluation showed that the scar formed in 
the gel treated groups had decreased density of collagen fibbers as evidenced on Masson‘s 
trichrome staining. In spite of extensive foreign body reaction due to Kaolin, there was 
significant reduction in the inflammation in the Chitogel with 20 mM Deferiprone site, but 
the same was not seen with higher concentrations of Deferiprone. Dose dependent anti-
inflammatory effects and dose-dependent effects on reducing fibroblast migration have been 
shown with dosages up to 20 mM
14,85
. This concentration seems to be ideal for wound
healing,  whereas higher dosage at 40 mM proved to be harmful, probably due to redox dis-
balance of ROS, a critical mechanism in injured tissues affecting the wound healing process 
482,483
One of the limitations in this study was the 5-level laminectomy done for every sheep to 
increase the power and reduce the number of animals required. This resulted in the death of 2 
sheep and post-mortem evaluation showed intrathecal bleeding which is not a rare 
complication, most often due to iatrogenic trauma to the spinal cord
484
. Our previous study
used a 3-level laminectomy in the same animal species which in future studies will be our 
preferred model as it appeared to be better tolerated without major operative morbidity (14). 
Conclusion: Chitogel with Deferiprone is a promising, composite immunomodulatory barrier 
agent possessing haemostatic and potent anti-inflammatory properties to prevent epidural 
adhesions and FBSS. 
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Supplementary Fig. 1. Safety profile of Serum Deferiprone. Deferiprone (Def) plasma 
concentrations (µg/ml) over 7 days ± SEM. The maximum Def concentration was reached 
after 12 hours (0.62 µg/ml Def) in the sheep treated with Chitogel-Def gel. After 7 days the 
Def plasma concentration decreased to 0.16 µg/ml and after 3 weeks Def was not detected 
anymore. 
223 
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Summary of Thesis: 
Scar formation after wound healing has  detrimental effects on surgical management of 
diseases in the human body.  The endeavour of this research was to identify various 
contributors to scar formation and to find ways to alleviate this complication by the use of  
Chitogel in 3 different systems: 1. Nose - ENT surgery, 2. Abdomen in General Surgery and 
3. Spine surgery after laminectomy. We aimed at studying the safety of Chitogel, a naturally 
derived polysaccharide that has properties of haemostasis and wound healing by inhibiting 
fibroblasts along with novel drugs -Deferiprone and Gallium Protoporphyrin, that are being 
repurposed from their original intended use in medical science. Deferiprone an Iron chelator 
that has been very successfully being used for the treatment of Thalassemia, a condition in 
which there is excess residual iron in the body due to abnormal red blood cells being broken 
down earlier than usual. Deferiprone has been tested in the lab and found to be safe and 
effective on human nasal epithelial cells in delaying the migration of fibroblasts which are 
essential component used by the body to build scar tissue. This along with Gallium – 
protoporphyrin which is a chemical with a similar structure to Haem in blood and has proven 
antibacterial effects invitro. Combining a hydrophilic haemostatic gel, a fibroblast migration 
inhibitor and a antibacterial drug is unique and therefore the subject of this thesis.  Chitogel 
has also proved to be an excellent drug carrier and releases these drugs in an appropriate 
timeline which enables the drugs to produce an anti-inflammatory action along with an 
antibacterial effect and fibroblast inhibition. This thesis explored the use of the gel-drug 
combination in various surgical specialities, in various models and in various dosage 
combinations to find a safe and effective product that will be beneficial in each condition.  
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Chitogel with Def-GaPP in ENT-Endoscopic Sinus Surgery (ESS): 
Surgical outcomes in endoscopic sinus surgery are influenced by adequate haemostasis at the 
end of surgery and may be influenced by certain packing materials. Scar tissue formation in 
the region of the sinus opening may cause ostial stenosis leading to persistent inflammation 
and recalcitrant infections, needing revision surgery. In this study we aimed to determine the 
safety and efficacy of Chitogel with and without Deferiprone (Def) and Gallium 
Protoporphyrin 
89
 as adjuvants of wound healing and their ability to improve surgical 
outcome both subjectively and objectively in patients undergoing Full House FESS(FHF) and 
FHF with Drill out (DO). A Phase 1 radomised, blinded human clinical trial was conducted 
on consenting patients diagnosed with CRS and undergoing endoscopic sinus surgery. The 
Chitogel with and without a drug combination was instilled in the sinuses immediately after 
surgery on one side in FHF and the other side was considered as control in the same patients. 
In DO patients this was not possible hence a group of patients who did not receive the gel 
was considered as controls. Post operatively these patients were followed up at 2 weeks, 6 
weeks and 12 weeks for evaluation of the validated quality of life Sino-Nasal Outcome Score 
(SNOT-22) and symptom based Visual Analogue score (VAS).  The surgeon performing the 
endoscopy scored healing with the validated – Modified Lund Kennedy Score(LKS). Other 
parameters that were evaluated were: culture sensitivity pattern of sinus swabs to determine 
the presence or absence of Staphylococcus Aureus or Pseudomonas Aeruginosa at surgery 
and at 12 weeks, drug safety profile by testing inflammatory markers-Total blood cell counts, 
Liver function tests and Serum Ferritin levels at 0 hrs and 2 weeks after surgery, along with 
serum Deferiprone levels at 0 hrs, 2 hrs, 6 hrs and 2 weeks after surgery.  
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At the end of 12 weeks, among the patients who underwent DO there was a significant 
reduction in SNOT 22(p<0.05) and VAS significantly improved over a time period of 12 
weeks in patient treated with Chitogel alone (p<0.05). The ostium size of all the sinuses were 
measured and compared to 12 weeks PO, sinus ostial openings made during surgery and 
treated with Chitogel and Chitogel with Def and GaPP remained 90-100% the size of their 
original openings made at surgery.  In comparison the DO patients who did not have any 
packing had shrinkage of the original ostium to 74% of the original ostial size.  Similar trends 
were seen in Chitogel alone treated maxillary and sphenoid ostium in comparison to control 
as compared to baseline at surgery. Chitogel with Def treated frontal sinus ostia in the FHF 
groups were more (p<0.065) patent as compared to their respective control (97%Vs 89%).  
The surgeon reported objective assessment with LKS score at 12 weeks, even though 
Chitogel treated sinuses appeared to heal better, there was no statistically significant 
difference in LKS for any of the test treatment groups when comparing the control untreated 
side with the test treatment side for each of those patient groups. Chitogel in combination 
with Def and GaPP as  an antimicrobial did not alter the culture status significantly. Thus we 
were able to reiterate the fact that, Chitogel is an excellent post-operative dressing after ESS 
and has best patient reported symptom scores. Combination of Deferiprone and Gallium 
protoporphyrin though being safe, it had no positive beneficial effect on the ostium patency. 
Chitogel with Def-GaPP in Abdominal Surgery: 
Adhesion formation after abdominal surgery is a common finding in the abdomen that leads 
to major and minor complications which include pain, obstruction and infertility. Even 
though there have been many anti-adhesive measures suggested none have been able to 
completely eliminate these abnormal scars.  These complications come with an enormous 
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social and economic burden. In order to be able to evaluate this novel new treatment a 
suitable validated small animal model was developed.  This study was a positive contribution 
as previously described models all lacked consistency in been able to produce a relatively 
standard adhesion.  The new rat model of abdominal adhesions was done using Kaolin as the 
adhesion-inducing agent at an optimised dosage in 2 different abdominal surgery settings: 1. 
Intestinal Abrasion- mimicking a blunt injury with inflammation  and 2. Abrasion + 
Enterotomy – a invasive procedure and infective model. In this model we evaluated the effect 
of  various volumes of a Kaolin irritant,  for adhesion formation as compared this to saline. 
The adhesion that formed were graded at 3 weeks and both macroscopically using pre-
determined adhesion scores and microscopically on histopathology. We found that Kaolin at 
0.005 g/mL caused consistent adhesions without compromising rat viability. Higher doses 
had significant morbidity and mortality. Using this newly proposed rat abdominal adhesion 
model we tested the anti-adhesive properties of Chitogel, Chitogel plus Deferiprone in varied 
dosages (5, 10 or 20 mM), together with Gallium Protoporphyrin (250μg/mL) as an anti-
infection combination. The abrasion with enterotomy rats were randomised to receive saline, 
Chitogel or Chitogel with Deferiprone (1 or 5 mM). At the end point adhesions were graded 
macroscopically and microscopically; and also, the tensile strength of the scar on the repaired 
caecum was determined by an investigator blinded to the treatment groups. 
We found that Chitogel with Deferiprone 5 mM significantly reduced adhesion formation 
(p<0.01) in the rat abrasion model. Chitogel with Deferiprone 5 mM and 1 mM also 
significantly reduced adhesions (p<0.05) after abrasion with enterotomy. Tensile strength 
testing of caecum specimens in the colon abrasion and enterotomy model showed Def-
Chitogel treatment did not weaken the enterotomy site with Def 1mM Chitogel treated sites 
having significantly better tensile strength compared to control saline treated enterotomy rats. 
In conclusion, Chitogel with Deferiprone 1 mM constitutes an effective preventative anti-
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adhesion barrier after abdominal surgery in a rat model.  Moreover, this therapeutic 
combination of agents is safe and does not weaken the healing of the sutured enterotomy site. 
Chitogel with Def in Spine Surgery: 
Failed Back Surgery Syndrome (FBSS) is increasingly occurring disease among the patients 
who have undergone spinal laminectomy - a common procedure performed to relieve neural 
compression in patients suffering from myelopathy or radiculopathy.  Excessive scarring in 
the surgical bed is implicated as a cause and many strategies have been evaluated with 
success and there remains no FDA approved product registered in the USA for this 
indication.   Hydrogels such as carboxy-methylcellulose and poly-ethylene-oxide (CMC-
PEO) have been tried post laminectomy, however, their efficacy has also not been proven. 
We proposed to use Chitogel in combination with the iron chelator Deferiprone (Def) which 
has been shown to have fibroblast inhibitory effects in various dosages to attempt to prevent 
adhesion formation in a sheep laminectomy model.   
Our research groups were Chitogel, Chitogel with Def at 20mM or 40mM or Carboxy-
methylcellulose and Polyethylene oxide (CMC/PEO) gel. Post operatively the  sheep were 
assessed at 3 months with Magnetic Resonance Imaging (MRI) and histology for the 
presence and extent of adhesions. MRI and histology assessment indicated that Kaolin 
induced severe inflammation with adhesion formation. Chitogel with and without 20 mM Def 
decreased inflammation (p<0.01) and trended to reduce adhesions (p<0.1). Chitogel with Def 
40mM was similar to CMC/PEO and did not reduce inflammation or adhesions compared to 
no-treatment control. Once again, we found that Chitogel in combination with Def 20 mM is 
safe and effective in decreasing the inflammatory process and subsequent post-operative 
adhesions following laminectomy. 
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CONCLUSION: 
This doctoral thesis aimed to assess novel possible solutions for commonly occurring 
undesired effects of surgical treatment, i.e., scarring in diverse systems in the human body. 
We proposed to test the safety and efficacy of Chitogel incorporating Deferiprone and 
Gallium Protoporphyrin which enhance Chitogels‘ healing and anti-bacterial properties.  
We are able to confidently conclude that Chitogel is an excellent hydrogel which not only 
promotes haemostasis and wound healing, but it acts as a drug carrier that is able to prevent 
ostial stenosis in the sinus cavity after sinus surgery. The patient reported outcomes were also 
significantly better than the no treatment control patients. One of the drawbacks of this trial 
was the number of patients we were able to test the gel-drug combination. Now that we know 
Chitogel with Def it is safe and there is not enough evidence for the combination with GaPP,  
a future study where Deferiprone in a lower dosage would be the ideal way forward. 
In the abdomen we found that 1% Chitogel with Deferiprone was an ideal barrier agent that 
was able to be instilled in the abdominal cavity and that this prevented adhesion formation as 
seen in a standardized rat model. The resultant scar tissue produced in the presence of gel and 
Deferiprone did not weaken the bowel anastomosis as seen in the stretch test. Furthermore, a 
large animal model and a future human clinical trial are necessary to support the use of 
Chitogel with or without Deferiprone in Surgical practice .  
Similarly,  the anti-adhesive effect of Chitogel with 20 Mm of Deferiprone on a Kaolin 
induced scar over the dura of the spinal cord was not very pronounced, hence further small 
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and large animal models are necessary to be done using Chitogel with a lower dosage of Def 
to fine tune the benefits.  
These findings certainly helped us to understand the nature of scar formation and the role of 
Chitogel in preventing the debilitating effects of scar. We hope that this body of information 
will help surgeons and researchers to envisage a scar free surgery in the future.  
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10 Appendix 
Appendix 1: Flow chart of Project 1 Clinical trial 
Recruitment of patients in Clinical trial and randomization 
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Date: 
Appendix 2: Consent and proforma 
Patient recruitment Checklist 
(to be completed by surgeon at Time = 0) 
Patient Name: 
Clinician Name: 
Inclusion criteria (Need to answer YES to all of these) 
Is the patient over 18 and able to give competent 
informed consent? 
Yes No 
Is the patient willing to return to the clinic at 2 
weeks, 6 weeks and 12 weeks after recruitment? 
Yes No 
Has the patient had a previous sinus operation? 





Does the patient have symptoms of CRS? Yes No 
Does the patient have symptoms of active 
infection? 
Yes No 
Does the patient have signs of CRS? Yes No 
Does the patient have signs of active infection? Yes No 
Has the patient failed oral antibiotics therapy at 
least once prior to their recruitment to the 
study? 
Yes No 
Have you taken a swab and sent it for MC&S? Yes No 
Exclusion criteria (Need to answer NO to all of these 
Chitogel Grading Pro forma – to be completed by surgeon            Date: 
Patient Name:  
Time of assessment: 0 week (at recruitment)/2 week/6 weeks / 12 weeks 
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1. Invitation to Participate  
 
We invite you to take part in this research project because you have chronic rhinosinusitis and are about to 
undergo surgery.  However, before you decide whether or not you want to participate, we need to be sure 
that you understand Why we are doing it, and What would it mean if you agreed.  
 
This research project is testing a new treatment for chronic rhinosinusitis by the use of a Chitosan-Dextran 
(Chitodex) gel mixed with medications to see if there is improved healing after sinus surgery and less infec-
tion. 
 
Please read this information carefully. Ask questions about anything that you don’t understand or want to 
know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, 
friend or your local doctor. You do not have to make an immediate decision, and should you agree to take 
part in the research project you are free to change your mind and withdraw at any stage of the trial without 
any effect on your relationship with your treating doctors or the hospital. 
 
2. Participation is Voluntary 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. You will receive 
the best possible care whether or not you take part and will not affect your waiting list position for sinus 
surgery. 
 
If you decide you want to take part in the research project, you will be asked to sign the consent section. By 
signing it you are telling us that, you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to have the tests and treatments that are described  
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
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3. What is the purpose of this research? 
 
Back ground: Chronic rhinosinusitis affects approximately 15% of the general population and is character-
ised by sinusitis symptoms persisting for more than 3 months. Patients who do not respond adequately to 
oral and topical steroids, antibiotics and nasal lavage require surgical management. The surgical procedure 
is termed endoscopic sinus surgery, and involves removing oedematous mucosa, pus and debris, as well as 
clearance of bony walls within the sinonasal cavity to open up blocked sinuses. You will receive the standard 
hospital information sheet about the sinus surgery, and you will sign the standard hospital consent form for 
the sinus surgery. 
 
Purpose: The purpose of this research project is testing in sinus surgery whether adding two new antimicro-
bial agents (Deferiprone and Gallium-Protoporphyrin) to a locally developed dissolvable nasal dressing 
(Chitodex gel) will improve the anti-microbial and wound-healing effects of Chitodex gel after sinus surgery 
compared to chitodex alone. 
 
Why is the research being done? 
 
The research is being done to improve the results from sinus surgery by: improving the   healing process in 
the nasal/sinus cavities; reducing infection; and reducing the need for revision sinus surgery. 
 
4. Who is sponsoring the trial and is there any benefits money being paid to the researcher/ Depart-
ment/anyone else. 
 
The Department of ENT and University of Adelaide is funding the research and there are no payments being 
done to the research or the department or participants or any company. Professor Peter-John Wormald, the 
Principal Investigator of this study is part of a consortium that owns the patent for Chitodex gel which is being 
used in this study. Professor Wormald is a cofounder of Chitodex and has been involved in the development 
of this product since its inception. He currently co-owns the patent for use of Chitodex in sinus surgery. 
However, he will not play any role in the data analyses since it is being done by the members of the ENT 
Department who do not have any financial interest in the outcome of this study.  
 
5. How and why have I been chosen as a possible participant in the research? 
 
You have been invited because you have been diagnosed to have chronic sinusitis and will be undergoing 
endoscopic sinus surgery (ESS). You will be randomly (like the toss of a coin) allocated to receive one of the 
three treatments to one side of the sinus surgery ( ie left or right) or if its a frontal drill out into a fourth group 
(control) receiving saline and the results compared to see if one treatment is more effective. . 
 
6. How many other people have been asked to consider participating? 
  
A total of 90 participants will be involved in this trial. 
 
7. What does participation in this research involve? 
 
Procedure and Treatment: Under endoscopic guidance, each participant will have a sinus swab performed 
prior to surgery and then undergo the planned sinus surgery-Endoscopic sinus surgery (ESS) or ESS with 
frontal drill out (explained and consented with separate forms). 
 
1. At the end of the procedure, each participant will receive 10 ml of gel (Chitodex or Chitodex+Defer-
iprone or Chitodex+Gallium-Protoporphyrin or Chitodex+ Deferiprone+ Gallium-Protoporphyrin) into 
one side of each of the three sinuses and the non-treated side would be referred to as the control and 
receive routine standard of care.  
2. If the surgery is meant to produce a larger frontal sinus cavity (ESS with frontal drillout) 20 ml of gel 
would be applied or 20 ml of saline if you are in the control group. 
3. Post-operative care will proceed as per standard care after sinus surgery (except for blood tests and 
questionnaire as described below). 
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4. You will return to the outpatient department 2 weeks, 6 weeks and 12 weeks after the surgery for 
post-operative review. During each visit we would perform a sinus swab and an endoscopic video 
recording of your sinuses. 
 
The recorded video examination will then be scored by an independent clinician, unaware of your treatment, 
for infection (pus), edema, granulation tissue, and crusting using a standardised scoring scales.   
 
8. What would I be asked to do at each visit? 
 
1. You will be asked to complete a self-directed symptom and comfort questionnaire at each review 
which is specific for each side.  
2. Routine blood tests (haematology with neutrophil counts and blood chemistry with liver enzymes) will 
occur at day 0 and at first post-operative visit at 2 weeks. Deferiprone and Gallium-Protoporphyrin 
serum concentrations will also be measured at the same time and also at 2 hrs and 6 hrs after surgery. 
  
9. What if my problems persist or I don’t feel relief? 
 
If there are signs of persistent infection at any visit, then a second swab will be taken and sent for repeat 
microbiological evaluation and you will receive antibiotics as directed by its report. If you have not improved, 
you will resume usual outpatient/surgical care for your symptoms. If there are no further clinical signs of 
infection at the 12-week post-surgery visit, you will have a final microbiology swab taken to confirm eradica-
tion of infection and would be considered as having completed the study. The research project has been 
designed to make sure the researchers interpret the results in a fair and appropriate way and avoids study 
doctors or participants jumping to conclusions. 
 
10. Does my participation involve extra cost? 
 
There are no additional costs associated with participating in this research project, nor will you be paid. All 
medication, tests and medical care required as part of the research project will be provided to you free of 
charge. Parking is available at the TQEH which is free for first 2 hrs and arrangements for longer stay will be 
done by the Department (discuss with the study doctor). Your local doctor will be advised of your decision to 
participate in this research project. 
 
11. Do I have any restrictions while participating in the trial? 
 
Participating in this study does not imply any restrictions in lifestyle, physical activity, diet or medication use, 
aside from that for the usual post-operative care for sinus surgery. There is no restriction of diet and can take 
all regular medication. You cannot participate in this study if you have allergy to shell fish and any specific 
drug allergy to the drugs being tested or have a history of being diagnosed with any type of hepatitis in the 
past or during the preparative evaluation. 
 
12. Other relevant information about the research project 
 
The results of this research will be used by the study doctor Dr. Rajan Sundaresan Vediappan to obtain a 
Doctorate in Philosophy (Ph.D.) 
  
13. What are the alternatives to participation?  
  
Participation in this trial is not compulsory to receive treatment at this hospital.  Other options are available; 
these include oral antibiotics with or without surgery & long term steroidal nasal spray. Your study doctor will 
discuss these options with you before you decide whether or not to take part in this research project.  You 
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14. What are the possible benefits of taking part? 
 
We cannot guarantee or promise that you will receive any benefits from this research; however, possible 
benefits may include better healing and decrease in the recurrence of infection. 
 
15.  What treatments are used in the research project? 
 
The research project involves use of a Gel called Chitodex (CD) containing Chitosan derived from crusta-
ceans and dextran with a new antimicrobial drug combination. 
 
Test Group 1: receives 10ml of CD gel in one side of the sinus after surgery 
 
Test Group 2: receives 10 ml of CD gel with Deferiprone (Def) in one side of the sinus after surgery 
 
Test Group 3: receives 10 ml of CD gel with Gallium-Protoporphyrin (GaPP) in one side of the sinus after 
surgery  
 
Test Group 4: receives 10 ml of CD gel with Deferiprone and Gallium-Protoporphyrin (GaPP) in one side of 
the sinus after surgery  
 
Test Group 5(only in ESS with Frontal drill out): 20 ml of saline  
 
In participants having a larger sinus cavity after surgery (ESS + frontal drill out)-double the usual dosage ie 
20 ml of gel, will be applied. Chitosan the main ingredient in Chitodex gel is already being used in numerous 
applications for its preservation function (in foods, agriculture, cosmetics and toothpastes), for its antibacterial 
function (as a coating to fruits and vegetables), for its hydrating properties (in cosmetics) . Medically, it is well 
recognised for its haemostatic properties (e.g. US Military as a haemostatic dressing), anti-adhesive and pro-
wound healing properties, as well as for its antimicrobial actions. At the TQEH we have been using this gel 
in the past few years in clinical trials and have found to have both anti adhesive properties and also helps in 
achieving haemostasis. This is currently approved by the FDA for use in treatment of sinusitis, but not ap-
proved by the TGA for use in Australia. 
 
Deferiprone is an iron chelator-which means it removes excess iron from the blood in patients with a blood 
disorder called Thalassemia major and also has properties that could treat infection. Deferiprone as an oral 
formulation is TGA approved for the treatment of iron overload in thalassaemia major: GaPP, Chitodex gel 
and Deferiprone have not been approved by the TGA for topical application.  
 




Medical treatments often cause side effects. You may have none, some or all of the effects listed below, and 
they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk 
with your study doctor. Your study doctor will also be looking out for side effects.  
 
There may be side effects that the researchers do not expect or do not know about and that may be serious. 
Tell your study doctor immediately about any new or unusual symptoms that you get. 
 
Many side effects go away shortly after treatment ends. However, sometimes side effects can be serious, 
long lasting or permanent. If a severe side effect or reaction occurs, your study doctor may need to stop your 
treatment. Your study doctor will discuss the best way of managing any side effects with you. The general 
drug allergy symptoms to watch for would be skin rashes, itching, burning sensation in throat and stomach, 
vomiting or bleeding from the nose. 
 
The only possible side effect would be allergy to Chitosan for individuals who have allergy to shrimps or other 
seafood. In all trials that have been conducted in this department involving Chitodex as a topical product in 
human subjects, there have been no adverse effects. 
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Deferiprone orally in large doses may cause decrease in white blood cells but this is unlikely to occur with 
the very low doses in this research project. You will be monitored by the team regularly. The doses of Defer-
iprone from the topical application are much times lower than the dose approved to treat iron overload in 
patients. The reported common side effects of colored urine, joint pains and aches, nausea, vomiting, ab-
dominal pain and lowering the white cell count in the blood for the tablet form of Deferiprone are extremely 
unlikely to occur with the topical Deferiprone in the gels being used in this study 
 
Gallium and gallium salts are safe and widely used in a range of biomedical applications including as (radio) 
pharmaceuticals. 
 
We therefore expect no local or systemic toxicity issues from the topical application of the Def-GaPP-CD-gel 
in this research project. 
 
Pregnancy & Child bearing: 
   
The effects of Chitosan gel and the drugs Deferiprone and Gallium-Protoporphyrin on the unborn child and 
on the newborn baby are not known. Because of this, it is important that research project participants are not 
pregnant or breast-feeding and do not become pregnant during the course of the research project. You must 
not participate in the research if you are pregnant or trying to become pregnant, or breast-feeding. 
 
All participants with the capacity to achieve a pregnancy ie women of child bearing potential or men with 
partners having child bearing potential must practice highly effective contraception one month prior to and 
during the study. Discuss with the study doctor’ 
 
17. What will happen to my test samples? 
 
Samples (blood and swabs) will be collected and stored safely in SA pathology/Clipath facility for evaluation 
of liver function test, routine blood analysis for markers of chronic infection once before surgery and 2 weeks 
post-surgery. Separate samples will be collected at these timings and also at 2 hrs and 6hrs post-surgery for 
evaluation of Deferiprone and GaPP levels in the serum. Once analysed, samples will be disposed of ac-
cording to SA Pathology protocol by the end of the study.  
 
18. What if new information arises during this research project? 
 
Sometimes during the course of a research project, new information becomes available about the treatment 
that is being studied. If this happens, your study doctor will tell you about it and discuss with you whether you 
want to continue in the research project. If you decide to withdraw, your study doctor will make arrangements 
for your regular health care to continue. If you decide to continue in the research project you will be asked to 
sign an updated consent form. 
 
Also, on receiving new information, your study doctor might consider it to be in your best interests to withdraw 
you from the research project. If this happens, he/ she will explain the reasons and arrange for your regular 
health care to continue. 
 
19. Can I have other treatments during this research project? 
 
It is important to tell your study doctor and the study staff about any treatments or medications you may be 
taking, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative 
treatments. You should also tell your study doctor about any changes to these during your participation in 
the research project.  
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20. What if I withdraw from this research project? 
 
If you decide to withdraw from the project, please notify a member of the research team before you withdraw. 
This notice will allow that person or the research supervisor to discuss any special requirements linked to 
withdrawing. 
 
If you do withdraw your consent during the research project, the study doctor and relevant study staff will not 
collect additional personal information from you, although information already collected will be retained to 
ensure that the results of the research project can be measured properly and to comply with law. You should 
be aware that data collected up to the time you withdraw will form part of the research project results.  If you 
do not want them to do this, you must tell them when you withdraw. 
 
21. Could this research project be stopped unexpectedly? 
  
This research project may be stopped unexpectedly for a variety of reasons. These may include reasons 
such as: 
• Unacceptable side effects 
• The drug/treatment/device being shown not to be effective 
• The drug/treatment/device being shown to work and not need further testing 
 
22. What happens when the research project ends 
 
You will receive standard care in the form of regular follow ups and routine blood tests in case of any more 
infections or anaemia. 
 
23. What will happen to information about me? 
 
By signing the consent form, you consent to the study doctor and relevant research staff collecting and using 
information about you for the research project. Any information obtained in connection with this research 
project that can identify you (eg: name, DOB, contact details) will remain confidential and be kept linked to 
your study code in a separate, securely stored file accessible to the investigators only. All information col-
lected in the research project will be re-identifiable by the investigators only, and will be stored securely in 
locked cupboards hard copy and on password protected computers in the Department of Otorhinolaryngology 
which is out of bounds for unauthorised staff or public. Your information will only be used for the purpose of 
this research project and it will only be disclosed with your permission, except as required by law. 
 
Information about you may be obtained from your health records held at this and other health services for 
the purpose of this research. By signing the consent form you agree to the study team accessing health 
records if they are relevant to your participation in this research project. 
 
Your health records and any information obtained during the research project are subject to inspection (for 
the purpose of verifying the procedures and the data) by the relevant authorities of Therapeutic Goods Ad-
ministration or CAHLN, or as required by law. By signing the Consent Form, you authorise release of, or 
access to, this confidential information to the relevant study personnel and relevant authorities as noted 
above.  
 
24. What would be done with the information gained regarding this study? 
 
It is anticipated that the results of this research project will be published and/or presented in a variety of 
forums. In any publication and/or presentation, information will be provided in such a way that you cannot be 
identified, except with your permission. In no instance except as demanded by law will the name of an indi-
vidual be revealed.  
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25. What if I have any injuries during the research project? 
 
If you suffer any injuries or complications as a result of this research project, you should contact the study 
team as soon as possible and you will be assisted with arranging appropriate medical treatment. If you are 
eligible for Medicare, you can receive any medical treatment required to treat the injury or complication, free 
of charge, as a public patient in any Australian public hospital. Your participation in this study does not affect 
any other right you may have to compensation under common law. 
 
26. Who is organising and funding the research is there any financial benefit? 
 
This research project is being conducted by Professor Peter-John Wormald and is the co-patent holder for 
the products used and also for the novel therapy.   
 
You will not benefit financially from your involvement in this research project even if, for example, your blood 
samples (or knowledge acquired from analysis of your samples) prove to be of commercial value to The 
University of Adelaide. 
 
In addition, if knowledge acquired through this research leads to discoveries that are of commercial value to 
The University of Adelaide, the study doctors or their institutions, there will be no financial benefit to you or 
your family from these discoveries. 
 
No member of the research team will receive a personal financial benefit (except potential benefit from patent 
held by the primary investigator) from your involvement in this research project (other than their ordinary 
wages). 
 
27. Who has reviewed the research project? 
   
All research in Australia involving humans is reviewed by an independent group of people called a Human 
Research Ethics Committee (HREC).  The ethical aspects of this research project have been approved by 
the Human Research Ethics Committee (TQEH/LMH/MH). This project will be carried out according to the 
National Statement on Ethical Conduct in Human Research (2007). This statement has been developed to 
protect the interests of people who agree to participate in human research studies. 
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28. Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query.  
 
If you want any further information concerning this project or if you have any medical problems which may 
be related to your involvement in the project (for example, any side effects), you can contact the assistant 
investigator at TQEH on 0423-674912 or any of the following people:  
 
Name Bernadette Swart 
Position CALHN Research Manager 




If you have any complaints about any aspect of the project, the way it is being conducted or any questions 
about being a research participant in general, then you may contact: 
 
Reviewing HREC name Human Research Ethics Committee (TQEH/LMH/LH) 
HREC Executive Officer Ms Heather O’Dea 
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CENTRAL ADELAIDE LOCAL HEALTH NETWORK 




Title Chitosan-dextran (Chitodex) gel with and without Deferiprone and Gallium-   
            Protoporphyrin wound healing and post-operative outcomes in Chronic rhino-sinusitis. 
 
Declaration by Participant 
 
I have read the Participant Information Sheet, or someone has read it to me in a language that I 
understand. The research worker has explained to me all the aspects of this study and I voluntarily 
consent to participate. 
 
I understand the purposes, procedures and risks of the research described in the Participant In-
formation Sheet. 
 
I give permission for my doctors, other health professionals, hospitals or laboratories outside this 
hospital to release information to The Queen Elizabeth Hospital/The Memorial Hospital concern-
ing my disease and treatment for the purposes of this project. I understand that such information 
will remain confidential.  
 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
 
I freely agree to participate in this research project as described and understand that I am free to 
withdraw at any time during the study without affecting my future health care.  
 
I have been explained in the presence of my family member that my identity will be kept confi-
dential and permit if any information has to be shared with my general practitioner.  
 
I understand that I will be given a signed copy of this document to keep. 
 
I the undersigned herby consent to my involvement in the research project explained above. 
Name of Participant (please print) 
 
Signature:  
        Date:  
 
Declaration by Study Doctor/Senior Researcher† 
 
I have given a verbal explanation of the research project, its procedures and risks and I believe 
that the participant has understood that explanation. 
 
 















 L R 
ADHESIONS 
% Middle Turbinate taken 
up by adhesion 0, 1-25, 26-50, >50% 0, 1-25, 26-50, >50% 
Adhesions Divided Yes/No Yes/No 
EVIDENCE OF INFECTION (PUS) 
Ordinal Scale 
(0-2) 
No visible evidence of infection 0 No visible evidence of infection 0 
Mild mucopurulent drainage 1 Mild mucopurulent drainage 1 
Gross mucopurulent drainage with 
obvious frank infection 
2 Gross mucopurulent drainage with 
obvious frank infection 
2 




No visible mucosal oedema 0 No visible mucosal oedema 0 
Mild mucosal oedema without obliteration 
of the ethmoid cavity 1 
Mild mucosal oedema without obliteration 
of the ethmoid cavity 1 
Severe mucosal oedema obliterating 
most of the ethmoid cavity 2 
Severe mucosal oedema obliterating 
most of the ethmoid cavity 2 




Absent 0 Absent 0 
Mild 1 Mild 1 
Severe 2 Severe 2 




No visible granulations 0 No visible granulations 0 
Mild 1 Mild 1 
Moderate 2 Moderate 2 
Severe 3 Severe 3 

























Frontal     
Maxillary     





Nasal Swab Infection present/absent  Infection present/absent  
     
     











CENTRAL ADELAIDE LOCAL HEALTH NETWORK 
The Queen Elizabeth Hospital & Lyell McEwin Hospital 
 
 
SELF-DIRECTED SYMPTOM AND COMFORT form 
 
Title: Chitosan-dextran (Chitogel) with and without Deferiprone and Gallium-




















Thank you for your participation in this study. 
The following evaluation form should only take you less than 5 minutes to complete. 
The purpose of this evaluation form is to assess symptom outcomes from your point of view 
as the patient, which is an important consideration in the outcomes of this study. 










Name:  ________________________________________ 
 
Today‘s Date: _________ 
 
Time of assessment: At recruitment, Time = 0 weeks 
 
2 weeks / 6 weeks/12 weeks since recruitment 
 





Explanations of scale: 
 
Facial Pain/Discomfort: 0 is no pain or discomfort, 10 is the worst pain you have ever 
experienced 
Bleeding: 0 is no bleeding, 10 is bleeding requiring re-operation to control it 
Nasal Obstruction: 0 is a perfect airway which is very easy to breathe through, 10 is 
completely blocked with no air movement through that side. 
Nasal Secretion/throat drip: 0 is no nasal secretions, 10 is copious secretions with constant 
nasal dripping. 
Throat drip: 0 is no nasal secretions, 10 is copious secretions with constant nasal dripping. 
Sense of smell: 0 is no smell ability at all, 10 is best smell ability. 
e.g. Moderate pain   
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Appendix 4: Rat abdominal study Clinical record sheet 
RESEARCHER NAME:  _____________________ CONTACT NO.____________________ START WEIGHT___________
































































































































































8-hourly monitoring for first 24 hours, then twice daily monitoring for the first week post-surgery
YES = 1 Scores of 2 require the animal to be checked 2 times per day
NO   = 0 Scores of 3 require the animal to be checked 3 times per day
Scores of 4 require Animal Welfare Officer advice & notify Facility Coordinator
Scores of higher than 4 or >15% weight loss* require Euthanasia
** back arch and/or writhing is a sign of pain in rats, after abdominal surgery
LABORATORY ANIMAL SERVICES (Form MSAH#101)
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